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Titolo: La definizione dei costi delle prestazioni sanitarie: il caso della Neuroradiologia 
dell'Azienda Ospedaliera di Padova 
 
Questa tesi sperimentale si propone l’obiettivo di dare una panoramica sulla misurazione dei 
costi e fornire i risultati di uno caso di studio. Questo caso riguarda il reparto di 
Neuroradiologia dell’Azienda Ospedaliera di Padova, realtà giuridicamente e 
managerialmente particolare. Funziona infatti come un’azienda privata (responsabilità del 
management, obiettivi di bilancio, contabilità per centri di costo) pur essendo un’azienda 
pubblica. Lo studio riguarda la costruzione di una tariffa per alcune prestazioni di 
interventistica del reparto di Neuroradiologia, diretto dal dottor Causin, a cui rivolgo i più 
sinceri ringraziamenti per la disponibilità e la collaborazione. La creazione di una tariffa parte 
dallo studio dei costi, che ho fatto usando il metodo Activity Based Costing, e finisce con 
un’analisi dei possibili ricavi, che nel mondo ospedialiero sono fissati a monte. Il problema 
che ha spinto l’ospedale a richiedere questo studio al reparto di Controllo di Gestione, diretto 
dalla Relatrice di questa tesi, la Professoressa Giulia Zumerle, è stato che spesso l’ospedale, 
nel gestire pazienti di altre istituzioni, si è trovato a non sapere cosa e come fatturare. Questo 
studio quindi, oltre a portare un risparmio per l’Azienda Ospedaliera Di Padova, ha ampia 
possibilità di applicazione perché va a supplire alcune lacune del Nomenclatore Regionale, il 
quale regola tutti i rimborsi per le prestazioni Ospedaliere. In questo senso tutti gli ospedali 
potrebbero, attraverso le tariffe create in questo studio, trarre spunto per lo studio dei loro 
costi per affrontare meglio le scelte di Make or Buy di queste prestazioni.  
 
 
La tesi è divisa in quattro capitoli. 
Il primo tratta della creazione del Sistema Sanitario Nazionale, la sua maturazione e lo stato 
dell’arte odierno. Vengono illustrati il suo metodo di finanziamento e i possibili punti critici. 
Il secondo tratta del concetto di costo, delle sue possibili misurazioni e delle applicazioni in 
sanità. 
Il terzo dell’azienda Ospedaliera Di Padova, la sua organizzazione ed in particolare il 
funzionamento dell’unità Operativa della Programmazione & Controllo Di Gestione. 
Il quarto spiega l’attività che ho svolto, il processo operativo e di analisi che ha portato allo 
studio dei costi di reparto e alla creazione delle tariffe. 
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Abstract (ENG): 
 
This experimental thesis has as objective to offer a panoramic view on the cost measurement 
and to report the result of a case study. This case study is about the Neuroradiology’s 
Department of the Padova’s Hospital, the Padova Health Firm (Azienda Ospedaliera di 
Padova).It is a particular and managerial institution. In fact, it operates as a private firm 
(Management responsibility, economic targets, Cost Centre Accounting) still being a public 
body. The operative study that I show is about the development of a tariff for some operations 
of the Neuroradiology’s department, directed by Doctor Francesco Causin, whom I sincerely 
thank. A study for the development of a tariff starts from a cost analysis, that I performed 
through the Activity Based Costing Method, and ends with the study of the revenues deriving 
from those procedures that, particularly in Healthcare, are fixed. The problem that pushed the 
Padova Hospital’s Management to request this study to the Programming and Management 
Control’s Department was that the hospital, dealing with some patients arriving from other 
institutions, didn’t know what and how to invoice these services. This study, beside leading to 
a saving for the Padova Health Firm, is largely applicable and could be used to fill some gaps 
in the regional Tariff List for the Health Services. Moreover, all Hospitals could take 
advantage by the study of these procedures, and eventually study their own costs to take Make 
or Buy decisions. 
 
 
 
The thesis is divided in four chapters. 
The first is about the birth of the Italian NHS, its growth and its actual state of art. Are shown 
its financing method and its critical points. 
The second is about the concept of cost, its possible measurements and its Healthcare 
applications. 
The third presents the Padova Health Firm, its organisation and in particular the functioning 
of the Planning and Management Control Department. 
The fourth explains the work that I’ve done, the operative process and the analysis that led me 
to the study of the costs for the procedures and to the tariffs creation. 
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Chapter 1 - The National Healthcare System in Italy 
 
 
Commonly, the history of the SSN (Italian NHS) is divided in four periods. 
 Before law 883/78 
 Foundation of National Healthcare System - Law 833/78 
 Second reform (Managerialism)– Law 502/92 and 517/93 
 Third Reform (Regionalization) - Law 229/99 
 
1.1 - Historic Background and Laws References – Foundation of the SSN 
 
The birth of the SSN (Italian NHS) takes its inspiration by the concept of health as a right, 
granted by the Italian Constitution. Both of the individual and the community. As descripted 
by article 32 it must not be affected by territorial differences and has to be granted to 
everybody.1 
Before Law 883/78 healthcare system in Italy can be described as a mutual aid system, where 
there was no universal coverage, control on expenses, no analytical balance sheet 
management control and moreover the absence of the integration of the services. Before the 
tax reform of 1970, the financing of the mutual systems was local and managed by the 
municipalities or “health funds”, each one responsible for a class of workers that had to 
register compulsorily. At the end the cures were paid by the workers themselves and often the 
system failed, leaving workers or their relatives without treatments. The 1974 reform 
extinguished the debts of these organizations and transferred the duties in the health system to 
the regions. At this point the only financer of the Healthcare system were the state’s taxes but 
this mechanism generated many wastes: “The waterfall-organised method of financing was 
not holding responsible anyone and worsen the public finance” (Maggi, 2003). The state 
reimbursed every expenses that the healthcare providers supported. This system maintained 
the financial situation of the Italian Healthcare System always in debt, also because there was 
not incentive by the single provider to grow in efficiency and absolutely no forecasting and 
managing of the expenses. The reimbursements were given ex post. Moreover, there was a 
strong injustice between the treatment a citizen was able to receive depending on the city of 
                                                 
1 Art. 32 Of the Constitution of the Italian Republic (2016): The Republic safeguards health as a fundamental 
right of the individual and as a collective interest, and guarantees free medical care to the indigent. No one may 
be obliged to undergo any given health treatment except under the provisions of the law. The law cannot under 
any circumstances violate the limits imposed by respect for the human person. 
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birth and to the mutualistic system of enrolment. This, once again, was conflicting with the 
article 32 of the Constitution. 
The Law 883/78 actually founded the SSN (NHS). Its inspiring principles are:  
 Equality: Every citizen, independently from t occupation, social class or city of 
residence, can access to standard levels of health services from the SSN. 2 
 Global Cure: In the new organization of the health system must be considered, other 
than the assistance post symptoms, also the prevention and the rehabilitation.3 
 Territoriality: For the first time the whole centralized administration of health was 
divided by region, in which operate the USLs (Unità Sanitaria Locale , Local Unit for 
Health), to which compete the managing of the single hospital or the local health 
system. 
 Dignity and Freedom of the human being: “The safeguard of the health, physical and 
psychical, must occur respecting the dignity and liberty of the human being” 
The aims of this reform were to overcome the territorial disequilibria of the health condition 
in the country (through centralized programming and distribution of resources), to provide 
Health education of all the citizens and the communities, to facilitate the prevention of 
sickness and injuries in life and in the workplace, to develop the diagnosis and treatment for 
the invalids, to safeguard the mental health to implement a responsible procreation and 
safeguard of maternity and childhood and to  develop laws for the regulation of 
sperimentation, production and distribution of drugs. 
 
This reform delegated some functions and created three levels of management where before 
there was only one attributed to the state: 
1. Central Level: The state. It has the functions of the General Programming. 
Actors are: Govern, parliament, health ministry. 
2. Regional Level: The regions. They have the functions of the legislation and 
programming in the local dimension. 
3. Operative Level: Towns, single or associations. This task is executed through 
ASLs, the new institution that substitute the Usl. The change has occurred due 
to the spirit of the law, that wanted to underline the concept that Usl (meaning 
                                                 
2 "..senza distinzione di condizioni individuali o sociali e secondo modalità che assicurino l’eguaglianza dei 
cittadini nei confronti del servizio.." (Art.1 L.833/78) 
3 "..Il SSN è costituito dal complesso delle funzioni, delle strutture, dei servizi e delle attività destinati alla 
promozione, al mantenimento ed al recupero della salute fisica e psichica di tutta la popolazione .." (Art.1 
L.833/78) 
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Local Health Union) is changed with Asl (Local Health Firm), that receive 
Autonomy and Accountability. 
Thanks to this reform the delivery of cures was de-monopolized (by the USL, their structures 
and the sponsored ones) and put on the same operative level. 
This first attempt to create a modern and manageable national healthcare system had 
nonetheless its shortcomings. The main were four: 
 Missing implementation of the reforms (fiscal, social services, local autonomies, 
regional empowerment) 
 Difficulties in promoting rights and duties in social communities (much moral hazard) 
 Obstacles to changes and to accountability policies 
 Blasting of the healthcare expenditure due to the expansion of the social demand. The 
funds, dispensed by the Fondo Sanitario Nazionale (National Health Fund), were 
managed centrally, and this, not necessary negative, in this case caused the less of the 
focus on the efficiency. In fact, was not founded on a forecast or budget. 
The expenditures of the system were raising year by year: 28.000 MLD in the 1982 and 
95.000 in 1992, the drugs expenditure passed form 4.600 MLD to 16.300 MLD  and the per-
person health expense form 131.000L in 1958 to 728.000 L in 1992 (Coppola, 2008)4. 
 
 
 
 
 
 
                                                 
4 1 Euro = 1936,27 Lire 
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In short the bureaucratic logics and the vertical decisions suffocated the managerial optic 
fundamental for a flexible and accountable system, the unions didn’t allow the evolution of 
the professional figures but the most serious factor was the missed emission of the National 
and regional Plans with the objectives. In this way nobody could really take actions and 
actuate the reform plans (fiscal, local autonomies, social services, regional management of the 
state). 
 
1.2 – The reforms of the SSN 
 
 
1.2.1 - Second Reform of the SSN (Law 502/92 and 517/93) The managerialism optic 
 
 
Many countries in the 90’s had to face the incredible rise up of the health expenses. To face 
this diffused problem, in the mid-80s, a few American scholars elaborated a new governance 
style. It is nowadays called New Public Management and is a new approach to the public 
sector management. The idea was born from the consideration that the stakeholders of the 
Public firms are many and much differentiated (private, citizens, institutions and other public 
firm). The solutions that these scholar elaborated led to the definition of new targets to which 
the public firm must  be directed: elasticity and sustainability of the activities, re-organization 
of the Accounting system, separation from management and politics , technological 
innovation and focus on quality. In the Healthcare field, the American hospitals followed 
these new indication creating a quasi-market and starting the process of managerialism in the 
Healthcare Service. In Italy this process took 3 years to be implemented. Formally is 
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considered from 1992 to the nomination of the new General Directors of the ASLs in the 
1995. Managerialism was necessary for three reasons, between others (E. Menichetti, 2001):  
 The failure of the USL, that didn’t catch the objectives of Health Outcome and 
Financial and Economic Sustainability. 
 The health was not granted for everyone 
 The separation between politics and management (missing regionalization). 
Moreover, the expenses were continuing to rise. The reasons were that, as often happens in 
the healthcare business, the demand pushes the offer, and that the number of citizens 
accessing the new cure system were rising. An example is that between the 1949 and the 1979 
the individual treated passed from 15 to 33 million (Mapelli, 2012) and, effectively, the 
expense for the healthcare per person had grown of 4.4% in the period 1990-1999 (OASI, 
2011). 
In general, the Law wanted to touch 2 points, uncompleted by norm 1978/883: the 
institutional architecture of the system (less politics, delegation in the financial responsibility 
more autonomy on the single structures) and the introduction of new managing mechanisms. 
 
The new elements were: 
 The commitment to the State of the producing of a triennial healthcare planning 
document 
 The identification of the LUA (Livelli Uniformi Assistenza Sanitaria), the minimum 
levels of assistance that must be granted by the system and defines the sum of 
resources to allocate for the issuing of this services 
 The healthcare system becomes more regional-managed. The regions receive 
important functions. Programming and controlling the activity that is executed by the 
new public Health companies (Aziende Opsedaliere, IRCCS, Private Accredited 
Hospitals)5.  
 The regional agencies for the health (USL) receive legal personality and autonomy 
over equity and organization. 
 The new financing method: reduction of the NHF and addressing of the profit and 
losses to the regions (see next paragraph) 
 Introduction of the DRGs system 
                                                 
5 Decree 502/92, at article 5 says: The Health Firms are obliged to use an accounting system by cost centres, that 
allows comparative analysis of costs, revenues and results. 
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 Managerialism of the USLs (later called ASL) and institution of the AOs with legal 
personality. The aim was to have someone accountable of the results (and of funds, 
equipment and indexes) and to grow in efficiency 
 Creation of the accreditation system: the institutions that wants to issue healthcare 
services must pledge an agreements with the ASL(the regional institution) to be in the 
list of the authorized bodies. Doing so they accept all the norms of health and 
payments of the SSN6. 
 Creation of Quality indicator that must be compelled by every actor and are controlled 
by the ASL. 
 Freedom for the citizen to choose in which structure receive the cure. 
The autonomy of the AO and ASL was actualized by giving them legal personality ad 
nominating the General Directors with a contract of 5 years and giving legal personality to 
them. So this Director will be held responsible to the managing of the organization and can be 
fired (only for severe reasons). He has the power to nominee the Health and Administrative 
director. The staff organs were reinforced (marketing, accounting management) and created 
the system of forecasting and controlling based on outputs (also wage adjusted by reached 
objectives). Was created separation of different responsibility centres and cost centres 
accountable to the General Director. Also, the single AO and ASL must compile the Atto 
Aziendale (the firm statute), the true constitution of the body, that expresses the value, the 
aims and the rules. It is the best expression of its autonomy by the Italian Regulations and is 
the final fulfilment of the Autonomy principle waited since the 1978 Law. 
 
1.2.2 - Setting Up the Quasi-Market 
 
 
To give sense to the autonomy and managerial characteristic of the AO and ASL, they needed 
a market to move and markets pressure to out-perform. On the other hand, a completely free 
market could not be created because the goods like health and cures are too important, 
complex and also protected as rights from the constitutions (they can be counted inside the 
category of “merit goods”7), so there has been the need to create some sort of quasi-market. 
The patients were not anymore forced to go to a certain institution to be treated, but had 
freedom of choice, the private institution have to be accredited to operate and were introduced 
                                                 
6 Law 229/99 at article 4, letter b) comma 2, states that having an accounting system for cost centres is a 
fundamental prerequisite to get the accreditation. 
7 Goods or services (such as education and vaccination) provided free for the benefit of the entire society by a 
government, because they would be under-provided if left to the market forces or private enterprise 
(http://www.businessdictionary.com/definition/merit-goods.html) 
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some fees for certain services. In the Law, the concept of competition inside SSN has not 
been strictly regulated, letting every Asl decide over the quasi-market configuration. 
Spontaneously emerged three types of institutional models:  
 
 
 
Adaptation from (Mapelli, 2012, p. 190) 
 
The “traditional model” (integrated) is constituted by the complete integration of the ASL and 
the other institutions. All the hospitals and the Healthcare structures are managed by the Local 
Health Firm. They are all buyers and providers of services.  
The Separated Model, so to have the ASL as insurer and buyer of services and the AO as 
producers and providers. The Mixed model is present where in the ASL there are both 
institutions that provide and buy and only buyer/insurer. 
In all of the three configuration is possible to pursue the efficiency due to the accountability 
and the development of the quasi market logic. So to say that there isn’t a “always-best” 
model. This system set up, for some Health Firms, particularly the ASLs, the condition to 
pursue the logic of “Make or Buy”. Also, this law regulated the many private Healthcare 
Institutions that deliver services to the public. Now they are called “Social-Private” because 
they must be accredited to the SSN but not follow its plans. It is clear that, having the priced 
fixed, the actors operate on the margin, and so to reduce the costs. The competition on the 
costs, more than on the prices, pushes the company to the efficiency and it is good also for the 
entire fiscal system and the SSN.  
 
To Sum Up ((Sanità, 1996) 
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USL by 883/1978 Law USL/ASL by 502/1992 Law
Definition
Structure managed by the 
municipality without legal 
personality
Company with public 
legal personality
Structure
•General Council 
•Managing Comitee 
•Direction Office
General Director, that 
nominates: •Social 
Services Coordinator 
•Administrative director 
•Health Director . 
Auditors Council
Organization Three functional areas: •Base •Integrative •Central
Process managing and not 
anymore the functional 
areas: •large autonomy      
•Spin off of some 
hospitals to be Aos 
•Contractual Agreements 
intra Aos and USLs           
• Plurality of deliverers
Management By beds/staying days DRG tariffs
Reimbursement System By inputs( a piè di lista) by numbers of services delivered
Control Preventive On management results
Quality
Development of 
indicators, internal audit, 
VRQ  
 
1.2.3 - Third Reform (Law 229/1999) – The regionalization 
 
After seven years of debating upon the autonomy of the regions that lamented on the one side 
the centralism of the decisions by state, and on the other the inability of the state to plan and 
manage the SSN, the government arrived to the law 229/1999. This law wanted explicitly:” 
To remove the ambiguities in a chaotic legislation that allowed a passive privatisation of the 
SSN” (Taroni, 2011). The aim was to conciliate the inspiratory principles of the Law 
883/1978 with the new regionalised and managerialised situation. Moreover, was still debated 
the relationship between SSN and the Universities. The most important article in the first, 
pointing the ratio of the reform. In substitution of article 1 of the law 502/1992 the SSN 
receive a new definition: “The complex of the functions and of the assistant activities of the 
Regional Health Services8”. These the most relevant manoeuvres: 
                                                 
8 Art 1 Legge 229/99: La tutela della salute come diritto fondamentale dell'individuo ed interesse della collettivita' e' 
garantita, nel rispetto della dignita' e della liberta' della persona umana, attraverso il Servizio sanitario nazionale, quale 
complesso delle funzioni e delle attivita' assistenziali dei Servizi sanitari regionali e delle altre funzioni e attivita' svolte dagli 
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 The LUA were converted to LEA (Essential Level of Assistance) and were enlarged 
with the coverage of several integrative funds. They had to be debated and associated 
to a forecast cost and sustainability plan, before the approval. 
 The diffusion of a economic culture within the doctors. They were now prepared to 
take in consideration the economic implication of a treatment other than the clinical 
ones (possibility of a second best option in the treatment). 
 The municipalities were involved in the designation and removal of the General 
Directors (Modifying Art. 3 Law 502/1992). 
 New contracts for the Doctors to reduce the waiting Lists, inviting private doctors to 
operate in the public hospitals’ structures 
 Creation of the Long Term care for the elderlies. Social manoeuvre other than 
healthcare 
 The slowing in the creation of AOs, separated from USL. It was realised by indicating 
from the top the criteria for a Hospital to be spun off (explained in other chapter). 
This reform, due to political convergences and to a change of govern in Italy was not really 
applied. After the constitutional reform of 2001 anyway, the competences of the region were 
risen and clarified. In the 2000s there has been a continuous debate around the criteria of the 
regionalization and the managerialism but having like stepping stone the Autonomy of the 
region and the SSN as complex of the SSR. 
The first phase of the regionalization was contemporaneous to the managerialism, and was 
adopted form the Regions even if the criteria of the law were unclear. The spin-off of the 
hospitals from the USL and the constitution of the AOs has been the real sign that the state 
was delegating power in the choices. The municipalities have lost some influence on the SSN 
in these reforms. They lost decisional power due to the birth of the General Directors and due 
to the dimension of the USL, often more extended than the municipality territory. The new 
layout combines the historic problems of vertical management, and specifically the 
governance structure overlapping and the horizontal arguing between operators. It generated 
the model of the “marble cake federalism” (cfr Morton Godzins) in which competences, 
powers programs s and resources intersect to pursue (different) objectives. 
 
1.2.4 – After 1999 
 
                                                                                                                                                        
enti ed istituzioni di rilievo nazionale, nell'ambito dei conferimenti previsti dal decreto legislativo 31 marzo 1998, n. 112, 
nonche' delle funzioni conservate allo Stato dal medesimo decreto. 
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Despite the continuous reforms the SSN during the 90s continued to accumulate financial 
deficits around 5% of its funds, this due to the lacking of control by the regions but also by 
the strategy of the SSN to underfinance the system to integrate resources ex post. This method 
is used also to have some leverage on the regional management and keep them under stress to 
grow in efficiency. The law 56/2000 pursued these aims and introduced three new elements:  
 The abolition, starting from 2001 of the transfer of funds from the FSN to the regions. 
The new quota in regional health of the state will be taken from the IVA fund. The 
institution of a National Fund for the region with scarce taxation capacity (different 
form the previous NHfund) 
 The funds destined to the regions will be calculated in the population through several 
indexes like resident population (age, distribution, common pathologies), fiscal 
capacity, health needs and geographical dimension. 
 The elimination of the constraints in the destination of the taxes collected by the 
regions. In fact, the Health Business becomes a service like the others inside the 
regions and the quantity of funds allocate to it is decided by the regions 
On the 18th October 2001 was approved a change in the constitution to determine the 
competences among the central state and the local institutions. It is attributed to the exclusive 
competence of the region what is not defined competence of the state like defining the LEAs 
and creating the Five-Year Plan. To the region is entrusted the operative level. The Last 
important law concerning the SSN has been the 42/2009 that ensured the coverage of the LEA 
to those regions with a low tax income. It has been achieved creating an equalization fund that 
subdivide some taxes through the regions. This law also launched the concept of standard 
costs in the SSN, but remains still unaccomplished. 
The last tendencies in the SSN regulation have been: 
 get closer the hospital and its operators and the citizens 
 Implementation of the “gain health” system 
 To put at work together managers and doctors, to have an efficient and sustainable 
SSN 
 Create Health Network on the local level 
 
 
 
 
23 
 
1.3 - SSN: The Financing System 
 
1.3.1 - Some figures  
 
The SSN is funded through national and regional taxes and integrated with co-payments 
(OOP) for certain services. During the 2012 the total health expenditure was 9.2% of GDP. 
The taxes and the contributions cover the 78.2% of the total expenses, the rest, the private 
quota, are covered through OOP payments (17.8%) and private spending in private hospitals 
(Ferrè, 2014). Before seeing how the money for the Healthcare are collected it must be 
understood how much money are needed to finance the SSN and if Italy is over or 
underperforming other similar countries. Italy spent 112.408 million Euro for the Healthcare 
system in 2014, with a growth of 1% respect to the previous year.  
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As a percentage of the GDP Italy has one of the lowest expenditure of the western Europe. 
The largest part of the expenses is public (77%) 
 
 
 
 
Reflecting the different types of organizations and the autonomy, trough Italy’s regions 
composing the SSN there are substantial differences and problems. In some regions the 
providing of certain LEA is at risk, or generates many debts. To implement the spending 
reviews and constraints, many regions have been put under control from the state and the 
ministry of Health, that created and negotiated many “Financial Recovery plans” to try to 
make the system sustainable. 
25 
 
  
1.3.2 - The Financing System 
 
Like the organization, the financing system has had different phases. The most important are 
three: 
 Between 1978and 1991 the SSN was financed exclusively by the state 
 From 1992 to 2000 there has been a gradual fiscal decentralization with the growing 
autonomy of the regions in managing the funds 
  From 2001 until today the aim has been the tax federalism (by law 68/2011) 
What complicates the financing system of the SSN is that usually who benefits of the service 
is not the one who pays, or at least not directly. It is called a system with a “third party” payer. 
So it must be distinct who pays in fact and who stands the price. The difference is between 
original sources, who puts the money, and who perform the act of paying, the derived sources. 
The transfer of money in the Healthcare is organised on 4 levels: The withdrawal from the 
families and the firms, the transfer to the regions, the allocation to the ASL and the payment 
to the providers of health good and services.  
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(Rebba, 2015-2016) 
 
 
The system is financed with taxes and with full payments, only for the non-urgent services. 
For the services that are not urgent the state puts a “participation” quota, the ticket (OOP), to 
model the demand and limit the abuse. It is interesting to cite the problem of the third payer, 
that is debated in the Healthcare financing field. It is clear that not every payer of the SSN 
receive the counter service. It depends on his tendency to get sick. So it is still open the 
argument that asks if this system is ethical or not. 
From 1st January 1998 the state abolished the centralized health taxes and passed to a system 
configured like the one in the previous figure. Around 50% of the contributions come from 
the VAT(IVA) and other state taxes, the other two contributions arrive from the Irap 
(Regional tax on productive activities) that depend on the employer and the Irpef (tax upon 
the wages of physical persons) that bundled cover for about the 35%. The autonomy given to 
the regions allow them to raise this tax of 0.92, raise or low in addition to the 3.9% that they 
request to the employers and to raise of 0.5% the 1.23% that they request to the employees. It 
needs to be said that the Healthcare Expenditure covers the biggest quota within the regional 
expenses. 
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Sources Families Firms
Modality Insurances quotas Ticket(OOP) Irap,Irpef VAT
Derived Sources Regions
Payers Insurances Asl
Providers Hygene General Medicine Pharmacy Hospitals
Receivers Families  State Firms
SSN Budget
 
 
 
A critical point in process of money transfer between state-regions-ASLs is the calculation of 
the single-region quota. Italy’s regions are profoundly different, in people number and age 
distribution, as well as typical illness and lifestyle. So a function to distribute the resources 
had to be introduced. As first thing the fund is divided in three level: Collective (5%), District 
(51%) and Hospital (44%) assistance9. Then the District assistance is divided in the sub-
levels. Some of these sub levels are weighted to divide the fund between the regions. This 
process ends with a formula that calculate the financial requirements of every region. The idea 
is to multiply the residing population for a medium value for inhabitant, corrected with health 
need indexes to keep count of the different medical needs by age (quota capitaria pesata): 
 
Where: 
R: need of the region “j” 
P: people resident in region “j” 
K: indicator of health needs “i” in region “j”, that is calculated multiplying the age of the 
regional population for national weighted indexes derived from the consumptive national 
consumptions 
E: pro-capita national expenses 
 
The state delivers the funds to the regions which in turn distribute them between the ASLs by 
their criteria, that usually are again the weighted per-capita quote. At the end of the chain the 
                                                 
9 Collective in this case stands for Prevention. For Hospital is considered the Hospitalization expenses and for 
District the structure inside the Asl’s area that grants the first-level of assistance 
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ASLs, which receive the state funds and the ticket paid by the users to cover their own costs 
and pay the service providers (single hospital, AOs10, pharmacy, specialists).  
The Italian legislation imposes to every region to grant a minimum level of service that every 
citizen must be able to receive, these are called the LEA, the minimum level of assistance 
(Livelli Essenziali di Assistenza). Between regions there are substantial difference and the 
state, in this phase at least, is delegating to the regions so they are achieving the full 
independence and the self-managing. Have also been instituted the practice of the inter-
regional tariff balance due to numerous citizen accessing to the cure in a region different from 
the residence’s one. Substantially the state moves some funds from one region to another 
considering where the citizen has been cured and reimburse the region that supported the 
expenses. 
 
 
1.4 - DRG system 
 
During the second reform of the SSN, with law 502/1992 and 517/1993, Italy has adopted a 
fee for service system of financing-against-service to fund the hospitals (AOs). The system is 
based on DRGs, that stands for Diagnosis Related Group. It is a system to classify illnesses 
into one of the actual 538 groups in which the catalogue is divided. It was developed by 
Robert Fetter and Joh Thompson. The original idea was to help the hospitals to consider the 
cures as products delivered by the hospitals. They had to be someway classified and studied if 
the hospital wanted to manage their profit/cost ratios. Also, this would have had the effect to 
operate a change in the attitude of the physicians that were used to act in a risk free world of 
cost reimbursement.  
The system is basically a classification of all the illnesses. The assumption is that similar 
illnesses require similar ward and consume the same amount of resources and materials. So 
the illnesses are grouped by the characteristic of the empirical treatments and the resources 
that consume (labour and not-labour), the length of the hospitalization and partially, the clinic 
profile. The objective was to create categories that could be exhaustive and derivable from a 
schematic mechanism, maintaining the numbers of categories under control, at a manageable 
level. So in this case, every hospitalization, by some characteristics, like age  and the presence 
of other illnesses, can be weighted and reimbursed through a medium tariff issued by the ASL 
to the AOs.  
                                                 
10 The AOs, as service provider, are paid with the DRG system 
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The use of this mechanism should help Hospitals and the regions to calculate the effective 
funds requirements and to keep under control the costs, making the AOs accountable and 
objective oriented.  
The system was first used in the USA, for the Medicare Program, to study the financing 
mechanism of the Hospitals. It entered in the PPS (Prospect Payment System) as way to 
calculate the cost of the single patient. Basically, every year an hospital received ex-ante an 
amount of money as if it would perform the same number of service as the previous year. The 
amount received, anyway, had nothing to do with the cost sustained to perform that operation. 
It was calculated through an equation considering three elements: the unit of payment at the 
dismissal, the DRG tariff and the outliers, those case that could not be compared with the 
common path of recovery for a certain sickness. 
Today the classes of DRGs are 25, called MDCs, from the first, nervous system disturbs, to 
the 25th HIV infections. The system works through the SDOs (Scheda Dimissione 
Ospedialiera), introduced in Italy from the USA by the Ministry of Health’s Decree of 
28/12/1991, that is compiled by the physician at the end of the hospitalization. In it are 
present all the data useful to define the classes of illnesses and the patient’s characteristics 
(age, diagnosis and surgery performed). Moreover, it contains the cost item that occurred 
during the hospitalization. 
Basically as first the patient is catalogued by an MDC and then, by the case he supports a 
surgical procedure or not, ends in the category of Medical or Surgical DRG. 
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The data indicating the procedures provided are then converted into codes, and the final DRG 
is identified. At this point the output code is useful for the reimbursement from the ASL to the 
provider, since it is associated with a specific tariff.  
The original equation, that has never been updated in Italy since its adoption, created a tariff 
book that considers the standard cost for stay in the hospital and attribute a weight to every 
treatment (every DRG code). So every illness receives a tariff, that is the result of:  
 
Where C is the medium cost for stay and  is the result of  with ci the medium cost for 
a particular kind of treatment and cm the medium cost of that class of illnesses’ cure11. 
At the end has been drafted a Regional Tariff List. 
 
This is the amount that the ASL will reimburse to the provider. The problem, for the AOs is 
that the costs are often more than the reimbursement. The tariff is underprized, as said before, 
to push the efficiency and keep costs under control. At the end of the day the deficit of the 
AOs will be anyway refunded by the region but for the macro-level is important to implement 
a constantly-improving system. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
11 Some treatments, called outliers receive the reimbursement of the full costs due to the too much deviation 
from the regular scheme. 
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Chapter 2 – The Programming & Control Systems in the 
Healthcare firms 
 
2 .1 – The Programming & Control Cycle 
 
As will be shown better in the third chapter, inside the Healthcare firms, the Cost analysis is 
made by the Management & Control department. It is a unit that has the task to collect data 
about the operations inside the firm and help the other units to reach their goals through 
periodically reports. It is a staff organ, so to say that its clients are inside the firm. It also has 
the responsibility to prepare the budget and periodically review the performances of the cost 
centres. Its operative cycle could be divided on three phases: planning (budgeting), 
controlling and reporting. Usually its cycle lasts a year, but the intermediate controls can be 
monthly or trimestral. It is an organ, born in the era of the New public management, as 
already explained in the first chapter, that actuated the need of a more precise and integrated 
analysis inside the public firms, other than reinforce accountability and reliability. From the 
General Accounting, Hospitals passed to the accrual accounting. Beside it, a new tool for the 
Hospitals, and the Health Firm in particular, has been the Cost Centres organization of the 
departments, aggregated in responsibility centres. This allowed the organizations to adopt an 
integrative way of measuring costs, and to have someone accountable for the resources’ 
consumption. So now will be shown the tools of the Management control: The Analytical 
Accounting, the Information System and the costing methods. 
 
 
2.2 – General Accounting and Analytical Accounting 
 
Due to the continuous growth of the Healthcare’s expenses, all around the NHSs have been 
implemented many techniques of budgeting and management control. Moreover, for the 
configuration of Healthcare reimbursement system, usually costs are more important, flexible 
and manageable than revenues within the Health Firms. In fact, a Health firm like the AOP, 
cannot act on price on the short period, because its services are reimbursed through the tariff 
mechanism based on the DRGs. The biggest issue for the Hospitals’ management is the 
efficiency, obtainable only through a systematic acquisition of information. In the SSN it has 
been introduced trough the 502/92 Decree12, modified with the 517/93 Decree13 within the 
                                                 
12 Art 4 Legislative Decree 502/92 paragrafo 1bis punto b):Nell’ambito della riorganizzazione della rete dei 
servizi conseguente al riordino del sistema delle aziende previsto dal presente decreto, le regioni possono 
proporre la costituzione o la conferma in aziende ospedaliere dei presidi ospedalieri in possesso di tutti i seguenti 
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“Managerialism Reform” and integrated in the last years with the Legislative Decree of the 
23/06/2011 n°118. The investiture of the Health Firms with the legal personality and the 
managing autonomy has been possible thanks to the change of the accounting system. Adding 
the reimbursement through DRG tariffs has been necessary to activate a system that allowed 
to work on cost margins. The decree 517/93 itself introduced 4 new types of Balance Sheets 
in the SSN: Plurennials, Previsional, Consumptive and Prospectical on cash14. 
Performing the Analytical Accounting is a task attributed to the Management Control. It is an 
instrument, mandatory implemented after Decree 286/99 and 229/99, to measure the internal 
performances that should lead to the responsabilization respect the target parameters. It is a 
repetitive process, total, systematic, internally oriented, that despite is conducted by a staff 
organ, is in touch with the line (Roffia, 2002). So to say that it receives and distributes data to 
the internal organs of the firm and data report that allow integrative analysis, but it is still in 
touch with the production line. It is part of the larger “Information system”, where data are 
collected and analysed. It can be divided in three parts: General Accounting, Analytical 
Accounting and Medium/long term plan (Budget and Management Control) (Facchineti, 
2007).  
The Analytical Accounting has become necessary due to the limits of the General Accounting 
(the synthetic data results and the focus about the past), when the firms needed an instrument 
that could help them taking decisions in the short period. The purpose of the Analytical 
Accounting is to elaborate data useful to strategic and operative choices and to determine the 
contribution of the single areas and responsibility centres to the generation of costs and 
profits. In the Healthcare System the Analytical accounting is focused on the costs and 
revenues in the responsibility cost centres.  
 
2.2.1 - The Information System 
 
As said before the Information System is composed by General Accounting, Special 
Accountings (between which the Analytical) and the Plan/Budget. The Analytical Accounting 
and the Budget compose what is called the Management Accounting. The Information System 
works thanks to the data, that can be of two types: Accounting and Extra-Accounting 
(Operative Facts) (Facchineti, 2007). Both must be considered when producing the reports on 
                                                                                                                                                        
requisiti: b) disponibilità di un sistema di contabilità economico patrimoniale e di una contabilità per centri di 
costo; 
13 Legislative Decree of 07/12/1993, Article 6, comma 1, Point d): Le regioni provvedono ad emanare norme che 
prevedano la tenuta di una contabilità analitica per centri di costo, che consenta analisi comparative dei costi, dei 
rendimenti e dei risultati 
14 Art 4 Decree 517/93 
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the firm’s activity (Balance Sheet, Cost-Centre Results, Statistics). The General accounting, 
the first and most diffused method of analysing the firm’s cost and profits is still used, but 
often is integrated with special methods of registration like the analytical one. It has been 
necessary to update the system due to the undeniable constraints that this system showed. This 
situation generated the need of a deeper level of analysis and this must be directed inside the 
firm. So the Analytical accounting differs from the general one in many characteristics 
(Facchineti, 2007) (Capodaglio, 2011): 
 Objectives: the objectives of the general accounting are limited to the determination of 
the profit, the working capital and the financial movements. The objectives of the 
Analytical accounting are multiples and, to obtain useful data, often must be changed 
also the measurement instruments and the analysis perspective. For example, the 
Analytical Accounting can be used to investigate the preventive or consumptive 
determination of cost for products or for class of products, for single operations or 
single activities (ABC), for the single responsibility centres or cost centres and finally 
to determine the prices of the products and so o set the budget and the results control. 
 Results Destination: The results from the General Accounting, or the balance sheet in 
its two parts and the integrative note, are usually destined to third parties, outside the 
firm, and to all the stakeholders. The results from the Analytical Accounting instead, 
are destined exclusively to the internal bodies of the management, to which are 
important control and directional instruments. 
 Execution manner: In the General Accounting the data collection is performed through 
the double entry method, while in the Analytical Accounting many instruments are 
considered (indexes, percentages, times). 
 The temporal period of reference: The General Accounting manages the data in a 
consumptive way, with the synthesis at the end of the year of the past management. In 
the Analytical Accounting the data collection is both preventive and consumptive, the 
preventive to obtain info for the decision and the consumptive to analyse the gaps 
from the budget projections. These operations have frequencies shorter than a year, 
usually trimestral. 
 Spatial Extension of facts: The General Accounting measures only the firm’s facts that 
influence the profit or the capital while the Analytical Accounting detect every fact 
that is possible to measure and moreover, the costs (there are costs that are detected by 
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both the Analytical and the General Accounting and costs that are detected by only 
one of them15).  
 Detection Moment: The General Accounting attributes importance to the phenomena 
when they appear trough numbers (financial moment) while for the Analytical 
Accounting a fact is relevant in the moment it consumes some resources or generates 
results (technical moment) also not economical. 
 Operational Destination: In the General Accounting, revenues and costs are divided by 
causal criteria, so by nature. In the Analytical Accounting instead, the costs are 
divided by destination, or in relation with the cause of the operation itself. 
 Compulsoriness: The General Accounting is compulsory while the Analytical 
Accounting not always. In the case of the SSN it has been made compulsory after 
1992. 
As the purposes of the General have been already showed, so there have to be explained the 
aims of the Analytical Accounting, that are different from those of the first. They are, the 
control of the costs in order to reduce them, to verify the firm efficiency, the control of the 
activity, to verify if they follow the program, to control the prices and to take decisions about 
marketing, wage policies and sales. Moreover, it must not be forgotten that the two types of 
accountability are connected, in fact the General furnishes data to the Analytical Accounting. 
 
 
2.3 - Cost accounting in the Healthcare Firms 
 
 
As any other firm, in the Health firms the cost analysis is fundamental. For the special nature 
of the reimbursement system in this kind of firm, the focus on the production efficiency has a 
predominant role in the short term performance control. Through the DRG tariff in fact, the 
Health Firm receive a reimbursement that often do not keep count of the cost sustained to 
produce a certain service. So the Firm must actuate a policy of continuous improvement of the 
activities and cost reduction. The literature about the cost says that the costs can be divided in 
categories. And that they behave differently due to their different nature.  
2.3.1 - Cost Classification 
 
The first possible cost discrimination is the one that follows the production volumes’ 
variation: the variable, fixed and semi-variable costs distinction. The accountant can 
                                                 
15 The cost of the resources interests both the AA and GA, the figurative costs are detected only by AA and 
Accounting expenses are measured only by GA. 
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distinguish the costs thanks to the movements respect to the units of output produced. The 
output level is variable is usually due to the demand, the production conditions, the 
environment and many other external factor, actually, is almost impossible that a firm 
conserve its output level stable. The firm adjust the level to maintain itself competitive in the 
market and not generate too much unsold warehouse. This change obviously generates 
changes on the costs. Maintaining the example of the NHS, the costs change with the more 
people accessing to the cures. But what costs change?  
 
2.2.1.1 -Variable Fixed and Semi-Variable 
 
Variable Costs 
 
The variable costs, that are those costs that are susceptible to changes of the production level. 
This class can be sub-divided in three other classes, the proportionally variable, the degressive 
and regressive proportionally variable. The proportional vary with the same path of the output 
level, so they are represented by the equation  
 
To know the cost for one unit it is sufficient to divide the total cost for the N° of output.  
The Degressive costs are those costs that vary less than proportionally, but still in the same 
direction of the production level. For example, when the N° of output is doubled the sum of 
the cost increases but less than the double. The equation that represent this cost is:  
 
Progressive costs (more than proportional) are those costs that vary in the same direction of 
the N° of output but more than them. If the volume doubles the costs are more than double. 
Usually this happens when in the production the level is over the optimum production 
quantity. The function is:  
 
The fixed costs        
     
Are those costs that do not vary with the output level, they remain stable most of the times. It 
must be said that could change for very big variation of production level, but in the order of 
double production, non for small changes. Moreover, they change slightly in long time 
horizon, due to factors not only productive. The distinction of variable and fixed costs is 
important only in a short period perspective due to the possibility of affecting of the decision 
that this data imply.  
Fixed cost are characterised, in the short period, by a constant trend. The only thing that varies 
is the fixed cost portion for unit produced, that is obviously decreasing. To perform a 
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complete and correct Management Control activity inside a firm it is necessary to understand 
and detect the distinction among fixed and variable costs, starting from the budget and the 
production plan, the firm must be able to estimate the costs (fixed variable and semi-variable) 
and use this data to manage them. The instrument of the flexible budget, with simulation of 
multiple case-scenario, is based on the cost projection and management. With the 
consumptive data then the firm will analyse the margins and the gaps. 
Semi-Variable Costs 
 
These costs are characterised by no changes within some intervals and changes when the 
production exceed those limits. These costs are constituted by the sum of fixed and variable 
components. Their formula is:  
With K the fixed component, b the unitary cost and X the variable component used. There are 
two semi-variable costs categories: the first in which the fixed component is easily separable 
orm the variable one and the other called “a gradini” (where the separation of fixed and 
variable components is subjective and an accounting choice) (Amodeo, 1960). 
To separate the two cost components there exist various methods, including mathematical and 
statistical. They are: the method of the two activity volume, the graphic interpolation and the 
least squares method.  
‐ The two activity volume method consists in calculate the difference between two 
volume of activity and between two costs. So the unitary cost Cu is given by 
 
And the fixed cost is obtained multiplying Cu for Q2 and subtracting C2 
 
‐ The Graphic interpolation method is based on the representation in a Cartesian 
Diagram of the costs, considering cost in the Y and quantity in the horizontal axe. 
Then it is sufficient to draw a line crossing the dots drafted, leaving an equal number 
over and under and then extending to the axes. In this way there appears the fixed cost 
‐ The least squares method is the most precise and reliable one. On the other 
hand, is more complicated and articulated. The interpolating straight line is 
represented by an equation, usually y=ax+b. The two variables “a” and “b” are 
obtained resolving with the equation of the least squares16. 
 
Special and common 
 
                                                 
5 Tot Cost= a + xb, where x= units produced, y= cost sustained, n= number of measurement, a= (∑xy-
∑x∑y)/(n∑x2-(∑x)2), b= (∑x-b∑y)/n 
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Another criterion to determine the cost is to differentiate them between special and common. 
This distinction has the task to detect whether the costs are relative to a single or to multiple 
outputs. A cost can be called special if can be referred to a single object, or service and so can 
be registered in the Information System with no doubt. More difficult to attribute are the 
Common costs, those costs that participate to various processes or that contribute to many 
outputs. They need a criterion to be attributed and distributed. These criteria allow to 
distinguish between specializables and not specializables. The first can be attributed to output 
factors trough some parameters, on the other hand for the latter is impossible to find adequate 
parameters if not strictly subjective or discretional. The issue with this kind of costs is they 
are not manageable if not attributable.  
 
Direct or indirect costs 
 
The Direct costs are those costs that can be attributed to an object directly, not passing 
through parameters or cost centres. The attribution of the cost to the object follows a 
functional  or physical criterion. The direct costs are always variable. As indirect cost, instead, 
it is possible to define all of those negative components that cannot be destined to the product 
directly and need a “overturn”17 through parameters. 
Controllable and Not Controllable Costs 
 
The last classification attributable to costs is about the control the firm can have on them. 
Some costs are simply not manageable. This distinction is the first to be done in the 
Management Control process, along with the decision of the controller of that cost, that 
possibly will stick to the budget.  When defined a cost centre, or the centre where the costs are 
grouped (buy may not be originated there), it is also necessary to define a Responsibility 
Centre, where are grouped only the cost generated inside it. Inside the responsibility centre is 
performed the efficiency and the strategic control. Every choices and strategy is here verified 
and analysed by its cost-profit analysis. Thanks to the budget then will be remunerated 
through prizes those cost centre that well performed and punished who under performed. 
The uncontrollable costs on the other hand, cannot be attributed to the single centre. 
 
2.3.2 - Costing Model in Healthcare 
 
Before talking about costing model, it must be defined what a cost is for an organization and 
how it is generated and detected. As cost, in management control, is defined everything that 
                                                 
17 Ribaltamento 
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consumes resources for a useful purpose (Facchineti, 2007). Some clarification must be made 
about the cost: it is a nominal value, so it may change with the change of the analysis 
perspective. Often is an abstract quantity, in the sense that the analyser ignores all the 
conjunctions that it has with many other components that affect it value. For example, in the 
General Accounting the cost is something that ends up only in the profit calculation while in 
the AA the cost is used to calculate the margin on some product and its resource consumption. 
As said before it is different also the time of the detection (in General Accounting the 
purchase moment, in Analytical the moment of the consumption). So different way of 
considering and analysing costs exist, which are called cost-configuration. These 
configurations follow different criteria, as said before. The cost can be classified as variable, 
semi-variable or fixed, referred to the object, so they differentiate between special or 
common, or defined through the modality of attribution, and so they are direct or indirect, 
controllable or not and as last how they are used, so that can be consumptive or budget 
(preventive). So every possible analysis, at turn, exclude some elements and include some 
others. 
 
2.3.2.1 -  Full costing and direct costing 
 
Usually the economic literature identifies two costing methods. They both need the Analytical 
Accounting to be performed. 
Full Costing 
 
The full costing method is a pretty simple method of costing that allows to attribute the 
common costs to the products through some drivers chosen by the Control Management. To 
the product are allocated all types of costs possibly related to it (direct, indirect, variable, 
fixed, special or common). The principle adopted by this method is the full absorbing of the 
costs participating to the process, by the product. The costs are attributed to the object even 
without a biunivocal relationship between the two. So it will be necessary to elaborate some 
sharing method to attribute the indirect costs to multiple products. These criteria usually are 
two: with an unique assigning criteria or with the distribution of the costs to the cost-centres 
and then moved to the objects. The first method is implemented adding all direct costs to the 
product and then the fixed costs are divided with the chosen drivers (time, space, operators, 
value of direct costs). It is an easy method, that is also very subjective so the quality of the 
calculus is consequential to the strength of the causal link between the cost and the process. It 
is not possible to elaborate a criterion valid for all the situations, the choice will be different 
depending by the product and the processes. Before the mechanization, the main criterion 
39 
 
followed was the labour (by the workforce), but with the arrival of machines that do most of 
the work and with services economy expanding, they had to be changed.  To overcome these 
issues, there exist a method called “Full costing on Multiple Basis”. It is applied inside 
complex firms, usually multiproduct, where an intermediate cost aggregation can be 
established, in other words to develop a cost centres system. Inside this centres are collected 
all those cost components that cannot be destined directly to the product. From here they are 
reversed to the different products or services. The identification of multiple cost bases must 
stick to the different cost classes of the production factors. For each class of costs can be 
found the most appropriate base, and obviously the costs that can be grouped are put together. 
The bases can be mostly two: those which evidence the absorption of services by the final 
product and those which follow some dimensional criterion to attribute the consumptionss. 
 
Direct costing 
 
Simple direct costing 
It is a simple method of cost attribution that put on the product only the variable costs. The 
fixed, are not considered. They are subtracted at the aggregated contribution margin to 
develop a BEP analysis. The output product in fact, has to cover the variable costs and leave a 
portion of margin to cover also the fixed costs. The problem is that, in this method, the fixed 
costs are not allocated through special and common and so the result is not useful to manage. 
For example, the special fixed cost portion attributable to a product, if no managed, leads to a 
missed comprehension of what the product relay cost and do not allow the efficiency 
reachment. 
Evolved direct Costing 
This method allows to overcome the limits of the simple direct cost, in fact it is based on the 
distinction between fixed and variable costs, and split the fixed between special and common. 
Through this method it is possible to calculate the first level margin and the second one, 
impossible with the previous system. The fixed costs are not added together but split in 
special, attributable to the product or service, and common, counted only in the aggregated 
second level margin. This method is applied on firms multiproduct and multidivisional. This 
calculus method is the base for the choice of Make or Buy.  
 
2.3.3 – Activity Based Costing: Development and Application 
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One of the last methods to study costs, and the one I will adopt in the fourth chapter, is the 
ABC, a new (when it was invented, in the 80’s) way to think about cost destination. It was 
invented and perfectioned by Robert Cooper and Robert S. Kaplan18 with many articles and 
case studies19. This method was appreciated since its invention by professors and 
professionals of the field. The idea is that the cost is no more attributed to the Cost Centre but 
to the Activities. It is a Full costing application, because it considers the Direct costs and the 
Indirect costs allocated between special and common. It ignores the concept of Production 
Volume or quantity, but focus on the Activities. The core concept is that the Activities 
consume resources, and generate costs, on the other hand the products requires activities. So 
the products generate costs in an indirect way. The problem that this method solves, is that the 
“old” costing techniques, focusing only on the product production, lose some information on 
the activities conducted inside the firm, on the other hand, the ABC can study all the activities 
performed and attribute them to the final product, so it is useful also for the price definition. 
In the end the costs are attributed to the products through a two steps procedure: as first the 
costs are attributed to the activities, and second the activities are attributed to the products. 
This method isn’t just a measurement technique, it is also a “Cost Management” instrument, a 
Management Control tool and a help in the Make or Buy decision. It can be said that the 
products’ production does not generate costs, it generates only activities, that require 
resources to be performed. The application of this method has been vast thanks to its 
characteristics. In fact, the ABC, contrary to the classic cost centres configuration, where the 
cost centres were extremely detailed, but lost all the service distribution activities, allows the 
Management to overcome this separation between production and activities necessary to it, 
and to develop an organic view of the firm. Basically the ABC method substitute the cost 
centres one. This approach consists in allocating the cost to pools, called cost centres, that are 
operative units that are identified by operative criteria. The cost centre can be: intermediate, if 
its costs are attributed to other cost centres, final centres, if their costs are attributed to the 
final products, virtual centres, if created artificially to collect general cost or auxiliary if its 
cost are attributed to the production support. With this method the calculation of the product 
cost is developed by a driver that represent the “usage” of that centre in the production of the 
final product or service. Through this driver, called unitary coefficient, the total cost, 
attributed to the cost centre, is allocated to the output. This driver usually refers to the 
                                                 
18 Professors at Graduate School of Business Administration in Harvard University 
19 R Cooper, RS Kaplan - Harvard business review, 1988 
Cooper, R. 1990. Implementing an activity-based cost system. Journal of Cost Management (Spring): 33-42 - 
Cooper, R. and R. S. Kaplan. 1992. Activity-based systems: Measuring the costs of resource usage. Accounting 
Horizons (September): 1-13. 
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workforce or time consumption. Often, inside the firms, the indirect costs are allocated with 
indistinction between resource consumption, especially in multiproduct firms where products 
may require different amount of resource consumptiond. In the end the product cost 
calculated like this does not allow to study the real resource consumption. With the ABC, 
instead, some indirect cost can become direct, through the Activity study, so the Product Cost 
will be more objective. 
Identifying the activities allows to identify numerous and more accurate Cost Driver, that will 
allow the Activity Pool to be better distributed between the costs. A new element is also that 
the activities are Transversal respect to the Production, some activities can be referable to 
many products and this is the strength of this Measurement System. At the same time, it is a 
help for the accounting system, the analytical one, to whom offers information about the 
activities and the product costs. So in potentially help in increasing margins also in activities 
disconnected to the physical production.  
 
2.3.3.1 -  The ABC phases 
 
The ABC method is characterised by different phases. Some authors group them in three, and 
other include the phase anticipating the application of the method. I choose to develop the 
method in 4 phases, as I will do in the case study:  
1. Allocate the resource directly to the products, or services (Direct Costs) 
2. Identify the activities that are performed in a department or in a firm 
3. Allocate the indirect costs, or the resources that are not directly attributable to the final 
product or service to the activities (Cost Pooling) 
4. Allocate the activities to the products, through the cost drivers 
 
Activity 1
Activity 2
Activity 3
The ABC Method
Direct Costs
Products / Services 1
Products / Services 2
Indirect Costs
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If the first step is easy to do, from the second on there are a few conceptual difficulties that 
the Manager may face. For example, before identifying the activities, it must be kept in 
consideration that the activities, to be defend, needs some requisites. They consume resources, 
generate costs and are absorbed by the products. All the indirect costs must be allocated to 
some activity, even if they are administrative, selling or marketing costs. All the activities 
inside a firm are addressed to produce products, and for this reason all costs must be absorbed 
by them. All costs are considered variable, since they are connected to the cost-driver, that are 
subjective. The attention is focused on the non-productive activities, the most difficult to 
attribute to the products. They usually vary not with the production volume but with the 
complexity of that activity, so it need elaborated cost drivers. 
It can be said that with the ABC the firm is looked with a horizontal optic, not vertical like the 
cost centres division. In fact, the activities are all at the same level and the processes run 
through them. As last the activities allow a systematic analysis of the firm, and overall a study 
of the steps that really add value to the product, and influence the profit. 
 
2.3.3.2– Identification of the Activities      
 
 
The meaning of Activity, as defined by Porter is: “All those actions that physically, 
technologically and strategically distinct that a firm implement to project, produce, sell, 
deliver and assist the products (Porter, 1985). So every activity needs some resources, has an 
object or client, has a definable output and is measurable with indicators (Roffia, 2002). To 
identify an activity, according to Roffia, would be sufficient to ask where and how the 
resources are consumed. Technically they could be almost infinitely subdivided (micro 
activities, elementary tasks etc.) but this would lead to a too complicate analysis system. It 
depends how much margin a firm supposes to have on the activities and where it thinks that 
the value is created or lost.   
 
Activities can be classified like this (Cooper-Kaplan, 1998): 
 Unit Level Activities: Those Activities necessary to the realization of the good or 
service. Usually there exist a quantitative relation between the goods or services 
produced and the resourced consumed. The cost of these activities can be attributed 
proportionally to the number of output produced. 
 Batch Level Activities: Those Activities that are performed when a batch of product is 
realized. 
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 Product Level Activities: Those activities referred to the projecting, engineering, tests, 
controls, in short all those process that supports the birth of a product. 
 Order related Level Activities: Those activities that are referable to the orders by the 
clients. 
 Customer Sustaining Level Activities: Those activities directed to specific clients, like 
visits to vendors, technical support and assistance. Not connected to products but to 
clients. 
 Channel Level Activities:  Those activities performed only in some selling channel, 
like advertising campaigns for specific channel. 
 Product Line Level Activities 
 Brand Level Activities: All those Activities relative to the maintenance of the brand, 
its revitalization and Management 
 Facility Level Activities: The category for all the activities that cannot fit in the 
previous and are indirect. Usually here there are production support, selling support 
and central structure activities. 
With the definition of activity, a firm can proceed to identify the various activities of its 
organization. Usually the first step is to identify the elementary processes. They are 
aggregation of activities, and so the best way to identify them is to ask to all the responsible 
of the cost centres which activity is performed inside it. Keeping in mind the Organizational 
chart it can be done through a simple survey. The special focus in this phase is on the 
production support activities, which carry the most of the indirect costs. They can be logistic, 
balancing (warehouse management), quality control and change (those activities that help to 
modify the firm structure at the organizational and production level) (Moisello, 2000). As 
already cited, Porter furnishes a criterion to detect the activities over the survey. It can be 
done following the Value Chain by Porter (Porter, 1985). 
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(Porter, 1985) 
 
This is the Activities configuration inside a firm following the Porter’s model. They are 
divided in Primary and Support Activities. The primary are: 
 Inbound Logistic, that are about the arrival, warehousing and resource acquisition. 
 Operations, all of the transforming activities on the resources that make the product. 
 Outbound Logistic, or the management of the final products 
 Marketing and Sales, or the activities through which the goods are sold and the 
management of the channels through which the customers get to know the firm. 
 Service, or the activities that aim to better or add value to the product in the market 
So can be considered primary all those activities that are implemented in the Physical creation 
of the product, its selling and transfer to the purchaser, and the post-sell assistance (Porter, 
1985). 
The support activities are characterised by the act that sustain the primary and furnish 
themselves inputs, technologies, HR and other functions (Porter, 1985). Porter detect these: 
 Procurement, or the activity of input acquisition 
 Technology development, or those activities that aim to better the products and the 
processes20. 
 HR Management, or the research, hiring, training and motivating the workforce 
                                                 
20 Porter call this activity “Technology” avoiding on purpose the Research & Development name to give a 
broader meaning, in fact keeping the technology updated means also updating the research method 
45 
 
 Firm Infrastructure, or those activities related to the Direction, Management, 
Financing, Quality control and relation with stakeholders. 
These distinction of activities is helpful to determine those activities that add value to the 
product or service and eventually improve the efficiency and efficacy. Obviously after the 
detection of the activities they have to be grouped in homogenous categories to simplify the 
calculus of the cost ant the cost driver choice. 
 
2.3.3.3– Attribution of Resource Cost to the Activities through the Cost Drivers    
 
The Cost Drivers are tools used to attribute a consumption of resources to an activity. Since 
not all costs can be directly ascribed to a specific activity, like the workforce that operate in 
more than one activity, when it is not possible to measure the time of application to a task, or 
a machinery in which is impossible to define the occupation per job, there is the need to 
elaborate some criteria to allocate these costs and define the amount of consumption of 
resource that the single activity needs. These criteria usually are mathematically expressed 
with some variables, it is the case of time, quantity of production and historical data. These 
are all subjective decision by the controller, that anyway need a correspondence with the real 
(causal relationship). These cost drivers must, in any case, allow to establish a direct and 
proportional relationship between the resource and the activity. The sum of all the cost 
associated will give a cost following the Full-Cost criterion. 
 
2.3.3.4– Attribution of activity cost to the Objects through the Activity Cost Driver 
 
 
When all the costs are distributed between the Activities, the next step is to impute the 
activities, proportionally, to the products. This is possible with Activity Cost Drivers. The 
important is to detect or create parameters through which link the activity (and its costs) to the 
final product or services. The innovative point of the ABC, in this case too, as the cost driver, 
is het the parameters chosen can also not be linked to the production quantity, and the sharing 
criteria is not proportional to the number of output produced. The decision about the choice of 
the cost driver are usually two: How many and Which cost driver choose. About the question 
of how many cost drivers choose, it must be said that higher the number of the cost drivers, 
more strong the causal link and better the analysis, but to high limits the analysis flexibility 
and speed. When more activities have homogeneous consumption of resources, they can be 
grouped in a resource pool and for them can be used only one driver (Roffia, 2002). Usually 
the choice of the number of cost driver should keep in count three arguments, the umber and 
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diversification of products, in fact if two objects utilize the activity in two different ways and 
quantity, it is better to elaborate at least two activity driver. The second element is the cost of 
aggregating the activities, and the third is the difference in the production quantity. If two 
products are produced in quantity very different, the N° of output will not be a good criterion 
and maybe considering two of them are better. The choice about which drivers to choose 
instead, should be based on the ease of getting the data, the behavioural effect induced by the 
driver and the correlation between the real consumption of resources and the consume 
indicated by the cost driver. The ease must be taken in count because the analysis should be 
economical, and minimize the measurement cost. Should be chosen parameters that are 
already known inside the firm and of easy access. The behavioural effect can be dangerous 
because if a worker knows he is measured, he may change his rhythm and efficacy. So the 
measurement should be taken always in agreement with the worker or letting him know the 
aim of the research. As last the correspondence of the consumption with the quantity indicated 
by the parameter. It should be kept in account when the driver expresses the consumption 
indirectly, so it is not immediately applicable on the real cost.   
 
2.3.3.5– The next step: Time Driven ABC 
 
An evolution of the model ABC is the Time-Driven-ABC. It is a tool, added to the basic 
ABC, that allow to distribute the indirect costs to activities and to products basing on time, it 
is clear that require mechanic measurement to be performed. The principal idea is that the 
costs are transferred to the objects through time criteria, so time is used as cost driver. The 
advantage is that the cost measurable by time does not need to be elaborated though 
mathematical operations, if not the calculus of the cost per hour, and then is applicable 
directly to the activity. Moreover, here is not need to interview the workers, because thanks to 
the measurement the time dedicated to the activities is clear (Kaplan&ANderson, 2007). 
This model requires two type of calculations: 
 
 
So as numerator it should be considered all the costs associated with supplying the resource 
(if it is a worker it would be the wage), as denominator the capacity, so the available time21. 
As second, “must be used the capacity cost rate to drive departmental resource costs to cost 
                                                 
21 In Kaplan and Porter “How to solve The Cost Crisis in Healthcare” (Cooper&Kaplan, 2011) is explained a 
pretty clear example: Annual compensation of a Physician, divided by month, and this value divided by hours 
available for him to work in a day multiplied by effective workdays in a month 
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object by estimating the demand for resource capacity that each cost object requires” 
(Kaplan&ANderson, 2007).  This tool needs only an estimation of the time requested by a 
client or order to be processed. It is sufficient to catalogue the activities’ variability and 
elaborate equations that give back the time for a certain operation with certain characteristic. 
The advantages of the TDABC over the ABC are: 
‐ the major speed and the expense reduction to the measurement 
‐ the more analytical definition of the variables and the availability of the capacity 
utilisation data 
‐ more access to efficiency analysis 
‐ estimation of the unused capacity 
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Chapter 3 – AOP 
 
 
3.1 – Organisation History and Important Numbers 
 
 
The Azienda Ospedaliera Di Padova (Padova’s Hospital) was formally born in 1994 
(Regional Law n°56 of 14/09/1994), but its institution type derives from national law 
30/12/1992 n° 502 (See chapter 1). However, the History of healthcare in Padova is very long. 
It starts in the fifteenth century with the Saint Francis Hospital. In the 1764, it became a very 
innovating institution thanks to the mix of treatments, education and experimentation. The last 
innovation was in the 1798, when, after a vast funds collection and a new project, the 
structure in the area that is still used today was completed. Until 1890 it remained Institution 
of Public Assistance and Charity (by law 17/07/1890 n°6792) and then converted to a public 
institution in 1968 (law 12/02/1968 n°132). As already explained in the first chapter, the 
reform of the NHS (SSN in Ialian) created a new type of institution, the Azienda Ospedaliera 
(Health Firm). This reform interested a few hospitals in Italy, in fact every Hospital that had 
certain characteristics could pass form a pure public institution to an institution with a 
particular autonomy and receive the name of Azienda Ospedaliera (i.e Helath Company). 
With law 16/11/2001 n° 405 the SSN allow every region to institute autonomously AOs, as 
long as they meet some characteristics. They are:  
 To have a departmental organization 
 To have a Cost Centres Analytical Accounting 
 To have least 3 Operative Units defined as “High Specialization” 
 To have a Second Level Emergency Service 
 To perform Integrated Regional Projects with the role of central Hospital 
 To Hospitalize at least 10% more of the medium hospitalized patients from other 
regions, respect to the region 
 To have a Hospitalization Complexity Index at least 20% more respect to the region 22 
 To have a personal real estate that allow the institution to perform its activities 
Thanks to these characteristics the Hospital of Padova could separate from the Local Health 
Trust and obtain the qualification that led it to have autonomy as long as responsibilities. In 
                                                 
22 It is an index that allow to confront the complexity of the patients treated. It is calculated through the ratio 
of the average weight of hospitalization of an Institution over the average weight of the national or regional 
hospitalization 
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fact, a General Director was nominated and held responsible for the results, economical and 
of performances.  
Due to the special nature of the core business of the AOP, merit goods, the firm has specified 
its institutional purposes and its core values. They can be found in the Corporate Deed (AOP, 
Atto Aziendale AOP, 2015) at article 4 and 5. The 4, states that the AOP helps the Regional 
Health System to pursue healthcare in the Padova area, and to offer high specialization in all 
the Padova province and in the Veneto region. The second aim is to contribute to the teaching 
Medicine in the Università di Padova.  
Its core values are (AOP, Atto Aziendale AOP, 2015):  
 People Centrality 
 Equity 
 Quality (of the Assistance and of the Management) 
 Teaching and Training 
 Innovation & Research 
 Ethic 
 Full transparency 
 Sustainability 
In the end the Vision of the AOP (art 6 Corporate Deed) is to be a firm oriented to: Realize 
the SSSR integration, to be the reference Institution for the Regional Healthcare, to maintain a 
central scientific role in the National Healthcare System, to promote the birth of assistance 
institutions in poor areas of the world and to develop a new model of collaboration between 
the AOP and the Padova University. 
These are the numbers that, in short, describes the AOP (AOP, 2016): 
 
Services Produced: 
110.388 First Aid ER accesses  
60.218 Hospitalizations 
61% Emergency Hospitalization 
45.044 Surgery Acts 
7.118.892 Outpatients Services  
5.757.048 Laboratory Tests 
6.310 High Complexity Hospitalization 
246 Million Euro as Hospitalization Value 
258 Organ Transplant 
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11% Extra-Regional Attraction (as compulsory to maintain AO status) 
 
About the HR:  
4733 employees, 960 volunteers 
74% women, 26% men 
Professional Role: 72% Healthcare, 19% Technic, 8% Administrative, 1% Professional 
 
Student Employees: 
2.758 student from Medicine and Surgery School 
400 apprentices, 376 in Post-Laurea Apprentice 
1.125 Specializing Students 
 
About the Facilitites: 
52 Buildings, 250.000 square meters 
 
 
3.2 –  Organizational Structure and Management Control System 
 
The organizational structure of the AOP can be derived from the Corporate Deed, the 
document, required by Regional Law n°56 of 14/09/1994, that give legal personality and 
management autonomy to this Health Firm. At title 2, page 12 (AOP, Atto Aziendale AOP, 
2015), this Act describes the bodies of the AOP, the main three are:  
 General Director 
 Board of auditors 
The general Director, nominated by the Region and the dean of the Padova University, 
dispose of the Management Power and the legal representation of the firm. He/She is 
responsible of the achievement of the goals of the organization and of the internal control. 
The two managers that collaborate with the him are the Health Director and the 
Administrative Director.  They manage the network of all the directors of the departments, the 
first focusing about the Hygiene and the Healthcare services, the latter about the management 
aspects.  
The Board of Auditors, instituted by Law Decree 502/1992 is a collegiate body, that is 
responsible of the institutional control of the firm respect to the law and the economic 
principles. It is nominated by the General Director, and lasts for 3 years.  It meets monthly 
and communicate to the region about the management and the institutional facts. 
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The Advisory board (Collegio di direzione), instituted by art 17 of Decree 502/1992, is a 
collective body too, that helps the General Director in the in the management of the clinical 
activities the programming of the Health activities, the organization and implementation of 
the services and the management of the human resources. It is composed by the General 
Director, the Health Director, the administrative director and the director of every Department 
of the hospital. Its tasks are: to help the General Director, to help elaborating the Activity 
program of the firm and to support the decisions about the purchasing of operative areas and 
about the operational plan of the firm. 
 
 
 
 
3.3 – Planning & Control Process in the AOP 
 
Due to its special institutional nature, a firm, in the AOP, by regional law 55/1994, all the 
strategic and operational choices are founded on the National Health Plan and the Regional 
Plan23. The law says, moreover, that the Hospital must draft a General Plan that:  
 Must be consistent with the regional plan 
 It must be adopted within the 31 December 
 It is annually updated 
The plan is Economically interpreted through the Preventive Triennial Balance Sheet which is 
divided in Economical, Financial and Net Assets. At article 13, law 5/94 prescribes also an 
annual Programming that leads to develop the Preventive Economical Balance Sheet, that, in 
                                                 
23 Regional Law 14/09/1994 Art 1 
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turn, is monitored through trimestral or monthly Control reports that evidence the gaps 
between the budget and the consumptive performances. This activity must be performed by 
the Management Control. The final prospect about the performances is the Annual Report (ex 
art 19) that closes the measurement period at the end of every year. 
After law 150/2009, another planning document was introduced, the Performance Plan. Since 
both documents cover a 3-year period and fulfil the same purposes, the Hospital edits and 
approves only this last one, responding in this way to both legal requirements. 
These are documents that the AOP uses to plan and monitor and report its activity (AOP, 
http://www.sanita.padova.it/sez,3652, 2016): 
 
  
 
The pluriennal Performance plan is then contextualized into an annual document called 
“Documento delle Direttive”, which includes the many goals set for the Company by the 
Regional government. 
Beside the Health targets, the Hospital has also balance sheet aims. As known, the Public 
health firm have not profit goals. Their institutional goal is to produce Health outcome 
respecting the budget, or in other words, being sustainable and not generating losses. Due to 
the complex financing system and the planned underfinancing by the central state and the 
region, this is not always possible, but recently, at state level, have been implemented the so 
called recouping plans (i.e. Piani di rientro) for the regions to forecast and plan the economic 
equilibria.  
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The Budgeted Balance Sheet of the AOP for the 2016 reports an annual Production Value 
around the 500 mln Euros, which is mostly composed by the revenues for the treatments 
performed (411 mln), reimbursed through the DRG tariff. The rest is the region Financing (79 
mln).  
The cost of the production amount to 606 mln. So the year result is a loss of 90 mln Euros 
that, added to the taxes for 16 mln Euros, brings the economic result of the year to a total loss 
of 105 mln Euros. 
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AZ.OSP. PADOVA
Importi in Euro
2
Anno 2016
A) VALORE DELLA PRODUZIONE 516.562.434
1) Contributi in c/esercizio 79.002.982
2) Rettifica contributi c/esercizio per destinazione ad investimenti -27.425.753 
3) Utilizzo fondi per quote inutilizzate contributi vincolati di esercizi precedenti 4.454.734
4) Ricavi per prestazioni sanitarie e sociosanitarie a rilevanza sanitaria 411.226.072
5) Concorsi, recuperi e rimborsi 18.092.478
6) Compartecipazione alla spesa per prestazioni sanitarie (Ticket) 8.821.672
7) Quota contributi in c/capitale imputata nell'esercizio 18.199.249
8) Incrementi delle immobilizzazioni per lavori interni -                                  
9) Altri ricavi e proventi 4.191.000
516.562.434
B) COSTI DELLA PRODUZIONE 606.485.730
1) Acquisti di beni 216.821.291
2) Acquisti di servizi sanitari 53.751.437
3) Acquisti di servizi non sanitari 61.228.876
4) Manutenzione e riparazione 21.671.845
5) Godimento di beni di terzi 4.316.150
6) Costi del personale 209.944.133
7) Oneri diversi di gestione 1.703.704
8) Ammortamenti 25.667.294
9) Svalutazione delle immobilizzazioni e dei crediti 546.000
10) Variazione delle rimanenze -                                  
11) Accantonamenti 10.834.999
606.485.729
-89.923.295 
C) PROVENTI E ONERI FINANZIARI -189.841 
-189.841 
D) RETTIFICHE DI VALORE DI ATTIVITA' FINANZIARIE -                                  
-                                  
E) PROVENTI E ONERI STRAORDINARI 465.373
-89.647.763 
Y) IMPOSTE SUL REDDITO DELL'ESERCIZIO 16.247.339
16.247.339
UTILE (PERDITA) DELL'ESERCIZIO -105.895.102 
Prospetto di cui all'art. 8, comma 1, DL 66/2014 - enti SSN
SCHEMA DI BILANCIO
Totale C)
Totale D)
Totale B)
DIFF. TRA VALORE E COSTI DELLA PRODUZIONE (A-B)
RISULTATO PRIMA DELLE IMPOSTE (A-B+C+D+E)
Totale Y)
CONTO  ECONOMICO
Totale A)
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More in detail, these tables show how much the constraints act on the final result. The 
Directive Plan for the 2016 (that is derived from the triennial plan 2016-2018, called general 
plan) (AOP, www.sanita.padova, 2016) offers a panoramic situation on the AOP economic 
trend. It illustrates the Budget Constraints that the AOP faced in the 2015 and will face in 
2016. 
 
  
 
Respect to the 2015 limits the IVD (In Vitro Diagnostics) is lowered, the personnel expenses 
are risen and the Drugs and the Medical Devices are lowered. As is possible to see in the next 
table, even if the costs were less than forecasted, the new constraints for the drugs and the DM 
are again less than the 2015 expenses. 
 
 
 
So the AOP administration is again stimulated to pursue efficiency, to develop action of cost 
reductions and correctness of Healthcare Goods use to respect the new limits. 
The AOP management indicates in this letter how the cause of the economic disequilibria is 
attributable to the underfinancing. This, according to the Direction, is certified and admitted 
by the fact that the region admits a Loss in the Balance sheet, even if decreasing. 
 
 
 
 
For the 2016, the Region assigned to AOP 27 objectives, measured by 53 indicators and 
divided within these areas: 
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 Observation of the guidelines about control and programming of the offices’ 
organization 
 The correct management of the resources (received and earned) 
 Health Outcome and services efficacy 
 Economic Equilibrium 
 Waiting List 
 Respect the timing ant the contents of the Informative flow 
  
 
 
From this graph, derived from “Documento di direttive 2016”, are represented the weight of 
the objectives (external circle) and the number of them (internal circle). So it is easy to 
understand how important are the objectives connected to the economic management and the 
respect of the waiting lists. In addition to the regional objectives the AOP individuated other 
objectives. Some respond to national laws and some are just internal problems that need to be 
solved. Among them, one is the transparency (by Law 33/2010) to prevent corruption. 
Moreover, the AOP is focusing on: credit collection, processes informatization and re-
definition of the processes, competences and responsibilities that were traced by the UOC 
Quality and Accreditation during 2015. 
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The Regional law 55/94, that converted in procedures what the National Law prescribed, 
introduced a new model of Accountability for the public institutions, and the AO in 
particular. The Hospitals passed from a cash to an accrual Accounting System and 
developed a Cost Centre Accounitng system. Moreover, the regional law 55/94 regards 
the Management Control System, made compulsory for all the public companies by Law 
Decree n°286 of the 30/07/1999. In the law it is defined as “the complexity of the criteria, 
instruments and procedures that aims to activate a process of programming and verifying 
the achievement of the objectives”. 
In the AOP, the accountability work by cost centres. Every centre prepares a budget 
considering the operative units inside it.  The Operative unit are grouped in a 
responsibility centre if: 
 Have homogenous activities 
 Meaningful consumption of resources 
 There exists a person responsible for the management and the result 
Inside the firm, there are two categories of centres: utilizer centres (activity centres) and 
purchaser centres (resource centres). 
The purchaser centres have responsibility over the efficacy and the efficiency of the 
purchasing, warehousing and distribution of the resources necessary to the firm’s 
operations. Moreover, they keep the General Accounting and produce trimestral reports. 
In 2016 these are the purchaser centres:  
 Accounting Centre 
 Independent Workers 
 Logistic 
 Superintendence Office 
 Informatics Centre 
 Clinic Engineering 
 Management of the real estate and implants 
 Technic tender 
 Relationships with the University Unit 
 Legal affairs 
 Human resources 
 Planning and Management Control 
 Pharmacy 
 Transfusion Center 
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The Activity Centres have responsibilities over the consumption of resources in the 
productive process, respond of the result about efficiency and efficacy. The identification of 
them is developed through the departmental model, as indicated by Law Decree 229/99 that 
overcome the Operative Unit model. 
 
They are: 
 MEDICINE -  COMPANY STRUCTURAL DEPARTMENT  
UOC Andrology and Reproductive Medicine  
UOC Dermatology  
UOC Dietetics and Clinical Nutrition  
UOC Haematology  
UOC Gastroenterology  
UOC Geriatrics  
UOC Endocrine Diseases  
UOC Metabolic and Nutrition Diseases  
UOC Infectious Diseases  
UOC General Medicine - Quick and Intensive Observation 
UOC General Medicine - Endocrine-Metabolic  
UOC General Medicine - Haepatology  
UOC General Medicine - Gender Specific  
UOC Sports and Physical Exercise Medicine  
UOC Nephrology  
UOC Rheumatology  
UOSD Coagulopathies  
UOSD Hypertension  
UOSD Thrombotic and Haemorrhagic Diseases  
UOSD Vascular Medicine  
UOSD Clinical Nephrology  
UOSD Studio and care of Cerebral Ageing (CRIC)  
 
SURGERY -  COMPANY STRUCTURAL DEPARTMENT  
UOC General Surgery 1  
UOC General Surgery 2  
UOC General Surgery 3  
UOC Hepatobiliary Surgery and Liver Transplants  
UOC Kidney and Pancreas Transplant Surgery  
UOC Multidisciplinary Day Surgery  
UOC Orthopaedics and Traumatology  
UOC Urology  
UOSD Spine Surgery  
UOSD Endocrine Surgery  
UOSD Minimally Invasive Surgery  
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UOSD Medical Emergencies and Liver Transplants  
UOSD Surgical Endoscopy  
UOSD Endourology  
UOSD Multivisceral Transplant  
UOSD Week Surgery  
 
WOMEN AND CHILDREN'S HEALTH  - COMPANY STRUCTURAL DEPARTMENT   
UOC Paediatric Acceptance and Emergency Room  
UOC Paediatric Heart Surgery  
UOC Paediatric Cardiology  
UOC Paediatric Surgery  
UOC Hereditary Metabolic Diseases 
UOC Child Neuropsychiatry  
UOC Paediatric Oncology  
UOC Obstetrics and Gynaecology 1  
UOC Obstetrics and Gynaecology 2  
UOC Paediatrics  
UOC Neonatal Intensive Care  
UOSD Food Allergy  
UOSD  Pelvic,  Minimally  invasive  and  Operational Obstetrics Surgery  
UOSD Paediatric Nephrology  
UOSD Paediatric Orthopaedics  
UOSD Paediatric Pulmonology and Allergology  
UOSD Paediatric Rheumatology  
UOSD Paediatric Hospice, Regional Reference Center for Paediatric Palliative Care 
UOSD Paediatric Intensive Care  
 
COMPANY STRUCTURAL DEPARTMENT – LABORATORY MEDICINE 
UOC Pathological Anatomy and Histology  
UOC Genetics and Clinical Epidemiology  
UOC Laboratory Medicine  
UOC Microbiology and Virology  
UOSD Cytology Diagnostics   
 
COMPANY STRUCTURAL DEPARTMENT – IMAGING DIAGNOSTIC AND 
INTERVENTIONAL RADIOLOGY 
UOC Nuclear Medicine  
UOC Neuroradiology  
UOC Radiology 1  
UOC Radiology 2 
 
COMPANY STRUCTURAL DEPARTMENT – LEGAL AND OCCUPATIONAL 
MEDICINE TOXICOLOGY AND PUBLIC HEALTH 
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UOC Occupational Medicine  
UOC Forensic Medicine and Toxicology  
UOC Preventive Medicine and Risk Assessment  
UOSD Poison and Doping Control Centre  
 
COMPANY STRUCTURAL DEPARTMENT – NEUROSCIENCE AND SENSE ORGANS 
UOC Maxillofacial Surgery  
UOC Plastic Surgery  
UOC Major Burns  
UOC Neurology  
UOC Neurosurgery  
UOC Paediatric General Neurosurgery  
UOC Ophthalmology  
UOC Dentistry and Stomatology  
UOC Otolaryngology  
UOC Recovery and Functional Rehabilitation  
UOSD Apnea and Dysphagias  
UOSD Clinical Neurophysiology  
UOSD Level 2 Stroke Unit 
 
COMPANY STRUCTURAL DEPARTMENT – CARDIO/THORACO/VASCULAR 
UOC Angiology 
UOC Heart Surgery 
UOC Cardiology 
UOC Thoracic Surgery 
UOC Vascular Surgery 
UOC Respiratory Pathophysiology 
UOC Cardiovascular Pathology and Anatomic Pathology 
UOC Pneumology 
UOSD Cardiac Pathology and Prevention of Sudden Death 
UOSD Cardiovascular Day Hospital 
UOSD Haemodynamics and Interventional Cardiology 
UOSD Pathology of Heart Transplant and Regenerative Medicine 
UOSD Cardiology Intensive Care 
 
COMPANY STRUCTURAL DEPARTMENT – EMERGENCY/URGENCY 
UOC Acceptance and Emergency Room  
UOC Anaesthesia and Intensive Care 1  
UOC Anaesthesia and Intensive Care 2  
UOC Operational Central Office SUEM  
UOSD Short Intensive Observation  
  
INTER-COMPANY STRUCTURAL DEPARTMENT – MENTAL HEALTH 
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UOC Psychiatry AOP 
INTER-COMPANY STRUCTURAL DEPARTMENT – TRANSFUSION MEDICINE 
UOC Transfusion Medicine AOP  
UOSD Transplant Immunology AOP  
INTER-COMPANY FUNCTIONAL DEPARTMENT – REHABILITATION HOSPITAL-
TERRITORY 
UOC Recovery and Functional Rehabilitation AOP 
UOC Recovery and Functional Rehabilitation (ULSS 16) 
 
INTER-COMPANY FUNCTIONAL DEPARTMENT – ONCOLOGY 
Reference to Veneto Oncology Network 
 
INTER-COMPANY FUNCTIONAL DEPARTMENT – DRUG POLICIES 
UOC Pharmacy AOP 
UOC Hospital Pharmacy (ULSS 16) 
UOC Territorial Pharmacy (ULSS 16) 
 
INTER-COMPANY STRUCTURAL DEPARTMENT – LEGAL AND OCCUPATIONAL 
MEDICINE TOXICOLOGY AND PUBLIC HEALTH 
UOC Prevention, Hygiene and Safety at the workplace (ULSS 16) 
UOC Hygiene and Public Health (ULSS 16) 
The staff of the Health Director are the UOC Medical Department "Adults", UOC Medical 
Department "Mother-Child", UOC Health Professions Department, UOC Pharmacy and 
UOSD Hospital Psychology. 
  
COMPANY STRUCTURAL DEPARTMENTS LIST 
NON MEDICAL AREA 
1. GENERAL ADMINISTRATIVE SERVICES DEPARTMENT 
• UOC General and Legal Affairs 
• UOC Hospital Administrative Department 
• UOC Relations with the University and Training 
• UOC Human Resources 
 
2. DEPARTMENT OF RESOURCES FOR TECHNICAL AND IT SERVICES 
• UOC Tender Management and Technical Area Contracts 
• UOC Real Estate and Systems Management 
• UOC Information Technology 
• UOC Clinical Engineering 
• UOC Design and Development of Hospital Construction Interventions 
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3. DEPARTMENT OF MATERIAL AND FINANCIAL RESOURCES 
• UOC Accounting and Financial Statements 
• UOC Logistics Management 
• UOC Freelance and Binding Loans 
• UOC Superintendency and Bursar 
 
4. DEPARTMENT OF STAFF SERVICES 
• UOC Communication and Relations with Citizens 
• UOC Planning and Management Control Manager 
• UOC Quality and Accreditation 
• UOSD Projects and Clinical Research 
 
 
The management control in the AOP is implemented by the department of “Planning and 
Management control”. This department, that is both a purchaser and a utilizer center, has the 
task of developing the budget process, the most diffused management control tool today. It is, 
like the management control, compulsory by law 55/94. The Management Control activity is 
developed through a three phases process: Assignment, Monitoring, Evaluation.  The Budget 
assignment is up to the strategic direction, while the monitoring and the evaluation are up to 
the management control. This staff organ develops and furnishes the infrastructure for the 
data collection to the other centers and supervise to the measurement. The Budget method 
helps in drafting the 3 documents necessary to the management: The directive documents, the 
General Budget and the responsibility centers’ budget. 
Usually a firm can assume two approaches to the budget policy, a top down and a bottom-up. 
In the top-down approach, the budget draft is demanded exclusively to the General Direction. 
Oppositely, in the bottom up, the drafting is a task assigned to all the department’s’ directors. 
In the AOP case, the budget approach is a mix. It is drafted by the General Direction and then 
negotiated by all the utilizer centers’ directors. 
 
The first phase, the Assignment process, is divided in 9 phases:  
1. The Direction individuates a responsible for the objectives 
2. This person, the spokesman, proposes to the direction a method to convert in budget 
the objective (specifying the limit value for its UO) 
3. The proposals accepted by the General Direction are discussed inside the Budget 
Committee, that suggest which objective to connect to the wage premium 
4. The Management control prepares the Budget proposes for every Utilizer Centre 
5. The proposes are discussed with the General Director and the Department Directors 
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6. The Department Directors set a meeting with the Utilizer Centers’ Responsibles and 
eventually propose some changes to the plan 
7. The Direction meets with the Utilizer Centers’ Responsibles and negotiate the 
objectives, the parameters and the wage premium 
8. All the Budget proposes are signed by both parts (direction and Utilizer Centers’ 
Responsibles) 
9. The Budgets are approved through a deliberation and published 
 
The monitoring phase allows to confront periodically the intermediate results with the budget, 
and apply the necessary measures. The intermediate data are diffused within the firm by 
Reportmed and Qlik, two informatics platforms, using reports, synthetic documents that 
collect all the variables relevant for the management control. The reporting system is taught to 
furnish to the directors the necessary data to reach to the objectives. More than an accounting 
tool it is an operative instrument, that has short-term effects on the operations and on the 
workforce. 
The reports must have some characteristics to be useful, like its form, or the way the data are 
presented, the frequency and timing, to be used to take decisions and the correctness and the 
simplicity, to be quickly understandable. They can be of various type. The principals are: 
consumptive (ex-post), pre-consumptive (monthly, trimestral or biannual, that still allow to 
take corrective actions) or forecasted, with alternative hypothesis. With this reports the 
manager, or the management control, is able to confront the results with the objectives. 
Usually this process can be divided in four phases:  
1. Confront between budget and results, and elaboration of the general gap 
2. Decomposition of the global gap in elementary gaps 
3. Individuation of the gaps’ causes 
4. Individuation of the responsible and elaborations of the corrective maneuvers 
 
At the end of the year, before the evaluation, are defined the decisional criteria to graduate the 
final results and the wage assigned to every objective. This system is implemented through 
the definition of intervals of gap from the objective. With all the collected data the 
Management Control prepares the final report, that before the publication is sent to the 
departmental directors to justify the possible incongruence or bad results. All of this process 
is connected to a salary compensation for the worker or the future budget for the department 
in the following year. 
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For example, for the 2016, the targets of the Neuroradiology Operative Unit, that will be 
taken in consideration in the next chapter, are many and with different points. 
Every target in fact, receives some points, with 100 as total. These points are divided by 
Directors and Operators. At the end of the year the two groups receive a mark thanks to the 
percentage result given by the sum of points gained (x%) 
The major classes of targets are 7, grouped by letters: 
 B: prevention of clinic risk (code 3.4), it requires the signalling of incidents on the 
workplace (10 points) 
 C: Number of reports on ADR drugs (code 13.2) (10 Points) 
 D: Respecting the cost constraints (infra annual monitoring (code 3) (10 points) 
             Respect of the Drugs cost constraint (Daily) (code 3.3) (10 points), the UO24 
consumed resource for 131.449 Euros in 2015, and the limit will be 130.000 Euros for 
the 2016 
             Respect of the cost of the medical Devices (code 3.4) (10 points) The UO consumed    
1.143.659 in 2015 and that figure was confirmed as limit for the 2016 
 E: Respect of the agreement with the ULSS 16 about the Magnetic resonances to 
perform tooutpatients (code 2) (10 Points), the UO performed 691 in 2015 and the 
new limit will be 600 in 2016 
To report the Diagnostic problem in the specialistic prescription (code 3.1) (20 Points). 
This is a new target and the limit value is at 90% 
 I: To perform a Cost Analysis (code 9) (0 Points) This target gave birth to this thesis 
 P: To reduce by 5% the vacation day of the previous years (code 1). During the 2015 
the remaining vacation days were 1355, the limit for the 2016 is 68 days of the 
previous years and 1002 days of the current year 
At the end of the year the Management Control Unit will produce a report on these points and 
the Neuroradiology will be marked. As already said this will influence the end-year wages 
and the next year’s budget.  To manage better the points scale and not to be too strict, 
considering also the nature of the operations that have to do with merit goods, has been 
established a scale with gaps. If an Operative Unit realizes from 0 to 39 points, receive the 0% 
of the compensation, from 40 to 59 points, receives the 60 %, between 60 to 79 the 80% and 
over 80 points receive the total compensation. 
 
                                                 
24 UO = Operative Unit 
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4 – AOP’s Neuroradiology’s Case 
 
Due to the necessity raised by the Neuroradiology Department, to elaborate a tariff for some 
clinic services, the Management Control of the AOP started a study to analyse some services’ 
cost. The tariffs created will be used to invoice Hospitals or institutions whom patients are 
treated in the AOP. Moreover, the particularity of this Unit is that it has no beds for 
Hospitalization, and its patients are dismissed from other units. In this case the department 
realizes no DRG reimbursement and it is therefore more difficult to perform a Cost-Profit 
analysis.  
 
4.1 – Neuroradiology Department 
 
The Neuroradiology’s Department of the AOP performs diagnostic and operative radiology 
activity directed to adult and infant patients. In general, the diagnosis are performed in the 
region of head and the spine while the operative sessions are directed to the endovascular 
illnesses’ treatment on the same districts. It is also a teaching workplace for the Padova 
University. It performs many procedures, including the ones studied in this thesis, aimed at 
treating several diseases: among others, stroke, aneurisms, vascular malformations, vascular 
tumours and carotidal and intracranial stenosis. It is a research centre with national and 
international studies about the Advanced Imaging with 3T MR Machinery.  
During 2015 this Unit performed 18.599 procedures for inpatients and 12.114 for outpatients. 
The value of these procedures is around 3.000.000 euros for the internals and 2.000.000 for 
the externals. 
The team is composed by 28 people: 4 doctors, 7 nurses, 10 technicians and 8 administrative 
employees. Their cost is about 1.400.000 Euros per year.  
 
According to Piano Socio Sanitario Regionale 2012-2016, Veneto’s health companies are 
organized into a hub & spoke system. This means that while common services are offered by 
any Local Health Trust, rare and complex procedures are performed only by major hospitals, 
where patients are referred to by the web of small hospitals. Le Schede di Dotazione 
Ospedaliera (hospital endowment) issued by Veneto Region in 2013 (DGR/CR 68 of 
18/06/2013) plan 6 Neuroradiology Departments, a number which is consistent with the 
design of Stroke Clinical Path. According to the OMS, in fact, the brain-vascular diseases are 
the second cause of death and the first of permanent disability. In particular, the stroke, in the 
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Italian context, appears between 1.5 and 2.9 cases every 1000 inhabitants (6.5% for people 
between 65 and 84 years). In the Veneto region, there are 9.000 Stroke Hospitalizations that 
result in a death in the 4.3% of the cases.  
Due to the system layout (Hub & Spoke), it happens that patients admitted to other hospitals 
are transferred to AOP in case they require complex procedures. After the procedure is 
performed by specialized services, such as Neuroradiology, in most cases the patient remains 
in AOP, originating a second hospitalization that is reimbursed to AOP according to the DRG 
tariff. In some cases, however, clinical conditions would allow the patient to go back to the 
sending hospital right after the procedure. This has several advantages: 
• the patients stay nearby his/her domicile; 
• bed’s occupation of 2nd level Departments is more efficient; 
• only one hospitalization is generated, instead of two. 
 
 
4.2 – Problems with the financing system 
 
For this system to work, a mechanism to reimburse the 2nd level hospital needs to be defined, 
as the DRG tariff will be earned only by the sending hospital, which dismisses the patient. An 
“institutional” reimbursement system has not been defined so far, therefore specific 
agreements between hospitals must be signed. This kind of agreements, besides organizational 
and clinical aspects, should arrange the economic aspect as well. It happened many times that, 
missing an institutional tariff for outpatients in the regional Agreements, the staff of the 
Neuroradiology invoiced services that were similar to the ones performed but often ended up 
in money loss or a wrong reimbursement. Moreover, the Hospitals that sent in the AOP their 
patients, after receiving the invoice, always disputed it due to the non-correspondence with 
the service received. This situation led to several economic and bureaucratic problems for the 
Neuroradiology Department and the Hospital. Besides this, the doctors of the department 
operate without knowing how much the procedures cost and cannot aim to the efficiency or 
perform a cost-benefit analysis. In this study the tariff will not be based on the DRG 
reimbursement method. The elements on which the tariffs will be based are the real cost that a 
procedure consumes. The Regional Tariff list in fact, collects the cost of the procedures for 
outpatients, that allow the treated person to leave the Hospital on its own, last less and usually 
does not consume resources as the procedures that are really performed. This leads to the fact 
that the reimbursement is much less than the real cost. I this sense, the AOP, considering that 
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often the Neuroradiology Department has no official data to invoice the sending institution, or 
ask a DRG reimbursement, will base the tariff on a real-cost study. 
This study was approved as a budget goal for year 2016 for both Neuroradiology Department 
and Planning and Control Unit. As already seen, this cost analysis will allow the definition of 
new tariffs, and subsequently the inter-hospital agreements, that will effect of the next year’s 
budget. An analysis of the Neuroradiology services had already been done in the 2010, but the 
data are now useless due to some cost changes in the resources utilized, to the overcoming of 
some scientific techniques and to the change of the drugs’ and the devices’ codes.   
 
 
4.3 – ABC approach and tariff elaboration 
 
To perform this study, the Planning and Control Unit chose the Activity Base Costing method 
(Chapter 2) because of its good adaptation in services contexts and to the nature of the 
activity, that has its better indicator in the time of the performance respect to the output 
composition. The analysis was conducted together with the Neuroradiology Department Chief 
Doctor Causin, that I often interviewed in order to obtain the data that cannot be retrieved 
automatically form the IT systems. 
 
To perform the ABC method, as already seen in the previous chapter, these steps are required: 
1. describing the activity, and each of its phases; 
2. assessing direct and indirect costs;  
3. allocating the costs, associating to each phase the type of resources adsorbed and 
pointing out the best driver for the allocation; 
A final step was then added, aimed at checking validity of results through several controls.  
 
4.3.1 – Design of the Activities and its phases 
 
The first step involved studying the Activity, breaking it up into several phases. In the 
Neuroradiology’s case, I have identified 2 groups of activities: the Preparatory and Post 
Operation Phases and the real procedure phase. While the first group is the same for each type 
of intervention, the second group varies as to resources consumption depending on the 
procedure performed, so it requires a more detailed analysis. The combination of them 
produce the complete services, the final output.  
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After describing the activities map, I compiled the activity list. The following chart describes 
the activities under study, along with the HR involved in each phase: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anaesthesist Nurse Techincian Radiologist Doctor
     
TAKING IN CHARGE
CONFIRM AND CONSENSUS ACQUISITION
ACCEPTANCE
ACCESS TO THE ANGIOGRAPHIC 
ROOM
PLACEMENT OF THE PATIENT ON THE 
TABLE
SEDATION 
ARRAGNEMENT OF THE STERILE 
ENVIRONMENT
DIAGNOSTICPHASE
OPERATIVE PHASE
MEDICATION
TAC FINAL CONTROL
MOBILIZAITON OF THE PATIENT
IF INTUBATED:
‐TI AOP
‐TI OSA if  TI AOP full
IF SEDATED:
‐ arrival departeent if 
in election
‐ stroke unit if urgent
‐Arrival hospital if 
external patient
IMAGES 
FILING
COUNTING 
AND 
PRINTING OF 
THE RX DOSE
MEDICAL
REPORT AND 
OPERATORY ACT
INTUBATION
IN EMERGENCY ( 
only from AOP):
‐ From Stroke Unit 
(Sedated)  
‐ From IT (Intubated)
ELECTIVE
‐From AOP 
Hospitalization           
(instubated or in 
aneaesthesia)
‐ From OSA and IOV 
(only in anaesthesia)
ONLT IN 
EMERGENCY: 
TAKING IN 
CHARGE
DOES THE 
PATIONET 
NEEDS 
ANAESTHESIA
?
NO
YESI
ONLY IN EMERGENCY ( IF 
NECESSARY TAC)
CLINIC RE‐
EVALUATION
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The patient can arrive from:  
If Elective Surgery 
a) From AOP hospitalization (intubated or sedated) 
b) From OSA and IOV (only sedation) 
If in Emergency (only form AOP) 
c) From Stroke Unit (sedated) 
d) From Intensive Therapy (intubated) 
 After the arrival the procedure is composed by 16 phases. They are25:  
1. Taking in charge of the patient (nurse and Anaesthetist) 
2. Acceptance (Technician and Neuroradiologist) 
3. Confirm and Consensus Acquisition (Neuroradiologist and Anaesthetist) 
4. Access to the Angiographic Room (Nurse, Operator and Technician) 
5. Placement of the Patient on the Table (Neuroradiologist, Anaesthetist, Nurse and 
Technician) 
6. Sedation (Anaesthetist and Nurse) 
 6a or Anaesthesia 
7. Arrangement of the Sterile Environment (Neuroradiologist, Anaesthetist and Nurse) 
8. Diagnostic Phase (Neuroradiologist, Anaesthetist, Nurse and Technician) 
9. Operative Phase (28 Procedures) (2 Neuroradiologists, Anaesthetist, Nurse and 
Technician). Being variable depending on the procedure performed, this phase will be 
analysed in detail later on. 
10. Medication (Neuroradiologist, Anaesthetist and Nurse) 
11. TAC final control (Neuroradiologist, Anaesthetist and Technician) 
12. Mobilization of the Patient (Anaesthetist, Nurse, Technician and Operator) 
13. Transfer of the patient (Nurse and Operator) 
13a in Neuroscience, in anaesthesia 
13b in Neuroscience, intubated or awake 
13c Other Intensive Therapy, in AOP 
13d Other Intensive Therapy, in other firm 
13e Arrival Hospital, if external patient    
14.  Room rearrangement (Nurse, Technician and Operator) 
15. Images Filing 
16. Counting and printing of the RX dose (Technician) 
                                                 
25 In brackets the operators that perform the phase 
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17. Medical Record and Operatory Act registration (Neuroradiologist) 
18. Clinic Re-Evaluation (Other Doctor) 
 
And the relative times: 
 
Name Time
1 Taking in Charge 20
2 Acceptance 5
3 Confirm and Consensus Acquisition 10
4 Access to the Angiographic Room 10
5 Placement of the Patient on the Table 10
6 Sedation 5
6.a General Anesthesia 10
7 Preparation of the Sterile Environment 5
8 Diagnostic Phase 15
9 Operative Phase
10 Medication 10
11 TAC Final Control 5
12 Mobilizaiton of the patient 5
13 Transfer of the Patient 15
13a In Neuroscience, in anesthesia
13b In Neuroscience, intubated or awake
13c Other Intensive Therapy, in AOP
13d Other Intensive Therapy, in other Firm
13e Arrival Hospital, in other firm
14 Room Rearrangement 20
15 Images Filing 5
16 Counting and Printing of the RX dose 5
17 Medical Record and Operatory Act Registration 15
18 Clinic Re-Evaluation 15  
 
 
For assessing the Pre and Post Operations timings, the problem has been that there is not a 
registry for them. I set them thanks to some consulting with doctor Causin. This is a limit of 
the Abc method, because sometimes it is based on interviews, that can be biased by personal 
feelings. Moreover, the inactivity time in the angiographic room must be taken into account, 
so I added an hour to the time calculations to keep account of them. 
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The second class of Activities identified are the Medical Procedures, the phase 9 of the 
previous catalogue. The operative phase, in fact, has not a defined time yet, because it 
depends on which of the 29 types of procedures are done to the patient: 
 
N° Name (ITA) Name (ENG) Time (mins)
1 Sclero/Embolizzazione angioma Sclero/Embolization of Vascular Malformation 40
2 Completamento Angiografico Integrative Angiography 30
3 Stent carotideo Carotid Stenting 48
3.a Stent Carotideo in Trombectomia Carotid Stenting in Thrombectomy 48
4 Stent intracranico Intracranial Stenting 91
4.a Stent Intracranico in Trombectomia Intracranial Stenting in Thrombectomy 91
5 Stent periferico Peripheral Stenting 68
6 Embolizzazione: FAV Cerebrale Embolization: Brain AVF 181
7 Embolizzazione: FAV Extracranica Embolization: Extra-cranial AVF 120
8 Embolizzazione: FAV Spinale Embolization: Spinal AVF 150
9 Embolizzazione: MAV Cerebrale Embolization: Brain AVM 163
10 Embolizzazione: MAV Spinale Embolization: Spinal AVM 130
11 Embolizzazione: MAV Extracranica Embolization: Extra-Cranial AVM 130
12 Embolizzazione: Aneurisma con spirali Embolization: Aneurism coiling 99
12.a Embolizzazione: Aneurisma con pallone Embolization: Aneurism BAC remodeling 132
12.a.b Embolizzazione: Aneurisma con stent Embolization: Aneurism SAC 149
12.a.b.c Embolizzazione: Aneurisma con Stent FD Embolization: Aneurism with Stent FD 127
12.a.b.c.d Embolizzazione: Altro Embolization: Other 127
13 Test occlusione Occlusion Test 75
14 Trattamento del vasospasmo Intracranial Vasospasm Treatment 80
15 Biopsia spinale-Ossea Spinal-Bone Biopsy 30
16 Ozonoterapia - Infiltrazione faccette Ozonetherapy - Facets Infiltration 30
17 Vertebroplastica Vertebroplasty 40
18 Tromboaspirazione Intracranica Thrombo-aspiration 84
18.a Trombectomia intracranica Intracranial Thrombectomy 49
19 Chemioterapia i.a. per RTB Intra-arterial Chemiotherapy of RTB 133
20 embolizzazione tumori pre-oper. Tumor Embolization - pre.op. 123
21 embolizzazione tumori spinali-capo-collo Tumor Embolization Spinal-Head&neck 123
22 embolizzazione traumi Trauma/bleeding Embolization 115  
 
The length of the Procedures has been defined in a more accurate way, being pulled out from 
a database that makes up for the lack of a traditional Operation Room’s Registry.  
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4.3.2 – Cost Definition 
 
From the Qlik platform, part of the Information System of the Analytical Accounting of the 
AOP, I obtained the list of the cost generated by the Neuroradiology Operative Unit. It 
sustains costs of Devices, Drugs, Services and Stationery Materials.   
 
Year 2014 2015 2016
Device Category Value Value Value 14-15 15-16 14-16 14-15 15-16 14-16
P-Medical Devices 765.353 714.261 578.294 -51.092 -135.967 -187.059 -7% -19% -24%
Q-Prothesical Devices 287.744 429.398 243.058 141.654 -186.340 -44.686 49% -43% -16%
F-Drugs with AIC 124.313 126.302 73.674 1.989 -52.628 -50.639 2% -42% -41%
X-Drugs without AIC 6.129 5.282 230 -847 -5.052 -5.899 -14% -96% -96%
C-Stationery 4.953 4.047 2.411 -906 -1.636 -2.542 -18% -40% -51%
H-Technical articles 772 2.631 830 1.859 -1.801 58 241% -68% 8%
D-In vitro Diagnostic Devices 1.385 1.764 1.608 379 -157 222 27% -9% 16%
L-Stationery 3.336 776 263 -2.560 -513 -3.072 -77% -66% -92%
AB-Other goods 436 612 91 176 -521 -345 40% -85% -79%
Z-Chemical Products 264 13 17 -251 4 -247 -95% 31% -93%
U-Services 36.026 138.691 58.603 102.665 -80.088 22.577 285% -58% 63%
Total 1.230.711 1.423.777 959.079 193.066 -464.698 -271.632 16% -33% -22%
ChangeChange
 
  
Moreover, this department sustains costs for the Personnel, the machinery (Technology: 
amortization quotas and maintenance) and for the general expenses (location, cleaning, heat 
etc.).  
The total cost of the personnel: 
 
2015
€ 413.223
€ 257.720
€ 371.987
€ 247.970
€ 92.639
€ 1.383.539Total
Role 2014
€ 404.790
€ 259.932
€ 286.646
€ 363.944
€ 93.585
€ 1.408.897
Taxes
Personnel Cost
Doctors
Nurses
Technicians
Admnistratives
 
 
The cost for the Machinery (Technology) 
 
Amortization Quotas 72 Objects € 555.573
Maintenance 16 Machinery € 356.970
€ 912.543
Technology Cost
Total  
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The quota of the general expenses will be considered adding a mark up to the tariff equal to 
the 30% of the cost. 
 
4.3.3 - Cost Allocation 
 
With many consultations with Doctor Causin, I drew a map of the allocation. It is divided in 5 
phases, following the nature of the costs: 
1. The devices. They are the only cost objects that can be directly allocated to the final 
service. The first part of their allocation will consist in attributing each specific device 
to the procedure or (Preparatory/Post-Operative) phase. The remaining will be 
allocated proportionally with two criteria (those that are consumed only by the 
Angiographic Room Activities and those consumed by all the Neuroradiology’s 
procedures). 
2. The second class of costs are the services. They will be proportionally allocated, but 
not only on the procedures studied here, but on all the Neuroradiology’s services. 
3. The drugs. Some of them are attributed only to the procedure performed in the 
Angiographic Room, and the rest of them to all the Neuroradiology’s services.  
4. The technology. Part of it will be allocated only to the procedures performed in the 
Angiographic Room, the remaining to all the services of the Department.  
5. The Personnel. The cost of the workforce will be calculated based on the time 
consumption of every phase and procedure.  
 
Allocation by weighting time and sample size
Allocation by time consume
Direct allocation
Resources Activities Products
Procedures
Phases (Pre and Post)
Procedures (with 
direct and indirect 
costs)General Services
General Devices
Workforce
Specific Devices
General Devices (Angiographic Room)
General Drugs
General Technology
Drugs (Angiographic Room)
Technology (Angiographic Room)
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1. Devices 
 
To allocate the Devices I separated them between the ones that are consumed by the 
preparatory and post-operative phases, those which are consumed in the operative procedures 
and those that are used generically26. 
 
Device Category's Name Count Allocation Device Category's Name CountAllocation
Generici 268 None Microcatetere a flusso 3 Procedure
Accessori Cestello Raccolta 1 Pre-Post Microcatetere Flusso Dipendente 1 Procedure
Adattatore Emostatico 1 Procedure Microcatetere Idrofilico 1 Procedure
ago aspirazione 1 Procedure Microcatetere Palloncino 2 Procedure
Ago Biopsia 2 Procedure Microcatetere per infusioni 1 Procedure
ago cannula venoso 10 Procedure Microcatetere per navigazione 13 Procedure
ago farfalla 3 Procedure Microcatetere Rigidezza Variabile 2 Procedure
Ago Vertebroplastica 2 Procedure Microcatetere Riperfusione 3 Procedure
Attribuito al CdC per errore 4 None Microguida 2 Procedure
Catetere 13 Procedure Microguida Idrofila 3 Procedure
Catetere a pallone 13 Procedure Microguida Idrofilica Hybrid 3 Procedure
catetere angio 2 Procedure Microguida Idrofilica Mirage 1 Procedure
Catetere distale 8 Procedure Microguida Neuroscout 2 Procedure
Catetere Guida a Palloncino 2 Procedure Microguida Transend 2 Procedure
Catetere Palloncino 1 Procedure monosof 1 Procedure
Catetere Tromboaspirazione 2 Procedure Pallone Dilatazione 3 Procedure
cavo collegamento 2 Procedure Premisacca 1 Procedure
Colla 1 Procedure Salviette 1 None
Dispositivo Emostasi 3 Procedure Sensore Saturimetro 3 Pre-Post
Dispositivo Gonfiaggio 1 Procedure Set Embolizzazione 2 Procedure
Dispositivo per embolizzazione Diversore 3 Procedure Set Occlusioni Temporanee 2 Procedure
Dispositivo Rimozione Meccanica 2 Procedure siringa 2 Pre-Post
Fase pre e post 37 Pre-Post Sistema di embolizzazione Web 4 Procedure
Fiala Embolizzante 3 Procedure sistema distacco 1 Procedure
Guida 1 Procedure sistema gonfiaggio 1 Procedure
Guida da cambio 2 Procedure Sistema Protezione Embolica 3 Procedure
Introduttore 8 Procedure Spirale 46 Procedure
Introduttore 6 Procedure Spirali Embolizzazion 15 Procedure
Kit Angiografia 2 Procedure Stent Autoespandibile Carotide 5 Procedure
Kit Angioplastica 1 Procedure Stent Carotideo 3 Procedure
Kit Cemento Spinale 1 Procedure Stent Diversore di Flusso FD 7 Procedure
Mandrino 2 Pre-Post Stent Intracranico 2 Procedure
Maschera 6 Pre-Post Stent Intracranico Autoespandibile 13 Procedure
Micorcaterere Idrofilico Flessibile 2 Procedure Stent Intracranico Autoespandibile FD 5 Procedure
Micorcatetere Idrofilo Armato 1 Procedure Stent Intracranico LVIS 4 Procedure
Microcatetere 1 Procedure Stent Periferico 1 Procedure
Stent su pallone 2 Procedure
Total = 584 Devices  
 
                                                 
26 Tag “None” 
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With these 3 groups I could proceed with the first allocation, the direct one. I built some 
tables, one for each phase or procedure, that groups all he devices used, the Unitary cost, the 
quantity utilised and the total cost27. 
 
Phase 5 chart:  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PATE89A-DEFLUSSORE X FLEBO S/ RACCORDO IN PARA L.180 CMFILTRO 15 MICRON 
S/AGO BIO DRIP (AVTI1/1) IN011060 0,21 2 0,41
PATC613-PROLUNGA  IN PE DIAM. INTERNO MM 1,5 LUNGH. CM 50LL/M/F (AVTI6/15)   
PB3205M 0,27 4 1,07
PATM60C-PROLUNGA PUR D.3MM  RACCORDI TERM. LUER LOCK M/FL.100CM 
LINKSET NO PVC (AVTI5/10) 090600/100/PU 0,43 2 0,85
PATE89L-RACCORDO LUER LOCK DOPPIO MASCHIO(AVTI13/32)   IN062001 0,26 1 0,26
PATC609-RAMPA A TRE VIE  5 USCITE FEMMINA(AVTI9/26)   RP3000 0,99 1 0,99
PATB79C-RUBINETTO 3 VIE ATTACCO MOBILE FLUSS.CONTEMPORANEOVYCLIC 
(AVTI10/28)   70876.20 0,24 3 0,71
PATB79K-TAPPO DOPPIO LUER LOCK MASCHIO/FEMMINATAPPO DOPPIO LLM/LLF 
ROSSO (AVTI12/30)   9888.00 0,04 1 0,04
PIA0916-AGO CANNULA VENOSO PERIFERICO 1 VIA DI INFUSIONES/ALETTE 16G 
X50MM (28/G105/13) JELCO  4032-INT 0,25 1 0,25
PIA0918-AGO CANNULA VENOSO PERIFERICO 1 VIA DI INFUSIONES/ALETTE 18G 
X32MM (28/G105/13) JELCO  4035-INT 0,25 1 0,25
DZH3255-ELETTRODO X MONITORAGGIO CARDIACO C/SUPP. IN MEDIPORE 
DIAM.CM.6 RED DOT 2255 S/LATTICE GOMMA 0,19 3 0,57
PIG3610-GUANTO IN POLIETILENE MONOUSO NON STERILEAMBIDESTRO MISURA 
UNICA 2901860000 (G102/04) 0,0037 8 0,03
PAVS610-TELO A 3 STRATI STERILE F.TO CM 78X95 C/BORDO ADESIVO TB31300CE 1,06 1 1,06
PATB796-RUBINETTO A TRE VIE - (SOLO PER RADIOLOGIE)INO31301 0,28 1 0,28
PSB3560-LAME RICAMBIO RASOIO ELETTRICO COD.4406 1,51 1 1,51
8,28
Fase 5 - Posizionalmento Sul Lettino E Preparazione
Phase 5 - Placement of the Patient on the Table
Procedure's Devices' Total Cost =  
 
The first column contains all the devices that have been directly attributed to this phase and 
for which the consumption is measurable and regular. The unit cost was obtained from the 
total Unit report, as ratio between the year consumption by value and the year consumption by 
quantity.  
 
 
 
 
                                                 
27 I report here 2 examples, one for the phases and one for the procedures, the rest is in the appendix. 
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Example for phase 5:  
 
Devices Year Cost Year Q Unit Cost
PATE89A-DEFLUSSORE X FLEBO S/ RACCORDO IN PARA L.180 CMFILTRO 15 MICRON 
S/AGO BIO DRIP (AVTI1/1) IN011060 76,29 370,00 0,21
PATC613-PROLUNGA  IN PE DIAM. INTERNO MM 1,5 LUNGH. CM 50LL/M/F (AVTI6/15)   
PB3205M 306,01 1.140,00 0,27
PATM60C-PROLUNGA PUR D.3MM  RACCORDI TERM. LUER LOCK M/FL.100CM 
LINKSET NO PVC (AVTI5/10) 090600/100/PU 307,45 720,00 0,43
PATE89L-RACCORDO LUER LOCK DOPPIO MASCHIO(AVTI13/32)   IN062001 46,13 180,00 0,26
PATC609-RAMPA A TRE VIE  5 USCITE FEMMINA(AVTI9/26)   RP3000 113,64 115,00 0,99
PATB79C-RUBINETTO 3 VIE ATTACCO MOBILE FLUSS.CONTEMPORANEOVYCLIC 
(AVTI10/28)   70876.20 226,01 950,00 0,24
PATB79K-TAPPO DOPPIO LUER LOCK MASCHIO/FEMMINATAPPO DOPPIO LLM/LLF 
ROSSO (AVTI12/30)   9888.00 25,47 720,00 0,04
PIA0916-AGO CANNULA VENOSO PERIFERICO 1 VIA DI INFUSIONES/ALETTE 16G 
X50MM (28/G105/13) JELCO  4032-INT 98,09 400,00 0,25
PIA0918-AGO CANNULA VENOSO PERIFERICO 1 VIA DI INFUSIONES/ALETTE 18G 
X32MM (28/G105/13) JELCO  4035-INT 173,56 700,00 0,25
DZH3255-ELETTRODO X MONITORAGGIO CARDIACO C/SUPP. IN MEDIPORE 
DIAM.CM.6 RED DOT 2255 S/LATTICE GOMMA 200,01 1.050,00 0,19
PIG3610-GUANTO IN POLIETILENE MONOUSO NON STERILEAMBIDESTRO MISURA 
UNICA 2901860000 (G102/04) 8,54 2.300,00 0,0037
PAVS610-TELO A 3 STRATI STERILE F.TO CM 78X95 C/BORDO ADESIVO TB31300CE 137,98 130,00 1,06
PATB796-RUBINETTO A TRE VIE - (SOLO PER RADIOLOGIE)INO31301 196,42 700,00 0,28
PSB3560-LAME RICAMBIO RASOIO ELETTRICO COD.4406 302,68 200 1,51
Fase 5 - Posizionalmento Sul Lettino E Preparazione
Phase 5 - Placement of the Patient on the Table
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After having allocated all the direct consumptions, the cost table for the phases is: 
         
N° Phase Devices
1 Taking in Charge € 0
2 Acceptance € 0
3 Confirm and Consensus Acquisition € 0
4 Access to the Angiographic Room € 0
5 Placement of the Patioent on the Table € 9
6 Sedation € 20
6.a General Anesthesia € 28
7 Preparation of the Sterile Environment € 94
8 Diagnostic Phase € 60
9 Operative Phase (See following Chart) / /
10 Medication € 123
11 TAC Final Control € 0
12 Mobilizaiton of the patient € 0
13 Transfer of the Patient € 0
13a In Neuroscience, in anesthesia € 0
13b In Neuroscience, intubated or awake € 0
13c Other Intensive Therapy, in AOP € 0
13d Other Intensive Therapy, in other Firm € 0
13e Arrival Hospital, in other firm € 0
14 Room Rearrangement € 0
15 Images Filing € 0
16 Counting and Printing of the RX dose € 0
17 Medical Record and Operatory Act Registration € 0
18 Clinic Re-evlauation € 0  
 
 
For some procedures, on the other hand, there may be some more calculations to do, due to 
the possibility of use of different models for the same devices (Perfect Alternatives). These 
variability is not measurable and so for the “alternatives” devices I weighted the values based 
on the real consumption during a two-year period. 
 
For example, in procedure 12.a.b.c.d, two pair of devices are alternative, the Microcatheteres 
and the Embolization Systems.  
 
80 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PIT0115-MICROCATETERE X LA NAVIGAZIONE DEL DISPOSITIVO WEBD..027" L.145CM VIA      VIA-27-154-01 976 alternatives A
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS COD.606-S255FX 597,8 alternatives A
PIT085A-SISTEMA EMBOLIZZAZIONE ANEURISMA INTRACRANICOMEDINA MEDICAL   ED -7-090-FR 6760 alternatives B
PIT0851-SISTEMA DI EMBOLIZZAZIONE ANEURISMI INTRACRANICIIN FILI NITINOL D.8MM L.4MM    W2-8-4 10400 alternatives B
PITSP25-CATETERE ARMATO PER PTA CURVA DIRITTA 6FR90 CM CAROTID SHEATH  DESTINATION   RSC07 244 244
PITM034-CATETERE PORTANTE PER CATETERISMO COASSIALENAVIEN   RFXA072-115-08MP 549 549
PIT0404-KIT  X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUTTORE TORQUE 16,47 16,47
PITY115-GUIDA METALLICA 035-260 CM.TIPO ANGOLATO TERUMO RFCOD.RFGA35263M  /ESC.R/ 115,9 115,9
PITZ27E-GUIDA TRANSEND FLOPPY 300 CM  COD.46-815TARGET 439,2 439,2
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALVE   23242 7,32 7,32
12095,9Procedure's Devices' Total Cost = 
12.a.b.c.d
Embolizzazione: Aneurisma con Stent altro
Embolization: Other
612,81
9672
 
 
 
For them I prepared two more tables. For the alternative “A”, the Microcatheteres indicated as 
alternatives, have been summed by value and by quantity to obtain an average Unitary cost, 
weighted for the value and use.  
 
 
Devices Year Cost Year Q Unit Cost
PIT0114-MICROCATETERE X LA NAVIGAZIONE DEL DISPOSITIVO WEBD..027" L.145CM VIA PLUS     VIA-33-13 976 1 976
PIT0115-MICROCATETERE X LA NAVIGAZIONE DEL DISPOSITIVO WEBD..027" L.145CM VIA      VIA-27-154-01 3.904 4 976
PITETBA-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS COD.606-S255 16.738 28 597,8
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS COD.606-S255 16.738 28 597,8
PIT0114-MICROCATETERE X LA NAVIGAZIONE DEL DISPOSITIVO WEBD..027" L.145CM VIA PLUS     VIA-33-13 0 0 0
PIT0115-MICROCATETERE X LA NAVIGAZIONE DEL DISPOSITIVO WEBD..027" L.145CM VIA      VIA-27-154-01 0 0 0
PITETBA-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS COD.606-S255 20.923 35 597,8
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS COD.606-S255 17.934 30 597,8
77.214 126 612,80794
Microcatheter
Alternative "a"
 
 
The alternative “b” is the Embolization System: 
 
Devices Year Cost Year Q Unit Cost
PIT085A-SISTEMA EMBOLIZZAZIONE ANEURISMA INTRACRANICOMEDINA MEDICAL   ED -7-090-FR 6.760,00 1,00 6760
PIT0851-SISTEMA DI EMBOLIZZAZIONE ANEURISMI INTRACRANICIIN FILI NITINOL D.8MM L.4MM    W2-8-4 10.400 1 10400
PIT0854-SISTEMA DI EMBOLIZZAZIONE ANEURISMI INTRACRANICIIN FILI NITINOL D.10MM L.6MM    W2-10- 10.400 1 10400
PIT0855-SISTEMA DI EMBOLIZZAZIONE ANEURISMI INTRACRANICIIN FILI NITINOL D.8MM L.6MM    W2-8-6 10.400 1 10400
PIT0856-SISTEMA DI EMBOLIZZAZIONE ANEURISMI INTRACRANICIIN FILI NITINOL D.8MM L.5MM    W2-8-5 10.400 1 10400
48.360,00 5,00 9672
Alernative "b"
Embolization System
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The total cost of the devices allocated directly for the procedures is: 
 
 
N° Name Devices
1 Sclero/Embolization of Vascular Malformation 17,82
2 Integrative Angiography 21,74
3 Carotid Stenting 2509,20
3.a Carotid Stenting in Thrombectomy 2266,42
4 Intracranial Stenting 7570,26
4.a Intracranial Stenting in Thrombectomy 5182,89
5 Peripheral Stenting 1904,68
6 Embolization: Brain AVF 6181,32
7 Embolization: Extra-cranial AVF 5593,91
8 Embolization: Spinal AVF 7065,96
9 Embolization: Brain AVM 8367,71
10 Embolization: Spinal AVM 3518,20
11 Embolization: Extra-Cranial AVM 6419,80
12 Embolization: Aneurism coiling 6185,88
12.a Embolization: Aneurism BAC remodeling 2020,32
12.a.b Embolization: Aneurism SAC 5383,93
12.a.b.c Embolization: Aneurism with Stent FD 13389,85
12.a.b.c.d Embolization: Other 12079,43
13 Occlusion Test 2374,12
14 Intracranial Vasospasm Treatment 1065,48
15 Spinal-Bone Biopsy 40,97
16 Ozonetherapy - Facets Infiltration 7,32
17 Vertebroplasty 801,96
18 Thrombo-aspiration 4174,82
18.a Intracranial Thrombectomy 4645,46
19 Intra-arterial Chemiotherapy of RTB 1512,09
20 Tumor Embolization - pre.op. 4732,99
21 Tumor Embolization Spinal-Head&neck 1974,91
22 Trauma/bleeding Embolization 2752,12  
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 At this point, of the overall device consumption, only the non-assigned remain to allocate. As 
already explained, they will be allocated with two criteria.  
The first group, regarding the devices used only for the procedures performed in the 
Angiographic Room, has a total cost of €26.290. 
 
To prepare the driver for allocating these costs, I obtained the number of procedures per year 
and considered the 2015 and 2016 data. 
 
Time 2007 2008 2009 2010 2011 2012 2013 2014 2015 31 ott. 2016
1 Sclero/Embolization of Vascular Malformation 40 14 9 6 12 24 16 27 43 43 48
2 Integrative Angiography 30 26 30
3 Carotid Stenting 48 46 14 26 32 42 41 27 26 24 17
3.a Carotid Stenting in Thrombectomy 48
4 Intracranial Stenting 91 0 0 5 6 4 8 7 6 9 1
4.a Intracranial Stenting in Thrombectomy 91
5 Peripheral Stenting 68
6 Embolization: Brain AVF 181 16 18 36 11 10 19 19 10 9 10
7 Embolization: Extra-cranial AVF 120
8 Embolization: Spinal AVF 150
9 Embolization: Brain AVM 163 32 24 36 20 26 12 13
10 Embolization: Spinal AVM 130
11 Embolization: Extra-Cranial AVM 130
12 Embolization: Aneurism coiling 99 14 16 14 12 13 9 14
12.a Embolization: Aneurism BAC remodeling 132 9 8 15 16 17 15 14
12.a.b Embolization: Aneurism SAC 149 7 4 7 6 3 5 3
12.a.b.c Embolization: Aneurism with Stent FD 127 4 8 11 12 14 14 15
12.a.b.c.d Embolization: Other 127
13 Occlusion Test 75 0 0 3 1 1 2 2 1 0 0
14 Intracranial Vasospasm Treatment 80 1 3 4 6 6 4 1 5 5 15
15 Spinal-Bone Biopsy 30 10 12 20 18 16 14 15 10 16 28
16 Ozonetherapy - Facets Infiltration 30 0 0 0 14 11 12 7 12 7 18
17 Vertebroplasty 40 19 17 25 21 24 25 38 38 36 43
18 Thrombo-aspiration 84 0 0 0 0 0 0 0 0 0 33
18.a Intracranial Thrombectomy 49 3 1 7 13 13 18 21 20 30 22
19 Intra-arterial Chemiotherapy of RTB 133 0 0 0 0 0 0 0 0 0 7
20 Tumor Embolization - pre.op. 123 2 4 2 0 1 7 10 10 10 15
21 Tumor Embolization Spinal-Head&neck 123
22 Trauma/bleeding Embolization 115 1 3 3 4 6 5 2
Total 111 78 134 201 215 252 244 260 275 348  
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With these numbers I produced the table for allocating the Angiography Room’s Devices. 
 
Name t Q Q. Weighted Distribution
Cost for 
Procedur
e's Type
Cost Per 
Procedur
e
Q Q weighted Distribution
Cost for 
Procedure'
s Type
Cost Per 
Procedur
e
Sclero/Embolization of Vascular Malformation 40 43 1720 9% 2341 54 48 1920 8% 1981 41
Integrative Angiography 30 26 780 4% 1061 41 30 900 4% 929 31
Carotid Stenting 48 24 1152 6% 1568 65 17 816 3% 842 50
Carotid Stenting in Thrombectomy 48 0 0 0% 0 0 0 0 0% 0 0
Intracranial Stenting 91 9 819 4% 1115 124 1 91 0% 94 94
Intracranial Stenting in Thrombectomy 91 0 0 0% 0 0 0 0 0% 0 0
Peripheral Stenting 68 0 0 0% 0 0 0 0 0% 0 0
Embolization: Brain AVF 181 9 1629 8% 2217 246 10 1810 7% 1868 187
Embolization: Extra-cranial AVF 120 0 0 0% 0 0 0 0 0% 0 0
Embolization: Spinal AVF 150 0 0 0% 0 0 0 0 0% 0 0
Embolization: Brain AVM 163 12 1956 10% 2662 222 13 2119 9% 2186 168
Embolization: Spinal AVM 130 0 0 0% 0 0 0 0 0% 0 0
Embolization: Extra-Cranial AVM 130 0 0 0% 0 0 0 0 0% 0 0
Embolization: Aneurism coiling 99 9 891 5% 1213 135 14 1386 6% 1430 102
Embolization: Aneurism BAC remodeling 132 15 1980 10% 2695 180 14 1848 8% 1907 136
Embolization: Aneurism SAC 149 5 745 4% 1014 203 3 447 2% 461 154
Embolization: Aneurism with Stent FD 127 14 1778 9% 2420 173 15 1905 8% 1966 131
Embolization: Other 127 0 0 0% 0 0 0 0 0% 0 0
Occlusion Test 75 0 0 0% 0 0 0 0 0% 0 0
Intracranial Vasospasm Treatment 80 5 400 2% 544 109 15 1200 5% 1238 83
Spinal-Bone Biopsy 30 16 480 2% 653 41 28 840 3% 867 31
Ozonetherapy - Facets Infiltration 30 7 210 1% 286 41 18 540 2% 557 31
Vertebroplasty 40 36 1440 7% 1960 54 43 1720 7% 1775 41
Thrombo-aspiration 84 0 0 0% 0 0 33 2772 11% 2860 87
Intracranial Thrombectomy 49 30 1470 8% 2001 67 22 1078 4% 1112 51
Intra-arterial Chemiotherapy of RTB 133 0 0 0% 0 0 7 931 4% 961 137
Tumor Embolization - pre.op. 123 10 1230 6% 1674 167 15 1845 8% 1904 127
Tumor Embolization Spinal-Head&neck 123 0 0 0% 0 0 0 0 0% 0 0
Trauma/bleeding Embolization 115 5 575 3% 783 78 2 230 1% 237 119
2016 - Total Cost 25.1752015 - Total Cost 26.204
 
 
 
In columns q there are the number of times in which each procedure has been performed in 
2015 and 2016. These number, multiplied by the lasting minutes of the procedure, gave me 
the total number of minutes of procedures performed (Q weighted). Dividing the number of 
minutes regarding each type of procedure by the total number of minutes, I obtained the share 
of minutes over the total that every procedure required (Distribution). Multiplying this share 
for the total cost I obtained the cost regarding every type of procedure (Cost for Procedure’s 
Type). Dividing this value for the number of procedures performed (of each type) the result is 
the cost per procedure.  
The quota of cost of some procedures that have not been performed in the last years is 0, and, 
according with the Neuroradiology Department, I set the cost of devices equal to the one of 
the procedure as similar as possible. Where this was not possible, I substituted with the 2016 
cost’s quota. 
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The cost of the Angiographic room Devices on the procedures: 
 
Name Cost Per Procedure
Sclero/Embolization of Vascular Malformation € 54
Integrative Angiography € 41
Carotid Stenting € 65
Carotid Stenting in Thrombectomy € 65
Intracranial Stenting € 124
Intracranial Stenting in Thrombectomy € 124
Peripheral Stenting € 124
Embolization: Brain AVF € 246
Embolization: Extra-cranial AVF € 246
Embolization: Spinal AVF € 246
Embolization: Brain AVM € 222
Embolization: Spinal AVM € 222
Embolization: Extra-Cranial AVM € 222
Embolization: Aneurism coiling € 135
Embolization: Aneurism BAC remodeling € 180
Embolization: Aneurism SAC € 203
Embolization: Aneurism with Stent FD € 173
Embolization: Other € 173
Occlusion Test € 173
Intracranial Vasospasm Treatment € 109
Spinal-Bone Biopsy € 41
Ozonetherapy - Facets Infiltration € 41
Vertebroplasty € 54
Thrombo-aspiration € 87
Intracranial Thrombectomy € 67
Intra-arterial Chemiotherapy of RTB € 137
Tumor Embolization - pre.op. € 167
Tumor Embolization Spinal-Head&neck € 167
Trauma/bleeding Embolization € 78  
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The second group of devices are attributable to all the activities of the Neuroradiology. It 
would generate too high a cost in term of data collection to repeat the ABC analysis as for 
these procedures for all the procedures performed by the Neuroradiology. For this reason, I 
chose to divide the cost of general devices for the total number of procedures and apply it to 
all the studied operations. This method is a simplification because it assumes that all activities 
consume the same amount of resources, but on the other hand this is a very small part of total 
costs, therefore it does not alter the analysis result. 
 
Value N° of Procedures Cost per Procedure
31398,957 30960 1,014  
 
 
2. Services  
 
The services that generated costs in this department are of 5 classes: 
 Rent of the Photocopier 
 Administrative Support 
 Private Pratictioners Consulting 
 Maintenances 
 Cleaning 
I chose to allocate the services to all the Neuroradiology’s procedure performed in 2015 due 
to their referral to all the department’s activity. 
 
Type Cost (2015)
UCA00001-CANONI DI NOLEGGIO FOTOCOPIATRICIDA PRIVATO - AREA NON SANITARIA 0
UZS00002-SERV. DI SUPPORTO ALL'ATTIVITA' AMMINISTRATIVADA PRIVATO NON INTERINALE 66.015
UCP00001-SERVIZI DI CONSULENZA SANITARIA DA PRIVATI 72.534
UMA00001-SER. DI MANUT. ATTREZ. SANIT. ESPLORAZ. FUNZION.DI PROPRIETA 0
UPU00001-SER. DI PULIZIA AREE INTERNE/ESTERNE 142
Total 138.691
Number of procedures 30960
Cost per procedure 4,48  
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3. Drugs 
 
There are three classes of drugs to keep into account, the first can be allocated to all the 
Neuroradiology’s activity, the second only to the one performed in the angiographic room and 
the third to some Pre and Post Operatory phases. 
I obtained the first dividing the total cost of the drugs for all the procedures of the department, 
not only the considered here. This calculus is basic, but it would have cost too much in term 
of data collection to repeat a study like this for all the department’s activity. 
 
Cost N° of Procedures Cost per Procedure
8903 30960 0,29  
 
I allocated the second class of drugs to the Procedures performed in the angiographic room 
weighting them for time and sample size:  
 
 
Name t Q Q. Weighted Distribution
Cost for 
Procedure's 
Type
Cost Per 
Procedure
Sclero/Embolization of Vascular Malformation 40 43 1720 9% € 9.787 € 228
Integrative Angiography 30 26 780 4% € 4.438 € 171
Carotid Stenting 48 24 1152 6% € 6.555 € 273
Carotid Stenting in Thrombectomy 48 0 0 0% € 0 € 273
Intracranial Stenting 91 9 819 4% € 4.660 € 518
Intracranial Stenting in Thrombectomy 91 0 0 0% € 0 € 518
Peripheral Stenting 68 0 0 0% € 0 € 518
Embolization: Brain AVF 181 9 1629 8% € 9.270 € 1.030
Embolization: Extra-cranial AVF 120 0 0 0% € 0 € 1.030
Embolization: Spinal AVF 150 0 0 0% € 0 € 1.030
Embolization: Brain AVM 163 12 1956 10% € 11.130 € 928
Embolization: Spinal AVM 130 0 0 0% € 0 € 928
Embolization: Extra-Cranial AVM 130 0 0 0% € 0 € 928
Embolization: Aneurism coiling 99 9 891 5% € 5.070 € 563
Embolization: Aneurism BAC remodeling 132 15 1980 10% € 11.267 € 751
Embolization: Aneurism SAC 149 5 745 4% € 4.239 € 848
Embolization: Aneurism with Stent FD 127 14 1778 9% € 10.117 € 723
Embolization: Other 127 0 0 0% € 0 € 723
Occlusion Test 75 0 0 0% € 0 € 455
Intracranial Vasospasm Treatment 80 5 400 2% € 2.276 € 455
Spinal-Bone Biopsy 30 16 480 2% € 2.731 € 171
Ozonetherapy - Facets Infiltration 30 7 210 1% € 1.195 € 171
Vertebroplasty 40 36 1440 7% € 8.194 € 228
Thrombo-aspiration 84 0 0 0% € 0 € 228
Intracranial Thrombectomy 49 30 1470 8% € 8.365 € 279
Intra-arterial Chemiotherapy of RTB 133 0 0 0% € 0 € 279
Tumor Embolization - pre.op. 123 10 1230 6% € 6.999 € 700
Tumor Embolization Spinal-Head&neck 123 0 0 0% € 0 € 700
Trauma/bleeding Embolization 115 5 575 3% € 3.272 € 654
2015 - Tot Cost 109.568
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The cost of the Angiographic room drugs on the procedures: 
 
Name Cost Per Procedure
Sclero/Embolization of Vascular Malformation 228
Integrative Angiography 171
Carotid Stenting 273
Carotid Stenting in Thrombectomy 273
Intracranial Stenting 518
Intracranial Stenting in Thrombectomy 518
Peripheral Stenting 518
Embolization: Brain AVF 1030
Embolization: Extra-cranial AVF 1030
Embolization: Spinal AVF 1030
Embolization: Brain AVM 928
Embolization: Spinal AVM 928
Embolization: Extra-Cranial AVM 928
Embolization: Aneurism coiling 563
Embolization: Aneurism BAC remodeling 751
Embolization: Aneurism SAC 848
Embolization: Aneurism with Stent FD 723
Embolization: Other 723
Occlusion Test 455
Intracranial Vasospasm Treatment 455
Spinal-Bone Biopsy 171
Ozonetherapy - Facets Infiltration 171
Vertebroplasty 228
Thrombo-aspiration 228
Intracranial Thrombectomy 279
Intra-arterial Chemiotherapy of RTB 279
Tumor Embolization - pre.op. 700
Tumor Embolization Spinal-Head&neck 700
Trauma/bleeding Embolization 654
2015 - Tot Cost 109.568
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The third class of Drugs, those allocated directly to the Pre & Post Operatory Phases: 
 
N° Phase Drugs
1 Taking in Charge 0
2 Acceptance 0
3 Confirm and Consensus Acquisition 0
4 Access to the Angiographic Room 0
5 Placement of the Patioent on the Table 1
6 Sedation 31
6.a General Anesthesia 36
7 Preparation of the Sterile Environment 4
8 Diagnostic Phase 10
9 Operative Phase (See following Chart) 0
10 Medication 0
11 TAC Final Control 0
12 Mobilizaiton of the patient 0
13 Transfer of the Patient 0
13a In Neuroscience, in anesthesia 0
13b In Neuroscience, intubated or awake 0
13c Other Intensive Therapy, in AOP 0
13d Other Intensive Therapy, in other Firm 0
13e Arrival Hospital, in other firm 0
14 Room Rearrangement 0
15 Images Filing 0
16 Counting and Printing of the RX dose 0
17 Medical Record and Operatory Act Registration 0
18 Clinic Re-evlauation 0  
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4.Technology  
 
From the analysis it emerged that only some of the machinery of the department are used for 
the procedures considered in this study. One in particular, the Angiography, is utilised only in 
the Number 8 of the Preparatory and Post-Operative Phases, the diagnostic phase. Its cost is 
then given by the sum of Amortization quotas and the maintenance cost. I obtained the 
number of procedures that required the Angiograph by a Qlik extraction looking for all the 
angiographies, for external and inpatients. 
 
 
 
 
 
 
 
 
 
The rest of the technology, instead, can be allocated to all the procedures indistinctly. 
Obviously, the cost for the year contains the Amortization Quotas and the Maintenance Costs. 
 
 
 
 
 
 
5.Workforce 
 
Each activity that I catalogued generates workforce costs. So I prepared two tables, one for 
the phases and one for the procedures. 
 
To elaborate a cost per minute I chose the six roles that intervene in the activities. For each 
role the standard cost has been obtained by dividing the Cost for the FTE (Full Time 
Equivalent Units). It is an average indicator of how many people works in the Firm yearly. It 
is calculated assigning a weight to all the class of workers. For example, if a worker is a 
Name Type of cost
ANGIOGRAFIA DIGITALE, SISTEMA Amortization quota 265.764,88
INIETTORE ANGIOGRAFICO Amortization quota 5.302,22
ALLURA XPER FD20 BIPLANE Maintainance 97.600,00                  
368.667,10
246
579
825
446,87
Tot Cost (A)
Total Number of Procedures (B)
Cost per operation (A/B)
Internal Patients
External Patients
Cost N° of Procedures Cost per Procedure
814942,77 30960,00 26,32
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student, its weight is 50%, if someone is part time, it is weighted by the weekly hours, if 
someone in Pregnancy Permission, she weights 0 for the time of the leave. In this way the 
firm obtains a count of the “Theoretical Productive Units” that better represent the real 
working capacity. The standard cost, then, is divided by weekly hours, working weeks and by 
minutes. 
 
(A) 
Personnel
(B) 
Equivalent Units
(C) 
Cost ( With 
IRAP)
(D)            
 STD Cost (With 
IRAP) (C/B)
(E)
Weekly Hours
(F)             
Working Weeks
(D) / (E) / (F) / 
(60)            
Minute Cost
Rounded Minute 
Cost
1 - Doctor 451,1 € 48.142.321,56 € 106.724,71 38 44 1,0638 1,06
1 - Doctor -  Anaesthesists 80,9 € 9.376.197,54 € 115.921,07 38 42 1,2105 1,21
1 - Doctors - Radiologists 28,9 € 3.125.648,77 € 108.320,55 38 42 1,1312 1,13
3 - Nurse 2.104,8 € 89.428.832,73 € 42.487,09 36 44 0,4470 0,45
4 - Health Technics - Radiol 87,4 € 3.716.203,29 € 42.530,13 36 42 0,4688 0,47
7898 - OSS 583,3 € 19.390.346,04 € 33.241,06 36 44 0,3498 0,35  
 
I multiplied the cost per minute of each role by the minutes consumed and for the numbers of 
workers operating. 
 
The Preparatory and Post-Operative phases: 
 
t N° Minute Cost Cost N°
Minute 
Cost Cost N° Minute Cost Cost
1 Taking in Charge 20 1 1,13 22,6 1 1,21 24,2 1 0,45 9
2 Acceptance 5 0 1,13 0 0 1,21 0 0 0,45 0
3 Confirm and Consensus Acquisition 10 1 1,13 11,3 1 1,21 12,1 0 0,45 0
4 Access to the Angiographic Room 10 0 1,13 0 0 1,21 0 1 0,45 4,5
5 Placement of the Patioent o on the Table 10 1 1,13 11,3 1 1,21 12,1 1 0,45 4,5
6 Sedation 5 0 1,13 0 1 1,21 6,05 1 0,45 2,25
6.a General Anesthesia 10 0 1,13 0 1 1,21 12,1 1 0,45 4,5
7 Preparation of the Sterile Environment 5 1 1,13 5,65 1 1,21 6,05 1 0,45 2,25
8 Diagnostic Phase 15 1 1,13 16,95 1 1,21 18,15 1 0,45 6,75
9 Operative Phase 2 1,13 0 1 1,21 0 1 0,45 0
10 Medication 10 1 1,13 11,3 1 1,21 12,1 1 0,45 4,5
11 TAC Final Control 5 1 1,13 5,65 1 1,21 6,05 0 0,45 0
12 Mobilizaiton of the patient 5 0 1,13 0 1 1,21 6,05 1 0,45 2,25
13 Transfer of the Patient 15 0 1,13 0 0 1,21 0 1 0,45 6,75
13a In Neuroscience, in anesthesia 0 1,13 0 1 1,21 0 0 0,45 0
13b In Neuroscience, intubated or awake 0 1,13 0 0 1,21 0 0 0,45 0
13c Other Intensive Therapy, in AOP 0 1,13 0 1 1,21 0 0 0,45 0
13d Other Intensive Therapy, in other Firm 0 1,13 0 1 1,21 0 0 0,45 0
13e Arrival Hospital, in other firm 0 1,13 0 0 1,21 0 0 0,45 0
14 Room Rearrangement 20 0 1,13 0 0 1,21 0 1 0,45 9
15 Images Filing 5 1 1,13 5,65 0 1,21 0 0 0,45 0
16 Counting and Printing of the RX dose 5 0 1,13 0 0 1,21 0 0 0,45 0
17 Medical Record and Operatory Act Registration 15 1 1,13 16,95 0 1,21 0 0 0,45 0
18 Clinic Re-evlauatin 15 0 1,13 0 0 1,21 0 0 0,45 0
Neuroradiologist Anaesthesist Nurse
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t N° Minute Cost Cost N°
Minute 
Cost Cost N° Minute Cost Cost
1 Taking in Charge 20 0 0,47 0 1 1,06 21,2 0 0,35 0
2 Acceptance 5 1 0,47 2,35 0 1,06 0 0 0,35 0
3 Confirm and Consensus Acquisition 10 0 0,47 0 0 1,06 0 0 0,35 0
4 Access to the Angiographic Room 10 1 0,47 4,7 0 1,06 0 1 0,35 3,5
5 Placement of the Patioent o on the Table 10 1 0,47 4,7 0 1,06 0 0 0,35 0
6 Sedation 5 0 0,47 0 0 1,06 0 0 0,35 0
6.a General Anesthesia 10 0 0,47 0 0 1,06 0 0 0,35 0
7 Preparation of the Sterile Environment 5 0 0,47 0 0 1,06 0 0 0,35 0
8 Diagnostic Phase 15 1 0,47 7,05 0 1,06 0 0 0,35 0
9 Operative Phase 1 0,47 0 0 1,06 0 0 0,35 0
10 Medication 10 0 0,47 0 0 1,06 0 0 0,35 0
11 TAC Final Control 5 1 0,47 2,35 0 1,06 0 0 0,35 0
12 Mobilizaiton of the patient 5 1 0,47 2,35 0 1,06 0 1 0,35 1,75
13 Transfer of the Patient 15 0 0,47 0 0 1,06 0 0 0,35 0
13a In Neuroscience, in anesthesia 0 0,47 0 0 1,06 0 1 0,35 0
13b In Neuroscience, intubated or awake 0 0,47 0 0 1,06 0 1 0,35 0
13c Other Intensive Therapy, in AOP 0 0,47 0 0 1,06 0 0 0,35 0
13d Other Intensive Therapy, in other Firm 0 0,47 0 0 1,06 0 0 0,35 0
13e Arrival Hospital, in other firm 0 0,47 0 0 1,06 0 0 0,35 0
14 Room Rearrangement 20 1 0,47 9,4 0 1,06 0 1 0,35 7
15 Images Filing 5 1 0,47 2,35 0 1,06 0 0 0,35 0
16 Counting and Printing of the RX dose 5 1 0,47 2,35 0 1,06 0 0 0,35 0
17 Medical Record and Operatory Act Registration 15 0 0,47 0 0 1,06 0 0 0,35 0
18 Clinic Re-evlauatin 15 0 0,47 0 1 1,06 15,9 0 0,35 0
OSSTechnic Radiologist Other Doctor
 
 
The workforce cost of the Phases: 
 
N° Name t Workforce Cost
1 Taking in Charge 15 77
2 Acceptance 5 2,35
3 Confirm and Consensus Acquisition 10 23,4
4 Access to the Angiographic Room 5 12,7
5 Placement of the Patioent o on the Table 5 32,6
6 Sedation 5 8,3
6.a General Anesthesia 10 16,6
7 Preparation of the Sterile Environment 5 13,95
8 Diagnostic Phase 15 48,9
9 Operative Phase 0
10 Medication 10 27,9
11 TAC Final Control 5 14,05
12 Mobilizaiton of the patient 5 12,4
13 Transfer of the Patient 15 6,75
13a In Neuroscience, in anesthesia 0
13b In Neuroscience, intubated or awake 0
13c Other Intensive Therapy, in AOP 0
13d Other Intensive Therapy, in other Firm 0
13e Arrival Hospital, in other firm 0
14 Room Rearrangement 15 25,4
15 Images Filing 5 8
16 Counting and Printing of the RX dose 5 2,35
17 Medical Record and Operatory Act Registration 15 16,95
18 Clinic Re-evlauatin 15 15,9  
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Workforce Cost of  the procedures: 
As from the flow chat, in every procedure the following team members are present: 2 
Neuroradiologist (1.13 €/Minute), one Nurse (0.46€/Minute) and one Radiology Technician 
(0.47 €/Minute) 
 
 
N° Name t Nurse Technician Neruoradiologist (2) Workforce Tot Cost 
1 Sclero/Embolization of Vascular Malformation 40 18,4 18,8 90,4 € 128
2 Integrative Angiography 30 13,8 14,1 67,8 € 96
3 Carotid Stenting 48 22,08 22,56 108,48 € 153
3.a Carotid Stenting in Thrombectomy 20 9,2 9,4 45,2 € 64
4 Intracranial Stenting 91 41,86 42,77 205,66 € 290
4.a Intracranial Stenting in Thrombectomy 20 9,2 9,4 45,2 € 64
5 Peripheral Stenting 68 31,28 31,96 153,68 € 217
6 Embolization: Brain AVF 181 83,26 85,07 409,06 € 577
7 Embolization: Extra-cranial AVF 120 55,2 56,4 271,2 € 383
8 Embolization: Spinal AVF 150 69 70,5 339 € 479
9 Embolization: Brain AVM 163 74,98 76,61 368,38 € 520
10 Embolization: Spinal AVM 130 59,8 61,1 293,8 € 415
11 Embolization: Extra-Cranial AVM 130 59,8 61,1 293,8 € 415
12 Embolization: Aneurism coiling 99 45,54 46,53 223,74 € 316
12.a Embolization: Aneurism BAC remodeling 132 60,72 62,04 298,32 € 421
12.a.b Embolization: Aneurism SAC 149 68,54 70,03 336,74 € 475
12.a.b.c Embolization: Aneurism with Stent FD 127 58,42 59,69 287,02 € 405
12.a.b.c.d Embolization: Other 127 58,42 59,69 287,02 € 405
13 Occlusion Test 75 34,5 35,25 169,5 € 239
14 Intracranial Vasospasm Treatment 80 36,8 37,6 180,8 € 255
15 Spinal-Bone Biopsy 30 13,8 14,1 67,8 € 96
16 Ozonetherapy - Facets Infiltration 30 13,8 14,1 67,8 € 96
17 Vertebroplasty 40 18,4 18,8 90,4 € 128
18 Thrombo-aspiration 84 38,64 39,48 189,84 € 268
18.a Intracranial Thrombectomy 49 22,54 23,03 110,74 € 156
19 Intra-arterial Chemiotherapy of RTB 133 61,18 62,51 300,58 € 424
20 Tumor Embolization - pre.op. 123 56,58 57,81 277,98 € 392
21 Tumor Embolization Spinal-Head&neck 123 56,58 57,81 277,98 € 392
22 Trauma/bleeding Embolization 115 52,9 54,05 259,9 € 367  
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4.3.3 - Activities Allocation 
 
At this point I have the cost of every phase and every procedure.  
 
N° Phase t Drugs Devices Technology Workforce Cost Tot Cost
1 Taking in Charge 20' 0 0 0 77 € 77
2 Acceptance 5' 0 0 0 2,35 € 2
3 Confirm and Consensus Acquisition 10' 0 0 0 23,4 € 23
4 Access to the Angiographic Room 10' 0 0 0 12,7 € 13
5 Placement of the Patioent on the Table 10' 1 9 0 32,6 € 42
6 Sedation 5' 31 20 0 8,3 € 59
6.a General Anesthesia 10' 36 28 0 16,6 € 81
7 Preparation of the Sterile Environment 5' 4 94 0 13,95 € 112
8 Diagnostic Phase 15' 10 60 447 48,9 € 565
9 Operative Phase (See following Chart) 0 0 0 0 € 0
10 Medication 10' 0 123 0 27,9 € 151
11 TAC Final Control 5' 0 0 0 14,05 € 14
12 Mobilizaiton of the patient 5' 0 0 0 12,4 € 12
13 Transfer of the Patient 15' 0 0 0 6,75 € 7
13a In Neuroscience, in anesthesia 0 0 0 0 € 0
13b In Neuroscience, intubated or awake 0 0 0 0 € 0
13c Other Intensive Therapy, in AOP 0 0 0 0 € 0
13d Other Intensive Therapy, in other Firm 0 0 0 0 € 0
13e Arrival Hospital, in other firm 0 0 0 0 € 0
14 Room Rearrangement 20' 0 0 0 25,4 € 25
15 Images Filing 5' 0 0 0 8 € 8
16 Counting and Printing of the RX dose 5' 0 0 0 2,35 € 2
17 Medical Record and Operatory Act Registration 15' 0 0 0 16,95 € 17
18 Clinic Re-evlauation 15' 0 0 0 15,9 € 16  
 
 
The total cost of the pre and post phases must be summed up to the procedures’ costs, keeping 
in mind that the procedure 15, 16 and 17 does not have the phase 8, the Diagnostic Phase and 
that the phases 6 and 6.a are alternatives.  This generates 4 possibilities: 
 
Sedation
1145,39
580,13
General Anestesia
Cost with Phase 8
Cost without Phase 8
1167,86
602,60  
 
In this study I will consider the average value for the combinations with and without the 
Diagnostic Phase. 
 
1156,62
591,36
Cost with Phase 8
Cost without Phase 8  
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At this point I can calculate the total cost of every procedure: 
 
N° Name Workforce Devices
Generic Devices  
( Angiograpghic 
Room)
General 
Devices
Angiographic 
Drugs
General 
Drugs
General 
Services
General 
Technology
 Procedure 
Cost 
1 Sclero/Embolization of Vascular Malformation 127,60 17,82 43,42 1,01 227,61 0,29 4,48 26,32 € 449
2 Integrative Angiography 95,70 21,74 32,56 1,01 170,71 0,29 4,48 26,32 € 353
3 Carotid Stenting 153,12 2509,20 52,10 1,01 273,14 0,29 4,48 26,32 € 3.020
3.a Carotid Stenting in Thrombectomy 153,12 2266,42 52,10 1,01 273,14 0,29 4,48 26,32 € 2.777
4 Intracranial Stenting 290,29 7570,26 98,77 1,01 517,82 0,29 4,48 26,32 € 8.509
4.a Intracranial Stenting in Thrombectomy 290,29 5182,89 98,77 1,01 517,82 0,29 4,48 26,32 € 6.122
5 Peripheral Stenting 216,92 1904,68 98,77 1,01 517,82 0,29 4,48 26,32 € 2.770
6 Embolization: Brain AVF 577,39 6181,32 196,46 1,01 1029,95 0,29 4,48 26,32 € 8.017
7 Embolization: Extra-cranial AVF 382,80 5593,91 196,46 1,01 1029,95 0,29 4,48 26,32 € 7.235
8 Embolization: Spinal AVF 478,50 7065,96 196,46 1,01 1029,95 0,29 4,48 26,32 € 8.803
9 Embolization: Brain AVM 519,97 8367,71 176,93 1,01 927,53 0,29 4,48 26,32 € 10.024
10 Embolization: Spinal AVM 414,70 3518,20 176,93 1,01 927,53 0,29 4,48 26,32 € 5.069
11 Embolization: Extra-Cranial AVM 414,70 6419,80 176,93 1,01 927,53 0,29 4,48 26,32 € 7.971
12 Embolization: Aneurism coiling 315,81 6185,88 107,46 1,01 563,34 0,29 4,48 26,32 € 7.205
12.a Embolization: Aneurism BAC remodeling 421,08 2020,32 143,28 1,01 751,13 0,29 4,48 26,32 € 3.368
12.a.b Embolization: Aneurism SAC 475,31 5383,93 161,73 1,01 847,86 0,29 4,48 26,32 € 6.901
12.a.b.c Embolization: Aneurism with Stent FD 405,13 13389,85 137,85 1,01 722,67 0,29 4,48 26,32 € 14.688
12.a.b.c.d Embolization: Other 405,13 12079,43 137,85 1,01 722,67 0,29 4,48 26,32 € 13.377
13 Occlusion Test 239,25 2374,12 98,23 1,01 722,67 0,29 4,48 26,32 € 3.466
14 Intracranial Vasospasm Treatment 255,20 1065,48 86,83 1,01 455,23 0,29 4,48 26,32 € 1.895
15 Spinal-Bone Biopsy 95,70 40,97 32,56 1,01 170,71 0,29 4,48 26,32 € 372
16 Ozonetherapy - Facets Infiltration 95,70 7,32 32,56 1,01 170,71 0,29 4,48 26,32 € 338
17 Vertebroplasty 127,60 801,96 43,42 1,01 227,61 0,29 4,48 26,32 € 1.233
18 Thrombo-aspiration 267,96 4174,82 68,42 1,01 278,83 0,29 4,48 26,32 € 4.822
18.a Intracranial Thrombectomy 156,31 4645,46 53,19 1,01 278,83 0,29 4,48 26,32 € 5.166
19 Intra-arterial Chemiotherapy of RTB 424,27 1512,09 108,33 1,01 699,91 0,29 4,48 26,32 € 2.777
20 Tumor Embolization - pre.op. 392,37 4732,99 133,51 1,01 699,91 0,29 4,48 26,32 € 5.991
21 Tumor Embolization Spinal-Head&neck 392,37 1974,91 133,51 1,01 654,39 0,29 4,48 26,32 € 3.187
22 Trauma/bleeding Embolization 366,85 2752,12 62,41 1,01 654,39 0,29 4,48 26,32 € 3.868  
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These costs, summed to the cost of the preparatory and Post Phases will create the base for the 
tariff (Full Cost).  
 
 
 
N° Name
Pre and 
Post       
t
t Pre Post cost
 Procedure 
Cost  Total Time Total Cost
1 Sclero/Embolization of Vascular Malformation 115' 40' € 1.179 € 449 155' € 1.627
2 Integrative Angiography 115' 30' € 1.179 € 353 145' € 1.532
3 Carotid Stenting 115' 48' € 1.179 € 3.020 163' € 4.199
3.a Carotid Stenting in Thrombectomy 115' 48' € 1.179 € 2.777 163' € 3.956
4 Intracranial Stenting 115' 91' € 1.179 € 8.509 206' € 9.688
4.a Intracranial Stenting in Thrombectomy 115' 91' € 1.179 € 6.122 206' € 7.301
5 Peripheral Stenting 115' 68' € 1.179 € 2.770 183' € 3.949
6 Embolization: Brain AVF 115' 181' € 1.179 € 8.017 296' € 9.196
7 Embolization: Extra-cranial AVF 115' 120' € 1.179 € 7.235 235' € 8.414
8 Embolization: Spinal AVF 115' 150' € 1.179 € 8.803 265' € 9.982
9 Embolization: Brain AVM 115' 163' € 1.179 € 10.024 278' € 11.203
10 Embolization: Spinal AVM 115' 130' € 1.179 € 5.069 245' € 6.248
11 Embolization: Extra-Cranial AVM 115' 130' € 1.179 € 7.971 245' € 9.150
12 Embolization: Aneurism coiling 115' 99' € 1.179 € 7.205 214' € 8.383
12.a Embolization: Aneurism BAC remodeling 115' 132' € 1.179 € 3.368 247' € 4.547
12.a.b Embolization: Aneurism SAC 115' 149' € 1.179 € 6.901 264' € 8.080
12.a.b.c Embolization: Aneurism with Stent FD 115' 127' € 1.179 € 14.688 242' € 15.866
12.a.b.c.d Embolization: Other 115' 127' € 1.179 € 13.377 242' € 14.556
13 Occlusion Test 115' 75' € 1.179 € 3.466 190' € 4.645
14 Intracranial Vasospasm Treatment 115' 80' € 1.179 € 1.895 195' € 3.074
15 Spinal-Bone Biopsy 100' 30' € 614 € 372 130' € 986
16 Ozonetherapy - Facets Infiltration 100' 30' € 614 € 338 130' € 952
17 Vertebroplasty 100' 40' € 614 € 1.233 140' € 1.846
18 Thrombo-aspiration 115' 84' € 1.179 € 4.822 199' € 6.001
18.a Intracranial Thrombectomy 115' 49' € 1.179 € 5.166 164' € 6.345
19 Intra-arterial Chemiotherapy of RTB 115' 133' € 1.179 € 2.777 248' € 3.956
20 Tumor Embolization - pre.op. 115' 123' € 1.179 € 5.991 238' € 7.170
21 Tumor Embolization Spinal-Head&neck 115' 123' € 1.179 € 3.187 238' € 4.366
22 Trauma/bleeding Embolization 115' 115' € 1.179 € 3.868 230' € 5.047
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To obtain the full cost, general cost should be added through a mark-up (Cost + 30%). The 
30% quota has been elaborated through a study by the AOP on the Structural Margins. The 
costs of the firm have been allocated by direct, indirect and general.  The indirect in this case 
have been set as general, because a driver to allocate them was missing. The general amount 
of cost has been divided by the total consumption of the firm.  In 4 years the percentage of the 
General costs has always been around 30%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Consumptive 
2012 
Consumptive  
2013 
Consumptive  
2014  
Consumptive  
2015 
Firm Total Cost 565.282.153 573.334.853 560.345.300 576.422.238 
Direct Costs 433.540.924 435.061.484 423.042.458 450.884.732 
General Costs 131.741.229 138.273.369 137.302.842 125.537.506 
% General Cost (B/A) 30% 32% 32% 28% 
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So was possible to include the general costs inside the study: 
 
 
 
N° Name Full Cost (Mark Up 30%)
1 Sclero/Embolization of Vascular Malformation € 2.164
2 Integrative Angiography € 2.037
3 Carotid Stenting € 5.584
3.a Carotid Stenting in Thrombectomy € 5.261
4 Intracranial Stenting € 12.885
4.a Intracranial Stenting in Thrombectomy € 9.710
5 Peripheral Stenting € 5.252
6 Embolization: Brain AVF € 12.231
7 Embolization: Extra-cranial AVF € 11.191
8 Embolization: Spinal AVF € 13.276
9 Embolization: Brain AVM € 14.900
10 Embolization: Spinal AVM € 8.310
11 Embolization: Extra-Cranial AVM € 12.169
12 Embolization: Aneurism coiling € 11.150
12.a Embolization: Aneurism BAC remodeling € 6.047
12.a.b Embolization: Aneurism SAC € 10.746
12.a.b.c Embolization: Aneurism with Stent FD € 21.102
12.a.b.c.d Embolization: Other € 19.360
13 Occlusion Test € 6.178
14 Intracranial Vasospasm Treatment € 4.088
15 Spinal-Bone Biopsy € 1.311
16 Ozonetherapy - Facets Infiltration € 1.266
17 Vertebroplasty € 2.456
18 Thrombo-aspiration € 7.981
18.a Intracranial Thrombectomy € 8.439
19 Intra-arterial Chemiotherapy of RTB € 5.261
20 Tumor Embolization - pre.op. € 9.536
21 Tumor Embolization Spinal-Head&neck € 5.807
22 Trauma/bleeding Embolization € 6.712
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4.3.4 – Control of result Coherence 
 
The last step to finish the study is a double check between the results and the initial data28.  
 
For the devices the total consumption registered in the management accounting system 
amounts to €1.145.860 for the 2015 and € 994.711 for the 2016 until October. If the study is 
correct, I expect the sum of the costs of the devices for the Phases and the Procedures to be 
almost equalt to the total consumption in the same period. It cannot be perfectly similar due to 
some stocks of materials in the warehouse. To bypass the “stock bias” we choose to consider 
a two-year period.  
To obtain the devices’ cost for the phases we need to multiply the total cost of the devices for 
all the phases (they are the same in every service) for the number of procedures in the 2015 
and 2016. 
 
Cost per Phase N° of Procedure 2015 N° of Procedure 2016
€ 333 275 348
Tot Cost € 91.575 € 115.884
Devices' Cost in the Phases 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
28 I will not perform the check for the Technology and the Services because they have been allocated without 
weight, only dividing the total cost for the number of procedures.  
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The cost of devices for the procedures (Sum of the devices cost multiplied by number of 
procedures in the 2015 and 2016): 
 
N° Name Devices
Generic Devices  
( Angiograpghic 
Room)
General 
Devices
N° of 
Procedures 
2015
N° of Procedures 
2016 Device Cost 2015 Device Cost 2016
1 Sclero/Embolization of Vascular Malformation 17,82 43,42 1,01 43 48 € 2.677 € 2.988
2 Integrative Angiography 21,74 32,56 1,01 26 30 € 1.438 € 1.659
3 Carotid Stenting 2509,20 52,10 1,01 24 17 € 61.495 € 43.559
3.a Carotid Stenting in Thrombectomy 2266,42 52,10 1,01 0 0 € 0 € 0
4 Intracranial Stenting 7570,26 98,77 1,01 9 1 € 69.030 € 7.670
4.a Intracranial Stenting in Thrombectomy 5182,89 98,77 1,01 0 0 € 0 € 0
5 Peripheral Stenting 1904,68 98,77 1,01 0 0 € 0 € 0
6 Embolization: Brain AVF 6181,32 196,46 1,01 9 10 € 57.409 € 63.788
7 Embolization: Extra-cranial AVF 5593,91 196,46 1,01 0 0 € 0 € 0
8 Embolization: Spinal AVF 7065,96 196,46 1,01 0 0 € 0 € 0
9 Embolization: Brain AVM 8367,71 176,93 1,01 12 13 € 102.548 € 111.093
10 Embolization: Spinal AVM 3518,20 176,93 1,01 0 0 € 0 € 0
11 Embolization: Extra-Cranial AVM 6419,80 176,93 1,01 0 0 € 0 € 0
12 Embolization: Aneurism coiling 6185,88 107,46 1,01 9 14 € 56.649 € 88.121
12.a Embolization: Aneurism BAC remodeling 2020,32 143,28 1,01 15 14 € 32.469 € 30.305
12.a.b Embolization: Aneurism SAC 5383,93 161,73 1,01 5 3 € 27.733 € 16.640
12.a.b.c Embolization: Aneurism with Stent FD 13389,85 137,85 1,01 14 15 € 189.402 € 202.931
12.a.b.c.d Embolization: Other 12079,43 137,85 1,01 0 0 € 0 € 0
13 Occlusion Test 2374,12 98,23 1,01 0 0 € 0 € 0
14 Intracranial Vasospasm Treatment 1065,48 86,83 1,01 5 15 € 5.767 € 17.300
15 Spinal-Bone Biopsy 40,97 32,56 1,01 16 28 € 1.193 € 2.087
16 Ozonetherapy - Facets Infiltration 7,32 32,56 1,01 7 18 € 286 € 736
17 Vertebroplasty 801,96 43,42 1,01 36 43 € 30.470 € 36.395
18 Thrombo-aspiration 4174,82 68,42 1,01 0 33 € 0 € 140.060
18.a Intracranial Thrombectomy 4645,46 53,19 1,01 30 22 € 140.990 € 103.393
19 Intra-arterial Chemiotherapy of RTB 1512,09 108,33 1,01 0 7 € 0 € 11.350
20 Tumor Embolization - pre.op. 4732,99 133,51 1,01 10 15 € 48.675 € 73.013
21 Tumor Embolization Spinal-Head&neck 1974,91 133,51 1,01 0 0 € 0 € 0
22 Trauma/bleeding Embolization 2752,12 62,41 1,01 5 2 € 14.078 € 5.631  
 
The Sum:  
Total 2015 Total 2016
€ 842.310 € 958.719  
 
 
The total cost of the devices, during years 2015 and 2016 was € 2.140.572. The sum of the 
devices’ cost from the study is:   
 
From Study € 2.008.488
From  Management Accounting System € 2.140.572
Coverage ( not considering Warehouse) 94%
Devices' Cost
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The coverage stops at 94%, that anyway can be considered a good result, because of the stock 
in the warehouse and a part of cost of the devices that has been allocated to all the 
Neuroradiology’s activity, also the diagnostic one. That cost is around €26.000 and would, 
with the warehouse, lead the percentage of coverage closer to 100%. 
 
 
The check of the Personnel costs is more difficult, as the team works not only in the 
angiographic room, but also in the diagnostic section of the Department, which is not 
considered in this study. For this reason, we need to estimate the percentage of workforce 
working for the angiographic room, which in not easy due to the frequent emergencies. To 
perform this calculation with effective precision I would have needed the turns registry of the 
department and the operatory Registries. Unfortunately, I couldn’t elaborate this data and I 
adopted an ABC approach. 
With a series of consulting with some Doctors of that department we estimated that the 
percentage of time and personnel on the procedures studied here, could be around 20-25% of 
the total time-personnel consumption. Moreover, here I take in account an hour, called factor 
“K” to consider the inactive time that the personnel of the Angiographic Room usually waits 
between 2 procedures 
 
Procedures € 61.423
Pre and Post Phases € 100.375
"K" Factor
Euro/min min tot N° Prest Tot
Doctor 1,13 60 68 275 18.645
OSS 0,35 60 21 275 5.775
Technician 0,47 60 28 275 7.755
Tot € 193.973
Tot € 1.100.000
18%
From Study
From Budget 
Coverage
Personnel Cost
From Study
€ 32.175
 
 
As estimated, the personnel cost is around 20-25%.  It would be useful to go deeper with this 
analysis,  
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The drug Cost Coverage: 
 
As first I multiply the Drugs consuming of the procedure for the numbers of procedures 
performed in the 201529. 
 
N° Name General Drugs
Angiographic 
Drugs
N° of 
Procedures 
2015
Drug cost 
2015
1 Sclero/Embolization of Vascular Malformation 0,29 227,61 43 € 9.800
2 Integrative Angiography 0,29 170,71 26 € 4.446
3 Carotid Stenting 0,29 273,14 24 € 6.562
3.a Carotid Stenting in Thrombectomy 0,29 273,14 0 € 0
4 Intracranial Stenting 0,29 517,82 9 € 4.663
4.a Intracranial Stenting in Thrombectomy 0,29 517,82 0 € 0
5 Peripheral Stenting 0,29 517,82 0 € 0
6 Embolization: Brain AVF 0,29 1029,95 9 € 9.272
7 Embolization: Extra-cranial AVF 0,29 1029,95 0 € 0
8 Embolization: Spinal AVF 0,29 1029,95 0 € 0
9 Embolization: Brain AVM 0,29 927,53 12 € 11.134
10 Embolization: Spinal AVM 0,29 927,53 0 € 0
11 Embolization: Extra-Cranial AVM 0,29 927,53 0 € 0
12 Embolization: Aneurism coiling 0,29 563,34 9 € 5.073
12.a Embolization: Aneurism BAC remodeling 0,29 751,13 15 € 11.271
12.a.b Embolization: Aneurism SAC 0,29 847,86 5 € 4.241
12.a.b.c Embolization: Aneurism with Stent FD 0,29 722,67 14 € 10.121
12.a.b.c.d Embolization: Other 0,29 722,67 0 € 0
13 Occlusion Test 0,29 722,67 0 € 0
14 Intracranial Vasospasm Treatment 0,29 455,23 5 € 2.278
15 Spinal-Bone Biopsy 0,29 170,71 16 € 2.736
16 Ozonetherapy - Facets Infiltration 0,29 170,71 7 € 1.197
17 Vertebroplasty 0,29 227,61 36 € 8.204
18 Thrombo-aspiration 0,29 278,83 0 € 0
18.a Intracranial Thrombectomy 0,29 278,83 30 € 8.373
19 Intra-arterial Chemiotherapy of RTB 0,29 699,91 0 € 0
20 Tumor Embolization - pre.op. 0,29 699,91 10 € 7.002
21 Tumor Embolization Spinal-Head&neck 0,29 654,39 0 € 0
22 Trauma/bleeding Embolization 0,29 654,39 5 € 3.273
€ 109.647Total  
 
 
 
 
                                                 
29 For the Drugs I consider only the 2015 because the data for the 2016 is too limited 
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The overview on the Drugs cost: 
 
Total
Procedure € 109.647 € 109.647
Cost per Phase N° of Procedure 2015
€ 81 275 € 22.275
€ 131.922
€ 131.603
100%
Tot Cost 2015
Total Drugs Cost
From IT extraction
Coverage  
 
To sum up on the coverages: 
 
Cost Devices Personnel Drugs
Coverage 94% 18%( as forecasted) 100%  
 
 
 
4.4 – Possible Applications 
 
The definition of the procedures’ costs can be helpful for the AOP by many point of views. 
The first regards the efficiency pursuing. With this data, the Department and the Hospital 
management can analyse if there is (and where) time waste, excessive material consumption 
and maybe personnel misallocation. It helps also, and this is confirmed by Doctor Causin, to 
grow in Doctors the awareness of the value they hold in their hands. This discourse may have 
ethical implications; in fact, I am not suggesting to treat patients differently considering the 
value of the material used, but to grow in awareness may benefit also in efficiency and 
efficacy.  
Several are then the pure economic implications for the AOP revenue management. Knowing 
the cost of a procedure, and knowing the DRG resulting, a cost-revenue comparison can be 
done.  
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As an example we can compare the different procedures which are catalogued under DRG 
453: “Craniotomy with implant, or principal diagnosis of severe pathology of the Neural 
System”. It is the possible DRG deriving from some of the procedures studied here. 
 
N° Name Tot Cost Cost With Mark Up DRG Tariff Gain/Loss
3.a Carotid Stenting in Thrombectomy € 3.866 € 5.142 543 € 11.695 € 6.553
4 Intracranial Stenting € 9.688 € 12.885 543 € 11.695 -€ 1.190
4.a Intracranial Stenting in Thrombectomy € 7.074 € 9.409 543 € 11.695 € 2.286
6 Embolization: Brain AVF € 9.196 € 12.231 543 € 11.695 -€ 536
9 Embolization: Brain AVM € 11.203 € 14.900 543 € 11.695 -€ 3.205
12 Embolization: Aneurism coiling € 8.383 € 11.150 543 € 11.695 € 545
12.a Embolization: Aneurism BAC remodeling € 4.547 € 6.047 543 € 11.695 € 5.648
12.a.b Embolization: Aneurism SAC € 8.080 € 10.746 543 € 11.695 € 949
12.a.b.c Embolization: Aneurism with Stent FD € 15.866 € 21.102 543 € 11.695 -€ 9.407
12.a.b.c.d Embolization: Other € 14.556 € 19.360 543 € 11.695 -€ 7.665
18 Thrombo-aspiration € 6.001 € 7.981 543 € 11.695 € 3.714
18.a Intracranial Thrombectomy € 6.345 € 8.439 543 € 11.695 € 3.256  
 
 
Knowing that the DRG are the results of groups of treatments, and that they should cover the 
average expense for those procedures, it is possible to perform a cost-revenue analysis with 
the sample size of this study. The result of the gain/loss for each procedure (in the chart), 
multiplied for the real yearly mix of procedures should result in a positive or at least 0 result. 
It is a pure theoretical application, considering that other procedures performed by Units 
different from the Neuroradiology department generate DRG 543, but such analysis gives a 
sense of the ordinary effect of the DRG reimbursement system on  Hospital’s revenues: 
 
N° Name
Mark Up      
(Full cost + 
30%)
DRG Tariff Gain /Loss Q 2015 Procedure's result
3.a Carotid Stenting in Thrombectomy € 5.142 543 € 11.695 € 6.553 0 € 0
4 Intracranial Stenting € 12.885 543 € 11.695 -€ 1.190 9 -€ 10.712
4.a Intracranial Stenting in Thrombectomy € 9.409 543 € 11.695 € 2.286 0 € 0
6 Embolization: Brain AVF € 12.231 543 € 11.695 -€ 536 9 -€ 4.822
9 Embolization: Brain AVM € 14.900 543 € 11.695 -€ 3.205 12 -€ 38.461
12 Embolization: Aneurism coiling € 11.150 543 € 11.695 € 545 9 € 4.905
12.a Embolization: Aneurism BAC remodeling € 6.047 543 € 11.695 € 5.648 15 € 84.717
12.a.b Embolization: Aneurism SAC € 10.746 543 € 11.695 € 949 5 € 4.744
12.a.b.c Embolization: Aneurism with Stent FD € 21.102 543 € 11.695 -€ 9.407 14 -€ 131.704
12.a.b.c.d Embolization: Other € 19.360 543 € 11.695 -€ 7.665 0 € 0
18 Thrombo-aspiration € 7.981 543 € 11.695 € 3.714 0 € 0
18.a Intracranial Thrombectomy € 8.439 543 € 11.695 € 3.256 30 € 97.695
€ 6.363Total  
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Looking at this table it is possible to say that the DRG 543, for the Neuroradiology 
Department, reported a gain for the AOP of € 6.363. According to this example, the tariff set 
for the DRG 543 makes the related procedures economically sustainable. 
This is not true for any DRG tariffs, as many studies show that some procedures, on the other 
hand, present severe losses in the tariff reimbursement, and it being not modifiable in the 
short period, this, in some situations and if an operator would want to cheat, could open the 
way for opportunistic behaviours, like patient selection by DRG profitability. 
 
The focus of this study is on the costs, but the goal is to arrive to a tariff list. The difference 
between the two is that the cost has an internal focus, and moreover, an internal use. The 
tariff, on the other hand, is for the external institutions or people. The term tariff, may lead to 
think that there exists a sort of market, and that the AOP could modify its tariff for outpatient 
at its will. This is true in part, because the system is organised to be a quasi-market, but also 
to operate as an integrate entities. Especially for the Stroke treatment this is true, with the new 
system of the Hub & Spoke, that allow the patients to obtain the best service thanks to the 
different specialization of the Hospitals for different treatments. In fact, each Hospital does 
not aim to perform everything at the best level, but to specialize in some treatments. The 
specialization is the base of the clinic profession. The tariff elaboration that the AOP will 
develop from this study may have different goals: one could be to look at the profit, and this 
maybe would lead to a tariff that covers the full cost. Another could be to leave the general 
cost coverage to other procedures and not to report the full mark up, this to favour the arrival 
of more patients to the AOP. The latter method is based on a Break Even point optic, that 
should allow the Hospital to cover its own production cost. Moreover, developing this tariff 
would offer the chance to other Hospitals, that have daily exchanges of patients with the AOP, 
to perform Make or Buy choices. This does not consider the episodically necessity to send the 
patient to a specialized centre, but give an idea of how an Hospital’s management could take 
some choices in making the agreements, especially in the Hub & Spoke system.  
Considering, instead, the whole Veneto’s Hospitals as an integrated system, the aim should be 
to ensure to the citizens the best possible service, and so this cost analysis should be seen as a 
starting point for the improvement of the Hub & Spoke System. 
 
The step further, for this study, would be the integration of these procedures into the regional, 
or even national, tariff list. As far as I know, this is the one of the few studies in Italy for these 
procedures, and they are not even present on the regional tariff lists. This led, in the past, to a 
wrong invoicing and wrong reimbursement. The adoption of the future tariff list, based on 
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real costs, would mean a better economically comprehension of these procedures and a 
possible National standardization. This, anyway, requires a long bureaucratic path, but could 
eventually lead to more realistic reimbursements and a better system accuracy. 
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Conclusions 
 
 
During my internship at the AOP, to compose my thesis, I have analysed the birth of the 
Italian National Health System, its development, its actual situation and its financing system. 
After this, I had the chance to study and experience the daily tasks, the structure and the 
economical concepts and techniques that are applied by the Programming & Control 
Operative Unit. Through the ABC method, I studied the cost of some Neuroradiology’s 
operative procedures performed in the Angiographic Room. Thanks to this method, I had the 
chance to interview Doctors and Administrative operators. With them, I went very deep in the 
analysis of the medical procedures, with their Clinic and Economical consequences. The 
output of this work has been the assessing of the Full Cost of certain procedures, and its 
possible use for the development of a tariff list. This work has been very interesting to me due 
to the very deep level of analysis and to the ethical consequences of the activities studied. 
Moreover, it has very concrete development possibilities. In fact, it is already programmed by 
the AOP to create the tariff list, and it will have this study as starting point.  
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N° Name Total Time Full Cost (Mark Up 30%)
1 Sclero/Embolization of Vascular Malformation 155' € 2.164
2 Integrative Angiography 145' € 2.037
3 Carotid Stenting 163' € 5.584
3.a Carotid Stenting in Thrombectomy 163' € 5.261
4 Intracranial Stenting 206' € 12.885
4.a Intracranial Stenting in Thrombectomy 206' € 9.710
5 Peripheral Stenting 183' € 5.252
6 Embolization: Brain AVF 296' € 12.231
7 Embolization: Extra-cranial AVF 235' € 11.191
8 Embolization: Spinal AVF 265' € 13.276
9 Embolization: Brain AVM 278' € 14.900
10 Embolization: Spinal AVM 245' € 8.310
11 Embolization: Extra-Cranial AVM 245' € 12.169
12 Embolization: Aneurism coiling 214' € 11.150
12.a Embolization: Aneurism BAC remodeling 247' € 6.047
12.a.b Embolization: Aneurism SAC 264' € 10.746
12.a.b.c Embolization: Aneurism with Stent FD 242' € 21.102
12.a.b.c.d Embolization: Other 242' € 19.360
13 Occlusion Test 190' € 6.178
14 Intracranial Vasospasm Treatment 195' € 4.088
15 Spinal-Bone Biopsy 130' € 1.311
16 Ozonetherapy - Facets Infiltration 130' € 1.266
17 Vertebroplasty 140' € 2.456
18 Thrombo-aspiration 199' € 7.981
18.a Intracranial Thrombectomy 164' € 8.439
19 Intra-arterial Chemiotherapy of RTB 248' € 5.261
20 Tumor Embolization - pre.op. 238' € 9.536
21 Tumor Embolization Spinal-Head&neck 238' € 5.807
22 Trauma/bleeding Embolization 230' € 6.712
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Deepening this economical field, that groups severe Law constraints, many ethical 
consequences and a limited budget, I realised that the spirit of the Managerialism reforms is 
still alive, and, even after huge steps, it is only at its initial stages of application. The lack of 
studies like this one shows how much there is still to do to really give accomplishment to that 
period’s reforms. 
On the other hand, the managerial aspect of an Hospital management necessarily steps back 
when a life is at stack, but this does not mean that a Managerial approach to Healthcare could 
not advantage the system.  
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Appendix 
 
 
Devices Year Cost Year Q Unit Cost Average Q. Utilized Tot Cost
PIA613L-SIRINGA CONO LUER ECCENTRIC S/AGO ST.20 ML 3 
PEZZIINJ/LIGHT (L27/GR)     20LE 32,28 540 0,05978 1 0,05978
PIA613H-SIRINGA CONO LUER ECCENTRIC S/AGO ST.10 ML 3 
PEZZIINJ/LIGHT (L27/GR)  10LE 181,54 4.800 0,03782 2 0,07564
PIA613G-SIRINGA CONO CENTRALE S/AGO STERILE 5 ML 3 
PEZZIINJ/LIGHT (L27B/GR)  55LC 12,75 500 0,025498 1 0,025498
PIT210F-CATETERE VESCICALE FOLEY IN SILICONE DUE VIE CH 16CM 
41 MONOUSO STERILE RUSCH-170605 (GAV/18) 45,02 30 1,5006 1 1,5006
PAAME11-ELETTRODI MONOUSO PER ECG 
RADIOTRASPARENTIF9069RM - (GR/4) 57,10 1.200 0,04758 3 0,14274
DCPS090-SENSORE X SATURIMETRO NELLCOR D25- MAX-A-I - ADULTI 1.476 6 10,248169 1 10,248169
PAVC951-UROMETRO - DISPOSITVO STERILE PER LA DIURESIORARIA 
158101110190 (GAV/7) 416,02 55 7,564 1 7,564
F21D000-FENTANEST INIETT 5F 2ML 0,1MGFENTANIL CITRATO 133,76 320 0,418 1 0,418
F22A650-DIPRIVAN 20 MG/ML 50 ML SIRINGA PRONTAPROPOFOL 7.732,92 290 26,665241 1 26,665241
F25A209-MIDAZOLAM ACC*10F 3ML 5MG/MLMIDAZOLAM CLORIDRA 77,42 220 0,3519 1 0,3519
F22A322-KETAMINA MOLT*5F 2ML 50MG/MLKETAMINA 16,39 5 3,278 1 3,278
50,329569Procedure's Devices' Total Cost = 
Phase 6 - Sedation
Fase 6 - Sedazione
 
 
Devices Year Cost Year Q Unit Cost Average Q. Utilized Tot CostPIT950B TUBO ENDOTRACHEALE CUFFIATO X ANESTESIA 
ADULTISTERILE MM. 5,5  IN-TUBE (L6G103/16) 80400055 2,44 5 0,49 1 0,49PIT125E CANNULA OROFARINGEA DI GUEDEL BIANCO 
70,00 MMSTERILE (G103/11)    900 0070 1 0,90 4 0,23 1 0,23
PAVD083-FILTRO ANTIBATTERICO ANTIVIRALE X ANESTE 83 100 0,83 1 0,83
PAVD13R-CIRCUITO PER LA SOMMINISTRAZIONE MANUAL 232 30 7,75 1 7,75
PAVD012-CATETERE MOUNT GIREVOLE IN PVC CM 10 SPAZ 13 20 0,67 1 0,67
PAVD159-CIRCUITO BASE PER VENTILATORI PER ANESTES 28 10 2,78 1 2,78PIA613H SIRINGA CONO LUER ECCENTRIC S/AGO ST.10 
ML 3 PEZZIINJ/LIGHT (L27/GR)  10LE 181,54 4.800 0,04 1 0,04PAV4703 MASCHERA X ANESTESIA TRASPARENTE 
BORDO GONFIABILETIPO BAMBINO  N. 3 (G103/11) 683T 51,09 29 1,76 1 1,76PIA6406 SIRINGA INFUSIONE IRRIGAZIONE CONO LUER 
LOCK TREPEZZI SENZA AGO 50/60ML  (L23F/G101/12)   66,21 300 0,22 2 0,44PATM60C PROLUNGA PUR D.3MM  RACCORDI TERM. 
LUER LOCK M/FL.100CM LINKSET NO PVC (AVTI5/10) 0,43 2,00 0,21 1 0,21
A0603-SACCHE E SISTEMI DI RACCOLTA LIQUIDI 416,02 55 7,56 1 7,56PIT210F CATETERE VESCICALE FOLEY IN SILICONE DUE 
VIE CH 16CM 41 MONOUSO STERILE RUSCH-170605 45,02 30 1,50 1 1,50
DCPS090-SENSORE X SATURIMETRO NELLCOR D25- MAX-A 1.476 6 245,96 1/24 10,25
PAAM931-NASO CANNULA RILEVAMENTO ETCO2 ADT/INF 305 25 12,20 0,5 6,10
F23B620-NIMBEX 2 5F 5ML 2MG/MLCISATRACURIO BESILAT 996,16 645,00 1,54 6 9,27
F22A650-DIPRIVAN 20 MG/ML 50 ML SIRINGA PRONTAPROP 7.732,92 290,00 26,67 1 26,67
F22A650-DIPRIVAN 20 MG/ML 50 ML SIRINGA PRONTAPROP 7.733 290 1 0,00
F21D000-FENTANEST INIETT 5F 2ML 0,1MGFENTANIL CITRA 133,76 320,00 0,42 1 0,42
76,96
Fase 6.1 - Intubazione
Phase 6.1 - General Anesthesia
Procedure's Devices' Total Cost =  
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Devices Year Cost Year Q Unit Cost Average Q. Utilized Tot Cost
PIA1818-AGO IPODERMICO MONOUSO CONO LUER G 18X1,10X40 MMBD 
MICROLANCE 3 (L1A/GR)   304622 35,64 3.000,00 0,01 1 0,01
PATE91B-DEFLUSSORE A 2 VIE IN PVC S/FTALATI C/FILTRO 0,45MICRON 
LUNGH. CM. 350 BIO DRIP IN011521 2.292,99 1.050,00 2,18 3 6,55
PITY310-INTRODUTTORI VALVOLATI ANGIOGRAFICI 6FR L10CMCOD. 
RSB60N10MQ  /AR35/ 1.366,40 70,00 19,52 1 19,52
PIG3265-GUANTO LATTICE S/POLVERE XCHIR.GEN. N. 7,5 STERILEPAIA (GR/L1) 
INTOUCH PF     INTW1075 315,37 1.100,00 0,29 2 0,57
PIA1822-AGO IPODERMICO MONOUSO CONO LUER G 22 0,70X40 MMBD 
MICROLANCE 3  (L1A/GR)  301000 5,90 500,00 0,01 1 0,01
PSB3511-LAME PER BISTURI MONOUSO - FIG. 11 - BB 511(CF. DA 100 PZ.) 36,17 5,00 7,23 1 7,23
PAT9061-PREMISACCA DA ML 1000ART. 5001.11.011 359,96 6,00 59,99 1 59,99
F46F093-SODIO CLORURO 0,9% 1000ML BAXTER VIAFLO 10SACCHESODIO 
CLORURO 707,71 1.010,00 0,70 3 2,10
FB-SANGUE ED ORGANI EMOPOIETICI 87,78 60,00 1,46 1 1,46
F46L071-LIDOCAINA CLOR. MNC 2% 200 MG/10 ML F.LELIDOCAINA (CARRELLO 
EMERGENZE-ANTIAR) 49,25 250,00 0,20 1 0,20
97,66
Phase 7 - Preparation of the Sterile Environment
Fase 7 - Preparazione Campo Sterile
Procedure's Devices' Total Cost =  
 
Devices Year Cost Year Q Unit Cost Average Q. Utilized Tot Cost
PITT299-RUBINETTO A 1 VIA-ALTA PRESSIONE-A SCATTO ATTACCOLUER-
LOCK   44-201 175,68 48,00 3,66 1 3,66
PATB796-RUBINETTO A TRE VIE - (SOLO PER RADIOLOGIE)INO31301 196,42 700,00 0,28 1 0,28
PITC256-CATETERE PER ANGIOGRAFIA SELETTIVA NYLON5F 100CM   451-
514H0 4184,60 350,00 11,96 1 11,96PIT152A-GUIDA ANGIOGRAFICA IDROFILA STANDARDD.0.035 180CM  
M00146152B1 10462,24 240,00 43,59 1 43,59PMM5251-FILM TRASPARENTE IN PUR STERILE CM 10X12TEGADERM 1626W 
(MS14A/13) 164,70 750,00 0,22 1 0,22
DZEI620-OMNIPAQUE 300MG I/ML FL 100MLIOEXOLO 1467,28 150,00 9,78 1 9,78
69,49
Fase 8 - Fase Diagnostica
Phase 8 - Diagnostic Phase
Phase's Devices' Total Cost =  
 
Devices Year Cost Year Q Unit Cost Average Q. Utilized Tot Cost
PITZ710-DISPOSIT. X  EMOSTASI ARTERIOSA ANGIOSEAL V.I.P.8 FR.   610133 8.625,40 70 123,22 1 123,22
PMC2116-MEDICAZIONE PREPARATA POST-OPERATORIA ADESIVA CON 
TAMPONE CM 7X5  (4AMPS13)   22670000000 8,80 440 0,02 1 0,02
123,24
Fase 10 - Medicazione
Phase 10 - Medication
Phase's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PIA0922-AGO CANNULA VENOSO PERIFERICO 1 VIA USO PEDIATRICOS/ALETTE 22G X25MM (28/G 0,25 0,25
PAV1413-CARTUCCIA MONOUSO DA 1,5 LITRI CF 50 PEZZIMEDIVAC FLEX  ADVANTAGE  COD. 656 1,74 1,74
PIA1423-AGO EPICRANICI A FARFALLA STERILI MONOUSOPIC MIRAGE G23X20  (4/G101/12) 03 044 0,07 0,07
PIA1641-AGO EPICRANICO A FARFALLA 25G X 19 MMCHEMIL FLY (L6/G101/12)   FLY25G 0,05 0,05
2,10
Sclero/Embolization of Vascular Malformation
Sclero/Embolizzazione angioma (MV)
1
Procedure's Devices' Total Cost =  
115 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITC229-CATETERE PER ANGIOGRAFIA SELETTIVA NYLON4F 65CM   451-415V0 12 11,96
PITT612-CATETERE PER ANGIOGRAFIA PANORAMICA PIGTAILD.E.5F 90CM   31-521 9 8,54
PITU162-INTRODUTTORE VALVOLATO ANGIOGRAFICO CON GUIDA5F .035'' 11CM  402-605X 10 9,76
PITU164-INTRODUTTORE VALVOLATO ANGIOGRAFICO CON GUIDA6F .035'' 11CM  402-606X 10 9,76
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7 7,32
47,34
Completamento Angiografico
2
Procedure's Devices' Total Cost = 
Integrative Angiography
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITBD3X-SISTEMA GONFIAGGIO  PRIORITY (INDEFLATOR+COPILOT+ INTRODUTTORE+TORQUE 1 18,30
PITY316-INTRODUTTORI VALVOLATI ANGIOGRAFICI 7 FR L25CMCOD. RSB70N25AQ /AR35/ 42,09
PITY115-GUIDA METALLICA 035-260 CM.TIPO ANGOLATO TERUMO RFCOD.RFGA35263M  /ESC.R/ 115,90
PIT2860-SISTEMA DI PROTEZIONE DA EMBOLO A FILTRO GUIDA 190 CM FILTER WIRE EZ  COD. 20 915,00
PITET7I-CATETERE GUIDA AMPIO LUME CON VALVOLA E DILATATOREVISTA BRITE TIP  8F 90CM 79,30
PIA9009-SIRINGA X INIETTORE ANGIOGRAFICO MARK V PKUSART. 200 FT Q 5,49
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47
PITRB51-CATETERE X PTA PICCOLI VASI 150CM 3.1FR 5,0-20ULTRA-SOFT SV   M0013895050200 108,58
PIT003T-CATETERI A PALLONCINO MONORAIL SU FILO GUIDA 0.014D.2,50 14MM 145CM FALCON 92,56
PITS96Y-STENT AUTOESPANDIBILE PER CAROTIDE ACCIAIO7/30MM  SCH-64707 alternatives
PITC92H-STENT CAROTIDEOTIPO NITINOL 7MMX30MM 5F 135CMPRECISE PRO RX   PC0730XCE alternatives
QPAFR32-STENT CAROTIDEO 9 MM X 30 MM MONOREIL 5 FRCASPER   CPR-0930-143RX alternatives
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32
2509,21
1.108 1108,20
3
Stent carotideo
Carotid Stenting
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITBD3X-SISTEMA GONFIAGGIO  PRIORITY (INDEFLATOR+COPILOT+ INTRODUTTORE+TORQUE 1 18 18,3
PIT2860-SISTEMA DI PROTEZIONE DA EMBOLO A FILTRO GUIDA 190 CM FILTER WIRE EZ  COD. 20 915 915
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16 16,47
PITRB51-CATETERE X PTA PICCOLI VASI 150CM 3.1FR 5,0-20ULTRA-SOFT SV   M0013895050200 109 108,58
PIT003T-CATETERI A PALLONCINO MONORAIL SU FILO GUIDA 0.014D.2,50 14MM 145CM FALCON 93 92,56
PITS96Y-STENT AUTOESPANDIBILE PER CAROTIDE ACCIAIO7/30MM  SCH-64707 1.199
PITC92H-STENT CAROTIDEOTIPO NITINOL 7MMX30MM 5F 135CMPRECISE PRO RX   PC0730XCE 882
QPAFR32-STENT CAROTIDEO 9 MM X 30 MM MONOREIL 5 FRCASPER   CPR-0930-143RX 1.019
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7 7,32
2266,42
1108,19
Carotid Stenting with Thrombectomy
Stent carotideo in corso di trombectomia
3.a
Procedure's Devices' Total Cost = 
1108,19
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITZ27E-GUIDA TRANSEND FLOPPY 300 CM  COD.46-815TARGET 439 439
PIT506A-PALLONE DA DILATAZIONE STENOSI INTRACRANICA OTWSEMICOMPLIANTE 9X3,0MM G 769 769
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16 16
PITBD3X-SISTEMA GONFIAGGIO  PRIORITY (INDEFLATOR+COPILOT+ INTRODUTTORE+TORQUE 1 18 18
QPAE462-STENT INTRACRANICO AUTOESPANDIBILE  NITINOL CONPUNTA DISTALE D.4MM 23MM 3.604 3.604
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS CO 598 598
PITSP25-CATETERE ARMATO PER PTA CURVA DIRITTA 6FR90 CM CAROTID SHEATH  DESTINATION 244 244
PITM034-CATETERE PORTANTE PER CATETERISMO COASSIALENAVIEN   RFXA072-115-08MP 549 549
PITNE02-GUIDA ORIENTABILE RIVEST. IDROFILICO NEUROVASCULARD.0.014 205CM SOFT NEURO 427 427
PITY318-INTRODUTTORI VALVOLATI ANGIOGRAFICI 8FR L25CMCOD. RSB80N25AQ  /AR35/ 42 42
PIT5082-PALLONE DA DILATAZIONE STENOSI INTRA/EXTRA CRANICASCAMBIO RAPIDO D.2.00MM 854 854
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7 7
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 3 3
7.570
Stent intracranico
Intracranial Stenting
4
Procedure's Devices' Total Cost =  
116 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITZ27E-GUIDA TRANSEND FLOPPY 300 CM  COD.46-815TARGET 439 439
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16 16
PITBD3X-SISTEMA GONFIAGGIO  PRIORITY (INDEFLATOR+COPILOT+ INTRODUTTORE+TORQUE 1 18 18
QPAE462-STENT INTRACRANICO AUTOESPANDIBILE  NITINOL CONPUNTA DISTALE D.4MM 23MM 3.604 3.604
PITSP25-CATETERE ARMATO PER PTA CURVA DIRITTA 6FR90 CM CAROTID SHEATH  DESTINATION 244 244
PIT5082-PALLONE DA DILATAZIONE STENOSI INTRA/EXTRA CRANICASCAMBIO RAPIDO D.2.00MM 854 854
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7 7
5.183
4.a
Stent intracranico
Intracranial Stenting in Thrombectomy
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16
PITZ710-DISPOSIT. X  EMOSTASI ARTERIOSA ANGIOSEAL V.I.P.8 FR.   610133 123,60 124
PAT4060-KIT RILEVAMENTO PRESSIONE A 1 VIA C/TRASDUTTOREMONOUSO T100209A (G4M/04) 8,86 9
PIT005T-CATETERI A PALLONCINO MONORAIL SU FILO GUIDA 0.014D.2,00 10MM 145CM FALCON 92,56 93
PITBD3X-SISTEMA GONFIAGGIO  PRIORITY (INDEFLATOR+COPILOT+ INTRODUTTORE+TORQUE 1 18,30 18
QPAPB09-PERIFERICO PREMONTATO ESPANSIONE PASSIVAD.E. 4MM 12MM   PALMAZ BLUE    PB 686,40 686
PITMC85-GUIDA X ANGIOPLASTICA CORONARICA PUNTA RAD.PREFOR.J D.0.14 190CM  1010480-H 62,40 62
PITY318-INTRODUTTORI VALVOLATI ANGIOGRAFICI 8FR L25CMCOD. RSB80N25AQ  /AR35/ 42,09 42
PIT5083-PALLONE DA DILATAZIONE STENOSI INTRA/EXTRA CRANICASCAMBIO RAPIDO D.2.50MM 854,00 854
1904,68
Stent periferico
Peripheral Stenting
5
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITM001-SET X  EMBOLIZZAZIONE LIQ.DO 2 FIALE ONYX 18 LD P+DMSO + 3 APPOSITE SIRINGHE C 967 4 3868,80
PITM00A-MICROCATETERE FLUSSO DIPENDENTE D.2.7F 1.3F 25CM170CM  MARATHON    105-5055 610 610,00
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16 16,47
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146 146,40
PITM006-MICROGUIDA IDROFILA MIRAGE GUIDEWIE .008"COD. 103-0608 317 317,20
PITY733-MICROCATETERI 2 MARKERS HEADWAY DUO MC162156S 610 610,00
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439 439,20
PITPN21-CATETERE ACCESSO INTRACRANICO LONG SHEAT6F 90/4 MPNEURON MAX   PNML6F08 341 alternatives
PITM034-CATETERE PORTANTE PER CATETERISMO COASSIALENAVIEN   RFXA072-115-08MP 549 alternatives
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7 7,32
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 3 2,88
6536,53
518,26
6
Embolizzazione: FAV Cerebrale
Embolization: Brain AVF
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITT299-RUBINETTO A 1 VIA-ALTA PRESSIONE-A SCATTO ATTACCOLUER-LOCK   44-201 3,7 3,7
PITM001-SET X  EMBOLIZZAZIONE LIQ.DO 2 FIALE ONYX 18 LD P+DMSO + 3 APPOSITE SIRINGHE C 967,2 4 3868,8
PITSP25-CATETERE ARMATO PER PTA CURVA DIRITTA 6FR90 CM CAROTID SHEATH  DESTINATION 244,0 244,0
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,5 16,5
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146,4 146,4
PITY733-MICROCATETERI 2 MARKERS HEADWAY DUO MC162156S 610,0 610,0
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PITM034-CATETERE PORTANTE PER CATETERISMO COASSIALENAVIEN   RFXA072-115-08MP 549,0 549,0
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,3 7,3
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 2,9 2,9
5887,73Procedure's Devices' Total Cost = 
Embolization: Extra-cranial AVF
Embolizzazione:FAV Extracranica
7
 
117 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITM001-SET X  EMBOLIZZAZIONE LIQ.DO 2 FIALE ONYX 18 LD P+DMSO + 3 APPOSITE SIRINGHE C 967 2 1.934
PITM00A-MICROCATETERE FLUSSO DIPENDENTE D.2.7F 1.3F 25CM170CM  MARATHON    105-5055 610 610
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16 16
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146 146
PITBL66-MICROGUIDA IDROFILICA  NITINOL .007 L.210CM CURVAD   HYBRID   2/HYBRID007D 549 549
PITY733-MICROCATETERI 2 MARKERS HEADWAY DUO MC162156S 610 610
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439 439
PITSP25-CATETERE ARMATO PER PTA CURVA DIRITTA 6FR90 CM CAROTID SHEATH  DESTINATION 244 244
PITM034-CATETERE PORTANTE PER CATETERISMO COASSIALENAVIEN   RFXA072-115-08MP 549 549
PAVD391-COLLA CHIRURGICA GLUBRAN 2 ML 1 A FIALAG-NB-2 (*D.D.185/07) 122 122
DZEI111-LIPIODOL ULTRA FLUIDE # ACIDO ETIODATO ML 10  F.(ESTERO) 195 195
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7 7
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 3 3
5425,38
8
Procedure's Devices' Total Cost = 
Embolization: Spinal AVF
Embolizzazione:FAV Spinale
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITT299-RUBINETTO A 1 VIA-ALTA PRESSIONE-A SCATTO ATTACCOLUER-LOCK   44-201 3,7 3,7
PITM001-SET X  EMBOLIZZAZIONE LIQ.DO 2 FIALE ONYX 18 LD P+DMSO + 3 APPOSITE SIRINGHE C 967,2 2 1.934,4
PITM00A-MICROCATETERE FLUSSO DIPENDENTE D.2.7F 1.3F 25CM170CM  MARATHON    105-5055 610,0 610,0
PIT152A-GUIDA ANGIOGRAFICA IDROFILA STANDARDD.0.035 180CM  M00146152B1 44,3 44,3
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,5 16,5
PITC21G-CATETERE GUIDA X NEURORADIOLOGIA CORDIS ENVOY-6F90 CM COD 670-256-90 146,4 146,4
PITBL73-CATETERE IDROFILICO PUR SIL MORBIDEZZA 1,2 F 15 CMBALT EXTRUSION COD. 2/MAGI 912,6 4 3.650,2
PITBL66-MICROGUIDA IDROFILICA  NITINOL .007 L.210CM CURVAD   HYBRID   2/HYBRID007D 549,0 549,0
PAVD391-COLLA CHIRURGICA GLUBRAN 2 ML 1 A FIALAG-NB-2 (*D.D.185/07) 122,0 2 244,0
DZEI111-LIPIODOL ULTRA FLUIDE # ACIDO ETIODATO ML 10  F.(ESTERO) 194,7 194,7
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,3 7,3
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 2,9 2,9
7403,4Procedure's Devices' Total Cost = 
Embolization: Brain AVM
Embolizzazione: MAV Cerebrale
9
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITM00A-MICROCATETERE FLUSSO DIPENDENTE D.2.7F 1.3F 25CM170CM  MARATHON    105-5055 610 610,00
PIT152A-GUIDA ANGIOGRAFICA IDROFILA STANDARDD.0.035 180CM  M00146152B1 44,3 44,30
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,5 16,47
PITC21G-CATETERE GUIDA X NEURORADIOLOGIA CORDIS ENVOY-6F90 CM COD 670-256-90 146,4 146,40
PITBL73-CATETERE IDROFILICO PUR SIL MORBIDEZZA 1,2 F 15 CMBALT EXTRUSION COD. 2/MAGI 912,6 2 1825,12
PITBL66-MICROGUIDA IDROFILICA  NITINOL .007 L.210CM CURVAD   HYBRID   2/HYBRID007D 549,0 549,00
PAVD391-COLLA CHIRURGICA GLUBRAN 2 ML 1 A FIALAG-NB-2 (*D.D.185/07) 122,0 122,01
DZEI111-LIPIODOL ULTRA FLUIDE # ACIDO ETIODATO ML 10  F.(ESTERO) 194,7 194,70
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,3 7,32
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 2,9 2,88
3518,20
Embolization: Spinal AVM
Embolizzazione: MAV Spinale
10
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITM001-SET X  EMBOLIZZAZIONE LIQ.DO 2 FIALE ONYX 18 LD P+DMSO + 3 APPOSITE SIRINGHE C 967,20 2 1934,40
PITM00A-MICROCATETERE FLUSSO DIPENDENTE D.2.7F 1.3F 25CM170CM  MARATHON    105-5055 610,00 610,00
PIT152A-GUIDA ANGIOGRAFICA IDROFILA STANDARDD.0.035 180CM  M00146152B1 44,30 44,30
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PITC21G-CATETERE GUIDA X NEURORADIOLOGIA CORDIS ENVOY-6F90 CM COD 670-256-90 146,40 146,40
PITBL73-CATETERE IDROFILICO PUR SIL MORBIDEZZA 1,2 F 15 CMBALT EXTRUSION COD. 2/MAGI 912,56 2 1825,12
PITBL66-MICROGUIDA IDROFILICA  NITINOL .007 L.210CM CURVAD   HYBRID   2/HYBRID007D 549,00 549,00
PAVD391-COLLA CHIRURGICA GLUBRAN 2 ML 1 A FIALAG-NB-2 (*D.D.185/07) 122,01 122,01
DZEI111-LIPIODOL ULTRA FLUIDE # ACIDO ETIODATO ML 10  F.(ESTERO) 194,70 194,70
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 2,88 2,88
5452,60
Embolization: Extra-Cranial AVM
11
Procedure's Devices' Total Cost = 
Embolizzazione: MAV Extracranica
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Devices Unit Cost Average Q. Utilized Tot Cost
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,20 439,2
PIT1442-EXCELSIOR SL 150CM  2 TIP MARKERSCOD.M0031681890 880,84 880,8
PITZ876-VALVOLA EMOSTATICA A Y PER MICROCATETERIBOSTON-TARGET COD. 4212421 34,07 34,1
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146,40 146,4
PITC21G-CATETERE GUIDA X NEURORADIOLOGIA CORDIS ENVOY-6F90 CM COD 670-256-90 146,40 146,4
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,5
PITT299-RUBINETTO A 1 VIA-ALTA PRESSIONE-A SCATTO ATTACCOLUER-LOCK   44-201 3,60 3,6
PITZA0A-SISTEMA DI DISTACCO PER SPIRALI INZONE 2.0 MONOUSOM00345100950 0,00 0,0
PITZ875-CAVO DI COLLEGAMENTO GDC-TARGET 451102-4(EX 451101) 0,00 0,0
PITZA0B-CAVO COLLEGAMENTO IZDS PER DISTACCATORE INZONE 2.0DISTACCO SPIRALI GDC   0,00 0,0
PIT152A-GUIDA ANGIOGRAFICA IDROFILA STANDARDD.0.035 180CM  M00146152B1 44,30 44,3
PITNE02-GUIDA ORIENTABILE RIVEST. IDROFILICO NEUROVASCULARD.0.014 205CM SOFT NEURO 427,00 427,0
PITEJ50-SPIRALI PER EMBOLIZZAZIONI TRUFILL DCS ORBITGALAXY 3MM X 8CM    640CX0308 707,20 alternatives
PITZA17-SPIRALE TARGET 360 ULTRA 3MM X 6CM M0035423060 655,20 alternatives
PITG709-SPIRALE  GUGLIELMI GDC-18 360 STANDARD18MM  X 40CM COD. 3481840 655,20 alternatives
PITMB8N-SPIRALE PLATINO NON MEDICATA NON FIBERED DISTACCOCONTROLLATO 10MM X 30 644,80 alternatives
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
2818,98Procedure's Devices' Total Cost = 
673,38
Embolization: Aneurism coiling
Embolizzazione: Aneurisma con spirali
12
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146,4 146,4
PITC21G-CATETERE GUIDA X NEURORADIOLOGIA CORDIS ENVOY-6F90 CM COD 670-256-90 146,4 146,4
PITY744-CATETERE A PALLONE PER OCCLUSIONE NEUROVASCOLAREEXTRA COMPLIANT SCEPT 1464 alternatives
PITBL79-MICROCATETERE A PALLONCINO X OCCLUSIONI INTRACER.TEMPORANEE L. 160CM 9M 1012,6 alternatives
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
2020,32
1281
Procedure's Devices' Total Cost = 
Embolizzazione: Aneurisma con pallone
Embolization: Aneurism BAC remodeling
12.a
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146,40 146,40
PITC21G-CATETERE GUIDA X NEURORADIOLOGIA CORDIS ENVOY-6F90 CM COD 670-256-90 146,40 146,40
PITZ27E-GUIDA TRANSEND FLOPPY 300 CM  COD.46-815TARGET 439,20 439,20
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,20 439,20
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS CO 597,80 597,80
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
QPAE462-STENT INTRACRANICO AUTOESPANDIBILE  NITINOL CONPUNTA DISTALE D.4MM 23MM 3603,60 alternatives
QPAR5021-LVIS JUNIOR - STENT INTRACRANICO 3,5 X 28 MM172530-CASJ 3120,00 alternatives
PIT5038-STENT INTRACRANICO AUTOES.LE NITINOL CELLE APERTE3X21MM NEUROFORM ATLAS 2652,00 alternatives
QPAE560-STENT INTRACRANICO PHENOX PCONUSMIS. 4X25 DIAM.LOOPS 6 - PCON-4-25-6-F 6760,00 alternatives
PIT5072-STENT INTRACRANICO AUTOESPANDIBILE IN NITINOLOBARREL VRD   BV-4065 5720,00 alternatives
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
5383,93
Embolization: Aneurism SAC
Embolizzazione: Aneurisma con stent
3591,14
12.a.b
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITSP25-CATETERE ARMATO PER PTA CURVA DIRITTA 6FR90 CM CAROTID SHEATH  DESTINATION 244 244
PITM034-CATETERE PORTANTE PER CATETERISMO COASSIALENAVIEN   RFXA072-115-08MP 549 549
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PITY115-GUIDA METALLICA 035-260 CM.TIPO ANGOLATO TERUMO RFCOD.RFGA35263M  /ESC.R/ 115,9 115,9
PITZ27E-GUIDA TRANSEND FLOPPY 300 CM  COD.46-815TARGET 439,2 439,2
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
QPAFR11-FRED - STENT DIVERSORE DI FLUSSO FRED3516 10400 alternatives
QPAE50H-STENT INTRACRANICO AUTOESPANDIBILE NITINOL2/SILK2.5X20 12480 alternatives
QPAE656-DISPOSITIVO PER EMBOLIZZAZIONE  3,50 MM 18 MMPIPELINE FLEX   PED-350-18 10400 alternatives
PITY73B-MICROCATETERE HEADWAY 27 3,1/2,6FR.MC272156S 610 610
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
D8CP513-HE077515 TEST ACT-LR -S10-(CONF. DA 45 PZ) (JACT - LR) 2,8792 2,8792
13389,9
12.a.b.c
10965,9
Procedure's Devices' Total Cost = 
Embolization: Aneurism with Stent FD
Embolizzazione: Aneurisma con Stent FD
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Devices Unit Cost Average Q. Utilized Tot Cost
PIT0115-MICROCATETERE X LA NAVIGAZIONE DEL DISPOSITIVO WEBD..027" L.145CM VIA      VIA- 976 alternatives A
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS CO 597,8 alternatives A
PIT085A-SISTEMA EMBOLIZZAZIONE ANEURISMA INTRACRANICOMEDINA MEDICAL   ED -7-090-F 6760 alternatives B
PIT0851-SISTEMA DI EMBOLIZZAZIONE ANEURISMI INTRACRANICIIN FILI NITINOL D.8MM L.4MM 10400 alternatives B
PITSP25-CATETERE ARMATO PER PTA CURVA DIRITTA 6FR90 CM CAROTID SHEATH  DESTINATION 244 244
PITM034-CATETERE PORTANTE PER CATETERISMO COASSIALENAVIEN   RFXA072-115-08MP 549 549
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PITY115-GUIDA METALLICA 035-260 CM.TIPO ANGOLATO TERUMO RFCOD.RFGA35263M  /ESC.R/ 115,9 115,9
PITZ27E-GUIDA TRANSEND FLOPPY 300 CM  COD.46-815TARGET 439,2 439,2
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
12095,9Procedure's Devices' Total Cost = 
12.a.b.c.d
Embolizzazione: Aneurisma con Stent altro
Embolization: Other
612,81
9672
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PIT506A-PALLONE DA DILATAZIONE STENOSI INTRACRANICA OTWSEMICOMPLIANTE 9X3,0MM G 768,6 768,6
PITBL79-MICROCATETERE A PALLONCINO X OCCLUSIONI INTRACER.TEMPORANEE L. 160CM 9M 1012,6 1012,6
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PITC21G-CATETERE GUIDA X NEURORADIOLOGIA CORDIS ENVOY-6F90 CM COD 670-256-90 146,4 146,4
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
2374,12Procedure's Devices' Total Cost = 
Occlusion Test
Test occlusione
13
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS CO 597,8 597,8
PUNU258-MONOSOF 2-0 45 CM NERO 3/8 TD 26 MM SN-764 11,886867 11,8869
F08E950-NIMOTOP PER INFUSIONE 10 MG  FLACONENIMODIPINA 9,2736286 9,27363
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
1065,48Procedure's Devices' Total Cost = 
Trattamento del vasospasmo
Intracranial Vasospasm Treatment
14
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PSB3511-LAME PER BISTURI MONOUSO - FIG. 11 - BB 511(CF. DA 100 PZ.) 7,88 7,88
PIAS43A-AGO X BIOPSIA OSTEOMIDOLLARE SISTEMA ANTI-LUSSAZ.13 G 15 CM FULLY REMOVE  32,94 32,94
DZG1574-CONTENITORE 60 ML RIEMPITO A 30 ML DI FORMALINAPRONTO USO (TAPPO ROSSO) 0,15 0,15
40,97
Biopsia spinale-Ossea
15
Procedure's Devices' Total Cost = 
Spinal-Bone Biopsy
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PIASA35-AGO X ASPIRAZIONE CITOLOGICA TIPO CHIBA 20G X 15CM(7/G105/13) CHIBELL   CH2015 3 3
PAV0036-FILTRO PER OZONO PER TRATTAMENTO OZONOTERAPIA11101046 5 5
7
16
Ozonoterapia - Infiltrazione faccette
Ozonetherapy - Facets Infiltration
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PSB3511-LAME PER BISTURI MONOUSO - FIG. 11 - BB 511(CF. DA 100 PZ.) 7,88 7,88
PIAS43G-AGO PER VERTEBROPLASTIC INPUGNATURA IN ABS13G X 15CM    KVT1315201C-A 46,116 46,12
PIE997-CONFIDENCE KIT CEMENTO SPINALE ALTA' VISCOSITA'7CC SENZA AGHI   283907000 747,968 747,97
801,96Procedure's Devices' Total Cost = 
17
Vertebroplastica 
Vertebroplasty
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Devices Unit Cost Average Q. Utilized Tot Cost
PITY318-INTRODUTTORI VALVOLATI ANGIOGRAFICI 8FR L25CMCOD. RSB80N25AQ  /AR35/ 42,09 42,09
PITPN21-CATETERE ACCESSO INTRACRANICO LONG SHEAT6F 90/4 MPNEURON MAX   PNML6F08 340,75 340,75
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PITY73C-CATETERE PER TROMBOASPIRAZIONE INTRACRANICA6F 131 DRITTA   SOFIA PLUS   DA6 2013 alternatives
PIT0841-CATETERE PER TROMBOASPIRAZIONE EMBOLI O TROMBI0.060" L.132 CM AXS CATALYST 1464 alternatives
PIT011W-CATETERE GUIDA A PALLONCINO SIST.RIMOZIONE TROMBIMERCI 9F   90074 1004,06 1004,06
PIA6406-SIRINGA INFUSIONE IRRIGAZIONE CONO LUER LOCK TREPEZZI SENZA AGO 50/60ML  (L2 0,2215317 0,22153
PITY73D-MICROCATETERE HEADWAY 21 2,5/2,0FR.HEADWAY MC212156S 610 610
4174,82
1738,5
18
Tromboaspirazione Intracranica
Thrombo-aspiration
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,2 439,2
PITY738-ERIC - DISPOSITIVO RIMOZIONE MECCANICA ENDOVASC TROMBI 4MM X 30MM ER1740 3660 alternatives
QPAE601-STENT INTRACRANICO AUTOESP. X  REMODELING NEUROVAS4MM X 20MM SOLITAIRE 3328 alternatives
PITCNV1-DISPOSITIVO PER TROMBECTOMIA STERILE MONOUSOREVIVE SE   FRS21452299  COMP 3904 alternatives
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PITY73D-MICROCATETERE HEADWAY 21 2,5/2,0FR.HEADWAY MC212156S 610 610
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VAL 7,32 7,32
4645,46
3556
Procedure's Devices' Total Cost = 
Intracranial Thrombectomy
Trombectomia intracranica
18.a
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITC227-CATETERE PER ANGIOGRAFIA SELETTIVA BERENSTEIN II0,38" 100CM 5F COD. 451-515HO 11,96 11,96
F01A620-ALKERAN 1FL 50MG LIOFILO+FL 10MLMELFALAN ( 1 fiala costa 148 euro, la Neuroradiologia ha 23,68 23,68
F01G933-TOPOTECAN TEVA*EV 5FL 4MG/4MLTOPOTECAN CLORIDRATO 7,57 7,57
PITBLX2-MICROCATETERE IDROFILICO FLESSIBIL.PROGRESSIVAPROSSIMALE RIGIDA 2.7X135 L.1 912,56 912,56
PITBL66-MICROGUIDA IDROFILICA  NITINOL .007 L.210CM CURVAD   HYBRID   2/HYBRID007D 549,00 549,00
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
1512,09Procedure's Devices' Total Cost = 
19
Chemioterapia i.a. per RTB
Intra-arterial Chemiotherapy of RTB
 
 
Devices Unit Cost Average Q. Utilized Tot Cost
PITM001-SET X  EMBOLIZZAZIONE LIQ.DO 2 FIALE ONYX 18 LD P+DMSO + 3 APPOSITE SIRINGHE C 967,20 2 1934,4
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146,40 146,4
PITY731-MICROCATETERE 2 MARKERS21 HEADWAY 21     MC212150S 610,00 610
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS CO 612,00 612
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,20 439,2
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
3765,79
20
Embolizzazione Tumori Pre-Oper.
Tumor Embolization - pre.op. 
Procedure's Devices' Total Cost =  
 
Devices Unit Cost Average Q. Utilized Tot Cost
PAVI052-FIALA EMBOLIZZANTE CONTOUR 355-500  MICRON760045 71,76 2 143,52
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146,40 146,4
PITY731-MICROCATETERE 2 MARKERS21 HEADWAY 21     MC212150S 610,00 610
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS CO 612,00 612
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,20 439,2
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
1974,91
Tumor Embolization Spinal-Head&neck
Procedure's Devices' Total Cost = 
embolizzazione tumori Spinali/Capo-collo 
21
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Devices Unit Cost Average Q. Utilized Tot Cost
PAVD391-COLLA CHIRURGICA GLUBRAN 2 ML 1 A FIALAG-NB-2 (*D.D.185/07) 122,01 122,009
PIT0404-KIT X ANGIOPLASTICA CONNETTORE A Y VALVOLA SCATTOPROLUNGA AGO INTRODUT 16,47 16,47
PITC21D-CATETERE GUIDA X NEURORADIOLOGIA ENVOYMULTIPURPOSE C  5 F 90CM   556-256-90 146,40 146,4
PITY731-MICROCATETERE 2 MARKERS21 HEADWAY 21     MC212150S 610,00 610
PITETBC-MICROCATETERE PER INFUSIONE  PROWLER SELECT LP-ESE PLUS LUNG.150  CORDIS CO 612,00 612
PITZ72P-GUIDA TRANSEND EX SOFT TIP.014" 205/2CM.TARGET 46-806 439,20 439,2
PAVI052-FIALA EMBOLIZZANTE CONTOUR 355-500  MICRON760045 71,76 2 143,52
PIT0405-VALVOLA EMOSTATICA ROTANTE 2 VIE D.INTERNO 0.096"ROTATING HEMOSTATC VALV 7,32 7,32
2096,92Procedure's Devices' Total Cost = 
Trauma/bleeding Embolization
embolizzazione tumori endocr.
22
 
 
 
 
 
 
 
 
 
 
 
 
 
